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Phosphatase and tensin homologue deleted on chromosome ten (PTEN) is one of the most 
commonly altered tumor suppressors in human cancer. It is a dual-specificity phosphatase that 
by converting the lipid second messenger PIP3 to PIP2 antagonizes the PI3K/AKT signaling 
pathway. PTEN also has numerous, albeit controversial nuclear functions, which thus far have 
been shown to be independent of its phosphatase activity. Although a number of studies have 
described that loss or gain of PTEN protein expression alters gene expression patterns, 
relatively little is known about the exact mechanism. In this research study, we investigated 
PTEN’s influence on gene expression and its role in transcription regulation. 
 
First, we established mouse embryonic fibroblasts (MEFs) as a suitable model system to study 
the effects of PTEN loss on gene expression. Using an Adeno-virus containing Cre-
recombinase, Pten expression could be ablated efficiently in MEFs carrying loxP sites flanking 
exon 5 of the endogenous Pten locus. Genome-wide mRNA microarray analysis revealed that 
Pten deletion decreased the transcript levels of a subset of genes and increased the transcript 
levels of a different subset of genes. Moreover, by uncoupling these effects from PTEN’s role in 
the PI3K/AKT pathway we discovered that Pten loss can alter gene expression in a PI3K/AKT-
dependent as well as a PI3K/AKT-independent manner. The upregulated genes were enriched 
for genes involved in DNA binding, replication, and repair, but also for regulation of gene 
 
 
expression. Gene expression can be influenced by histone modifications. However, loss of 
PTEN did not affect histone modifications globally as evidenced by western blotting. Using 
native ChIP-Seq experiments we showed that loss of PTEN altered the levels of H3K36me3 and 
H3K27me3 on a subset of genes and markedly decreased levels of H3K27ac at most 
enhancers as well as super-enhancers. However, RNAPII occupancy on enhancer-associated 
genes did not decrease, suggesting that the modulation of enhancer strength did not affect 
RNAPII recruitment to TSS. 
 
In Chapter 3 we identify a nuclear pool of Pten that could associate with chromatin. 
Furthermore, we are the first to report that nuclear PTEN can directly interact with components 
of the transcription machinery including CDK7, CDK9, Cyclin T1, AFF4, and RNAPII. Loss of 
PTEN increased phosphorylation of Ser2 and Ser5 of the RNAPII CTD as well as RNAPII 
occupancy on promoters of expressed genes indicating an increase in transcriptional activity in 
PTEN-/- cells. Furthermore, PTEN deletion resulted in the upregulation of genes which are part 
of the important “Achilles cluster”, previously shown to confer sensitivity to transcription 
inhibition. We believe that it is over-expression of those genes that render PTEN deficient cells 
especially sensitive to transcription inhibitors such as THZ1, Triptolide, Flavopiridol and 
LDC000067. Over-expression of wild type PTEN but not a phosphatase-dead mutant of PTEN 
could decrease cells’ sensitivity to treatment with THZ1 or Flavopiridol. It also decreased protein 
levels of p-AKT Ser473 as well as RNAPII Ser2P and Ser5P suggesting that the phosphatase 
activity of PTEN is important for its role in transcription regulation. 
In sum, we propose a model in which PTEN binds to CDK7, CDK9, Cyclin T1, RNAPPII and/or 
AFF4 thereby exerting a negative regulatory effect on the activity of transcription complexes. 
Upon loss of PTEN the negative regulatory effect is eliminated and transcription of a subset of 
genes increases. It is most likely these genes that confer sensitivity to transcription inhibition on 
 
 
PTEN-/- cells. The better understanding of this oncogenic mechanism may reveal novel 
therapeutic opportunities, and ultimately we propose that the sensitivity of PTEN deficient cells 
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CHAPTER 1: Introduction 
PTEN: an overview 
PTEN in its traditional role 
Phosphatase and tensin homologue deleted on chromosome ten (PTEN) is a tumor suppressor 
that was identified by homologous deletion mapping of human chromosome 10q23. It is 
frequently lost from chromosome 10q23 in multiple human cancers, including brain, breast and 
prostate cancer and is considered one of the most commonly mutated tumor suppressors (Li et 
al., 1997; Steck et al., 1997). Hereditary loss of PTEN is the cause of several autosomal 
dominant disorders, including Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, 
Lhermitte-Duclos disease, Proteus syndrome and Proteus-like syndrome, which are 
characterized by the presence of developmental defects, benign hamartomas and an increased 
risk of cancer (Arch et al., 1997; Liaw et al., 1997; Marsh et al., 1998; Zhou et al., 2001; Zhou et 
al., 2003). Moreover, mutations in PTEN are associated with macrocephaly and autism 
spectrum disorders (Butler et al., 2005). 
As the name implies PTEN is a protein with phosphatase activity, specifically a dual-specificity 
phosphatase that can dephosphorylate lipid as well as protein substrates. Despite its dual-
specificity its primary cellular substrate is the lipid second messenger 
phosphatidylinositol(3,4,5)-triphosphate (PIP3) (Lee et al., 1999). By dephosphorylating the D3 
position of the inositol ring of PIP3 PTEN generates phosphatidylinositol(4,5)-bisphosphate 
(PIP2), thereby antagonizing phosphatidylinositide 3 kinase (PI3K) signaling (Myers et al., 1998; 
Stambolic et al., 1998). In the cytosol, stimulation of a variety of cell surface receptors mediates 
the activation of Type I PI3Ks, which generate PIP3. PIP3 binds effector proteins via their 
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phosphoinositide binding domains, such as pleckstrin homology (PH) domains and this binding 
promotes the activation and localization of these proteins to the plasma membrane. Most 
notable is the PIP3-dependent membrane recruitment and activation of AKT, which promotes 
cell survival, cell growth, and proliferation by activating downstream effectors like CREB or 
mTOR, by inhibiting p27 or by localizing FOXO in the cytoplasm (Franke et al., 1997). 
 
(Keniry and Parsons, 2008) 
Figure 1.1: The PTEN/PI3K/AKT signaling pathway regulates many aspects of cancer 
biology. 
This basic schematic representation of the pathway predominantly depicts the membrane/cytoplasmic 
localization of select PTEN/PI3K/AKT pathway components. Stimulation of specific cell surface receptors 
activates Ras and Type I PI3Ks, which generate PIP3. Most notably this results in the PIP3-dependent 
membrane recruitment and activation of AKT, a kinase that regulates many critical processes involved in 
cancer such as cell cycle progression, apoptosis, cellular growth and translation by activating 
downstream effectors like CREB or mTOR, by inhibiting p27 or by localizing FOXO in the cytoplasm. The 
dual-specificity phosphatase PTEN acts as a critical negative regulator of PI3K/AKT signaling by 
dephosphorylating the D3 position of the inositol ring of PIP3 thereby generating PIP2. 




PTEN domains and phosphorylation 
PTEN consists of 403 amino acids (aa) and contains several distinct domains (Fig 1.2). Amino 
acids 7–179 make up the phosphatase domain (PD), whose amino acid sequence contains the 
signature motif HCXXGXXRS/T that is also found in the active sites of other protein tyrosine 
phosphatases and dual-specificity protein phosphatases. Additionally, the phosphatase domain 
contains sequence homology to two proteins without catalytic activity, namely the actin-binding 
protein tensin 1 and the cofactor of ATPase heat shock cognate 70, auxilin (Li et al., 1997). The 
crystal structure of PTEN amino acids 14-351 revealed that the phosphatase domain contains a 
deep and wide catalytic pocket with a positive charge that is capable of accommodating 
phospholipid substrates (Lee et al., 1999). The phosphatase domain together with the C2 
domain, ranging from amino acids 186–351, constitutes the minimal catalytic region of PTEN. 
The C2 domain is formed by two anti-parallel β-sheets and lacks the canonical Ca2+-chelating 
residues. It binds to phospholipid membranes in a Ca2+-independent manner involving stretches 
of basic residues (Georgescu et al., 2000). In addition, PTEN possesses an N-terminal 
phosphatidylinositol-4,5-bisphosphate-binding domain (PBD), which is important for membrane 
localization and PTEN catalytic activity (Campbell et al., 2003; Walker et al., 2004). At the very 
C-terminus of PTEN the C-terminal tail is located, which contains several phosphorylation sites 
and a PSD-95, Discs-large, ZO-1 (PDZ)-binding domain that is involved in PTEN regulation and 
stability (Vazquez et al., 2000). The main phosphorylation sites in the C-terminal tail are Thr366, 
Ser370, and a cluster containing Ser380, Thr382, Thr383, and Ser385 (Miller et al., 2002; 
Vazquez et al., 2000). Two kinases were identified that can phosphorylate the C-terminal tail; 
casein kinase 2 (CK2), which phosphorylates PTEN at Ser370 and the Ser380–Ser385 cluster, 
and glycogen synthase kinase 3 beta (GSK3β), which phosphorylates Ser362 and Thr366 (Al-
Khouri et al., 2005; Torres and Pulido, 2001). Phosphorylation of these residues is important for 
an intramolecular interaction between the C-terminal tail and the catalytic region of PTEN and 
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results in a ‘closed’ PTEN conformation that restricts PTEN recruitment to the plasma 
membrane and PIP3 access (Rahdar et al., 2009; Tibarewal et al., 2012). Moreover, 
phosphorylation of the C-terminal tail increases the half-life of PTEN, but inhibits its 
phosphatase activity (Vazquez et al., 2000). Additional phosphorylation sites in the C2 domain 
of PTEN can be phosphorylated by RhoA-associated kinase (ROCK) and Src family kinases 
and have been implicated in regulating PTEN phosphatase activity and protein-protein 
interactions (Hopkins et al., 2014).  
 
Lipid phosphatase-independent functions of PTEN 
Despite its essential role in antagonizing the PI3K/AKT pathway, PTEN also has important lipid 
phosphatase-independent functions. Most notably, PTEN protein phosphatase activity has been 
implicated in regulating cellular migration (Leslie et al., 2007). For example, in fibroblasts PTEN 
dephosphorylates focal adhesion kinase, resulting in reduced cell migration and spreading 
(Tamura et al., 1998). In glioma cells PTEN protein phosphatase activity is required to induce 
PTEN auto-dephosphorylation and to inhibit cellular migration, potentially by suppressing Src 
family kinases (Dey et al., 2008; Raftopoulou et al., 2004). Furthermore, it was shown that 
PTEN can activate tyrosine kinase Src in a protein phosphatase-dependent manner, thereby 
conferring human epidermal growth factor receptor 2 (ERBB2 or HER2)-inhibitor resistance in 
breast cancer cells (Zhang et al., 2011).  
Lastly, PTEN also has numerous, albeit controversial nuclear functions, which thus far have 





PTEN in the nucleus: Historical skepticism 
Without a classical nuclear localization signal (NLS) and with its primary role as an antagonist of 
the PI3K/AKT pathway, whose components had not been discovered in the nucleus at that time, 
PTEN was initially considered solely a cytoplasmic protein. This was corroborated by early 
immunohistochemical (IHC) studies that, using either overexpression systems (Furnari et al., 
1997) or tumorigenic cell lines (Whang et al., 1998), found PTEN primarily in the cytoplasm. 
Therefore, first reports of PTEN being found in the nucleus of normal cells, for example normal 
primary neurons and endothelial cells (Sano et al., 1999), myoepithelial cells of normal breast 
ducts (Perren et al., 1999) and normal follicular thyroid cells (Gimm et al., 2000) were met with 
skepticism. However, in short order a number of reports were published that started to overturn 
the notion of PTEN as a purely cytoplasmic protein. These reports seemed to suggest a distinct 
correlation of PTEN nuclear localization with severity and progression of disease. For example, 
compared to normal thyroid tissues malignant thyroid carcinomas showed a distinct loss of 
nuclear PTEN, while still maintaining cytoplasmic expression of PTEN. The correlation of 
nuclear PTEN expression in normal tissues and cytoplasmic PTEN expression in malignant 
tissues was subsequently supported by studies in other tissue types. Normal islet cells exhibited 
predominantly nuclear PTEN staining, while the majority of endocrine pancreatic tumors showed 
predominantly cytoplasmic PTEN staining (Perren et al., 2000). In primary cutaneous melanoma 
almost 70% of tumors retained cytoplasmic PTEN staining whereas only 10% showed nuclear 
PTEN staining when compared to normal tissue. Moreover, this study provided compelling 
evidence for an association between the lack of nuclear PTEN and the mitotic index. While 
nuclear PTEN is apparent in quiescent cells, in actively dividing cells it localizes mostly to the 
cytosol (Whiteman et al., 2002). In esophageal squamous cell carcinoma, patients with nuclear 
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expression of PTEN had a significantly better 10-year overall survival rate than patients with 
negative nuclear PTEN staining (Tachibana et al., 2002). Overall these studies indicate that the 
absence of nuclear PTEN is associated with more aggressive cancer. 
However, even after the multitude of reports placing PTEN in the nuclear compartment, many 
sceptics still considered nuclear PTEN an artifact. This was mainly due to these studies relying 
on immunohistochemical stainings using PTEN antibodies of variable quality. To substantiate 
the immunohistochemical studies, nuclear localization of PTEN was investigated by means of 
fluorescence microcopy and subcellular fractionation. In MCF7 cells localization of PTEN was 
cell cycle dependent, with higher nuclear PTEN levels being found in G0-G1 phase and lower 
levels being found in S phase (Ginn-Pease and Eng, 2003). This was in accordance with 
findings from normal and tumor tissues; that is, in normal, quiescent tissue, PTEN is localized 
primarily in the nucleus, whereas in neoplastic, actively dividing tissue cytoplasmic PTEN 
predominates. Overall it is now acknowledged that a change in intracellular localization of PTEN 
is involved in neoplastic transformation of cells and might modulate PTEN’s activity. 
 
Mechanisms of PTEN nuclear localization: A multitude of possibilities 
Given the absence of a classical nuclear localization signal (NLS) as well as a classical 
cytosolic localization signal (CLS) in PTEN, a definite mechanism of nuclear import and export 
remains elusive to this day. However, numerous reports have been published resulting in a 
multitude of postulated import and export mechanisms ranging from simple diffusion, active 
shuttling by RAN GTPase or major vault protein (MVP) and phosphorylation-dependent shuttling 
to monoubiquitination-dependent import. Moreover, it is clear, that the process is very dynamic 
and complex, dependent on differentiation and cell cycle status and therefore might not be the 
same for different tissues and cell types.  
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The first mode of PTEN nuclear import, namely import by simple diffusion was proposed by Liu 
et al. (Liu et al., 2005). Diffusion through nuclear pores is thought to be possible yet inefficient 
for proteins with a molecular weight larger than 20 kDa, with an upper limit for proteins with a 
molecular weight of 60 kDa. Despite this limit, GFP-PTEN fusion proteins (about 75 kDa) were 
shown to enter the nucleus, whereas larger fusion proteins could not. Even though the 75 kDa 
GFP-PTEN fusion protein exceeds the 60 kDa nuclear pore diffusion limit, Liu et al. argue that 
the cut-off is not just a simple function of molecular weight, but depends also on the shape of 
the protein. Overall, without the fusion of GFP, PTEN has a molecular weight of about 50 kDa, 
making it suitable for simple diffusion.  
It was also proposed that PTEN might contain a functional NLS. Fusion of residues 1-20 or 1-
173 of PTEN to pyruvate kinase (PK) did not enable PK to enter the nucleus, indicating that 
these residues do not contain a functional NLS. However, mutation of residues 13 and 14, but 
not 11 and 15 slightly impaired the nuclear import of PTEN, suggesting that residues 11-15 do 
form a weak NLS. Liu et al. (Liu et al., 2005) explain their findings with a model of cytosolic 
sequestration where PTEN interacts with proteins in the cytosol that affect its nuclear import. In 
this model, mutation of residues 13 and 14 decreases the interaction of PTEN with cytoplasmic 
proteins and reduces its cytoplasmic motility, which in turn leads to a decrease of its nuclear 
localization.  
Interestingly, residues 11-15 were identified by another group (Chung et al., 2005), as one of 
four NLS-like sequences. In accordance with Liu et al. mutation of any individual NLS-like 
sequence did not affect PTEN localization. However, mutation of two or more of the NLS-like 
sequences excludes PTEN from the nucleus, suggesting the existence of bipartite NLS motifs in 
PTEN. 
Despite the identification of the bipartite NLS motifs, PTEN does not have a classical NLS. 
However, Denning et al. (Denning et al., 2007) suggest a mechanism of PTEN nuclear-cytosolic 
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localization based on a cytoplasmic localization signal (CLS) situated in the N-terminal region of 
PTEN comprising amino acid residues 19-25. Immunofluorescence studies in U87MG cells 
revealed that PTEN proteins harboring mutations within the putative CLS localized primarily to 
the nucleus. However, how the putative CLS might facilitate the nuclear export of PTEN remains 
elusive. Mutations within the putative CLS not only affected PTEN cellular localization but also 
resulted in a loss of PTEN’s growth suppressive activity while leaving its lipid phosphatase 
activity unaffected. This suggests that the cellular localization of PTEN is as important for its 
growth regulatory activities as is its lipid phosphatase activity.  
More recently another mechanism of PTEN nuclear import has been reported by Terrien et al., 
who found that the nuclear localization of PTEN is dependent on an interaction of the PDZ 
binding domain of PTEN with microtubule-associated serine and threonine kinase 2 (MAST2) 
(Terrien et al., 2012). In human neuroblastoma cells the disruption of this interaction by a viral 
glycoprotein produced by the rabies virus promoted the nuclear exclusion of PTEN and 
neuronal survival. 
The first report of active shuttling of PTEN to the nucleus was published by Gil et al. (Gil et al., 
2006), who explored a Ran-GTPase as a putative transporter for PTEN. Using immuno-
fluorescence studies in PTEN Null U87MG cells over-expressing wild-type or mutant PTEN 
constructs they identified a potential nuclear localization domain located at the N-terminus 
(amino acid residues 8-32) of PTEN that seemed to be required for active nuclear import 
mediated by wild-type Ran GTPase. A GTPase-deficient, dominant-negative, RANQ69L mutant, 
was unable to facilitate PTEN localization to the nucleus. Moreover, truncations of the C-
terminus and point mutations of phosphorylation sites located in the C-terminal region (aa 370-
385) seemed to favor the nuclear localization of PTEN. However, the importance of the C-
terminal phosphorylation sites in PTEN nuclear localization could not be corroborated by Chung 
et al. (Chung et al., 2005). They did not observe an altered nucleo-cytoplasmic localization of 
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PTEN when over-expressing some of these PTEN phospho-mutants in PTEN WT MCF7 cells. 
The different findings of these studies might be a result of different model systems (brain cancer 
versus breast cancer) or the PTEN status of the cell lines. The first study used U87MG 
glioblastoma cells lacking endogenous PTEN protein whereas the second study used MCF7 
breast cancer cells, which express wild type PTEN. Endogenous PTEN protein could potentially 
alter the subcellular localization of the phospho-mutants through protein-protein interactions.  
A second potential mechanism of active shuttling of PTEN to the nucleus was described by Yu 
et al. (Yu et al., 2002), who identified the major vault protein (MVP) as a new interaction partner 
of PTEN using a yeast-two hybrid screen. MVP is a component of vault, a 13 MDa 
ribonucleoprotein complex, thought to be involved in nuclear-cytoplasmic transport (Mossink et 
al., 2003). Co-immunoprecipitation experiments confirmed the interaction in HEK293T and HeLa 
cells. The binding of PTEN and MVP was mediated by the C2 domain of PTEN and the EF 
hand-like motif of MVP. Further studies showed that this interaction is Ca2+-dependent 
(Minaguchi et al., 2006; Yu et al., 2002) but does not seem to require PTEN phosphorylation or 
PTEN lipid or protein phosphatase activity (Chung et al., 2005). Interestingly, the binding of 
PTEN and MVP could be disrupted by mutations in putative non-traditional NLS-like sequences 
found in PTEN. Site-directed mutagenesis and immunofluorescence studies in MCF7 cells 
identified four different NLS-like sequences (NLS1 to NLS4). However, mutation of any 
individual NLS-like sequence does not affect PTEN localization. Only mutations of two or more 
of these sites, specifically NLS2 and NLS3 or NLS3 and NLS4 excluded PTEN from the nucleus 
and inhibited binding to MVP (Chung et al., 2005).  
Another potential mechanism of PTEN nuclear import requires the monoubiquitination of PTEN, 
specifically at lysine 289 (Trotman et al., 2007). A mutation of this residue from lysine to 
glutamate (K289E) was identified in a Cowden syndrome (CS) patient and resulted in the 
nuclear exclusion of PTEN. Immunofluorescence studies of GFP-PTEN and GFP-PTEN K289E 
10 
 
showed that the K289 mutant was predominantly found in the cytosol whereas wild type PTEN 
was localized to the nucleus and the cytosol. The decrease in nuclear import of PTEN K289 was 
thought to be independent of PTEN phosphatase activity as the K289E mutation does not 
disrupt PTEN phosphatase activity or PTEN membrane localization (Georgescu et al., 2000). 
Interestingly, lysines 289 and 13 were identified as ubiquitination sites that can be ubiquitinated 
by neural precursor cell expressed developmentally downregulated protein 4-1 (NEDD4-1). 
Mutation of either K289 or K13 led to a shuttling defect, which could be rescued by forced 
monoubiquitination. Moreover, knockdown of NEDD4-1 resulted in PTEN cytosolic localization, 
whereas overexpression of NEDD4-1 increased nuclear localization of PTEN. The same year 
NEDD4-1 was identified as a proto-oncogenic ubiquitin ligase responsible for the 
polyubiquitination of PTEN (Wang et al., 2007). PTEN has two canonical PEST motifs, which 
are sequences associated with proteins that have short intracellular half-lives and are targeted 
for degradation by the ubiquitin pathway. Purification of ubiquitinated GST-PTEN from HeLa 
cytosolic fractions followed by mass spectrometry identified NEDD4-1, a member of the NEDD4 
family of E3 HECT ubiquitin ligases, as a PTEN binding partner and E3 ligase. Overexpression 
of NEDD4-1 resulted in the polyubiquitination and proteasomal degradation of endogenous 
PTEN, whereas knock-down of NEDD4-1 by RNAi led to an increase in PTEN levels and protein 
stability. In summary, the PTEN-NEDD4-1 relationship seems to be of a complex nature, in 
which monoubiquitination of PTEN by NEDD4-1 leads to its nuclear localization and has a pro-
apoptotic effect, whereas polyubiquitination results in the degradation of PTEN and the loss of 
its tumor suppressive activity. To add even more complexity, Fouladkou et al. found that 
NEDD4-1 is dispensable for the regulation of PTEN localization and stability (Fouladkou et al., 
2008). Using cells and tissues generated from two different mouse strains deficient of Nedd4-1 
they could not confirm the interaction between PTEN and Nedd4-1. Moreover, PTEN stability 
and ubiquitination were indistinguishable between wild type and Nedd4-1-deficient cells. PTEN 
subcellular distribution was independent of the presence of Nedd4-1, suggesting that NEDD4-1 
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may not be a universal E3 ligase for PTEN. In fact, the X-linked inhibitor of apoptosis protein 
(XIAP), a RING domain E3 ligase and the WW domain-containing protein 2 (WWP2) as well as 
a NEDD4-like E3 ligase were later proposed to facilitate PTEN ubiquitination (Maddika et al., 
2011; Van Themsche et al., 2009). However, for now it remains unclear whether all three 
ubiquitin ligases can mediate both mono- and polyubiquitination of PTEN and how their 
activities are regulated in different cell and tissue types. 
The deubiquitinating enzyme that can remove ubiquitin from PTEN marking it for export from the 
nucleus has been identified as herpes virus-associated ubiquitin-specific protease (HAUSP or 
USP7) (Song et al., 2008). Using co-immunoprecipitation experiments a direct interaction 
between PTEN and HAUSP was shown. Moreover, knockdown of HAUSP by siRNA increased 
PTEN monoubiquitination and promoted the nuclear localization of WT PTEN and PTEN, which 
was mutated at either lysine residues 289 or 13. This suggests that monoubiquitination/de-
ubiquitination of either lysine is sufficient to modulate PTEN compartmentalization. Moreover, 
PTEN is aberrantly localized in acute promyelocytic leukemia, in which promyelocytic leukemia 
protein (PML) function is disrupted, so that it cannot form functional nuclear bodies. In these 
nuclear bodies PML opposed the activity of HAUSP towards PTEN through a mechanism 
involving the adaptor protein death domain-associated protein (DAXX), suggesting a PML–
DAXX–HAUSP molecular network controlling PTEN deubiquitination and trafficking that can be 
perturbed in human cancer. 
SUMOylation (small ubiquitin-like modifier, SUMO) of PTEN has been proposed as yet another 
mechanism of PTEN nuclear localization. SUMO proteins are a family of ubiquitin-like 
molecules, which, using an enzymatic cascade similar to that used by ubiquitin, can be 
covalently attached to or detached from proteins to modify their functions. SUMOylation is a 
post-translational modification involved in various cellular processes, such as nuclear-
cytoplasmic localization, transcriptional regulation, apoptosis, protein stability, response to 
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stress and progression through the cell cycle (Geiss-Friedlander and Melchior, 2007). Using the 
SUMOplot prediction system Gonzalez-Santamaria et al. (Gonzalez-Santamaria et al., 2012) 
identified a conserved SUMOylation sequence (IKVE, aa 253-256) and three additional lysines 
(K102, K266, and K289) as putative SUMO-conjugation residues in the PTEN protein sequence. 
Point mutations of lysines 266 and 289, both located in the C2 domain of PTEN confirmed these 
residues as SUMO acceptor sites. Interestingly, a point mutation of lysine 289, which had 
previously been identified as an ubiquitination site in PTEN (Trotman et al., 2007) decreased the 
conjugation of SUMO to PTEN harboring a lysine 266 point mutation. Overall, these 
SUMOylation deficient PTEN mutants localized predominantly to the cytosol and were excluded 
from the nucleus. The identification of lysine 266 as a monoubiquitination site and the 
observation that SUMOylation of PTEN reduces its conjugation with monoubiquitin, suggests a 
crosstalk between PTEN SUMOylation and ubiquitination (Gonzalez-Santamaria et al., 2012). 
Bassi et al. (Bassi et al., 2013) identified a ~75 kDa species of PTEN that was absent from 
PTEN-/- cells and that was sensitive to treatment with N-ethylmaleamide (NEM), an inhibitor of 
cysteine-based enzymes including deSUMOylases and deubiquitinases. Given that mono-
SUMOylation could explain an apparent ~20 kDa increase in molecular mass of PTEN, they 
concluded that this species represented a SUMOylated form of PTEN. SUMOylation prediction 
software identified lysine 254, located in the C2 domain of PTEN as the SUMO acceptor site. A 
lysine 254 mutant (K254R) that cannot be SUMOylated, confirmed lysine 254 as the major 
SUMOylation site in PTEN (Bassi et al., 2013). 
Overall, the multitude of mechanisms proposed for the nuclear import of PTEN suggests that 
PTEN nuclear localization is likely influenced by a variety of factors and is cell type, tissue- and 
situation-specific. Moreover, it is clear that there is a delicate balance between PTEN protein 





Figure 1.2: PTEN domains and post-translational modifications involved in nuclear 
import and regulation of PTEN. 
The 403 amino acid protein PTEN contains a PIP2-binding domain (PBD), a phosphatase domain (PD), a 
C2 domain (C2), a tail domain (TAIL), and a PDZ-binding domain (PDZ-BD). A putative cytoplasmic 
localization signal (CLS) spans residues 19-25. Four separate non-classical NLS motifs (NLS1 to NLS4) 
have been proposed to span residues 10-14 (NLS1), 160-164 (NLS2), 233-237 (NLS3) and 265-269 
(NLS4). They are involved in binding to MVP and MVP-mediated nuclear import of PTEN. Ubiquitination 
of PTEN at lysines 13 and 289 by neural precursor cell expressed developmentally downregulated protein 
4-1 (NEDD4-1), X-linked inhibitor of apoptosis (XIAP), or WW domain-containing protein 2 (WWP2) 
regulates PTEN stability and nuclear localization. SUMOylation of PTEN at lysines 266 and 289 is 
involved in nuclear localization of PTEN. SUMOylation of PTEN at lysine 254 is critical for the nuclear 
import of PTEN and its role in homologous recombination-mediated repair (HR). Dynamic phosphorylation 
of multiple sites in the TAIL domain of PTEN by casein kinase 2 (CK2) or glycogen synthase kinase 3 
beta (GSK3β) affects protein stability, phosphatase activity, protein–protein interactions, and potentially 




Functions of nuclear PTEN 
After establishing the presence of PTEN in the nucleus and many proposed mechanisms for its 
nuclear import, the search for a function of nuclear PTEN began. Initially, the discovery of 
nuclear pools of PIP2 and PIP3 (Lindsay et al., 2006; Martelli et al., 2004) as well as the 
presence of PI3Ks in the nuclear compartment (Irvine, 2003; Watt et al., 2004) suggested that 
nuclear PTEN could have a similar role as its cytoplasmic counterpart by opposing the 
PI3K/AKT pathway. However, only cytoplasmic pools of PIP3 are sensitive to PTEN 
phosphatase activity (Lindsay et al., 2006). Lindsay et al. applied on-section labeling and 
immunogold electron microscopy using the GST-labeled PH domain of Grp as a probe to map 
the cellular distribution of PIP3. In Swiss 3T3 cells, this approach revealed accumulation of PIP3 
in all cell compartments after stimulation with platelet-derived growth factor (PDGF) with the 
greatest amounts localizing to the plasma membrane (35-50%) and the nuclear matrix (20-
30%). In PTEN deficient U87MG cells a similar pattern of PIP3 accumulation in the plasma and 
nuclear membranes was observed. In both cell lines PIP3 pools were sensitive to PI3K 
inhibition. Re-expression of PTEN in U87MG cells decreased the plasma membrane pool of 
PIP3, but not the nuclear PIP3 pool. Moreover, the nuclear PIP3 pool proved to be resistant to 
re-expression of a PTEN construct with a strong nuclear localization signal. This suggests that 
nuclear PTEN might have functions independent of its lipid phosphatase activity. 
First evidence of a function of nuclear PTEN was presented by Chung et al. (Chung and Eng, 
2005; Chung et al., 2006), who observed that nuclear PTEN is required for cell cycle arrest. In 
MCF7 cells, PTEN localized to the nucleus and this localization coincided with the G0-G1 phases 
of the cell cycle. The cell cycle arrest appeared dependent on the down-regulation of cyclin D1, 
the regulatory subunit of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which regulate 
the G1/S phase transition and entry into the S-phase. Previously, it had been shown that the 
protein phosphatase activity of PTEN is required for the down-regulation of cyclin D1 as well as 
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the dephosphorylation of mitogen-activated protein kinase (MAPK) (Weng et al., 2002; Weng et 
al., 2001). Taken together this suggests that in a protein phosphatase-dependent manner 
nuclear PTEN down-regulates MAPK, resulting in the down-regulation of cyclin D1 transcription 
and that this cascade is responsible for PTEN-mediated cell cycle arrest.  
Another piece of evidence linking nuclear PTEN to cell cycle control came from Song et al., who 
proposed that nuclear PTEN regulates the anaphase-promoting complex/cyclosome (APC/C) in 
a phosphatase-independent manner (Song et al., 2011). APC/C is one of the two major E3 
ubiquitin-ligases regulating cell cycle progression by ubiquitin-mediated proteolysis and it is 
thought to be active from mitosis to late G1 phase. APC/C maintains G1 by limiting the 
expression of cyclin D1 through promoting the degradation of the transcription factor ETS proto-
oncogene 2 (Ets2). The fully functional APC/C complex contains at least 11 different subunits 
and its activity is controlled by CDC20 and CDH1. Using immunoprecipitation experiments of 
Myc-tagged PTEN from PTEN-deficient PC3 cells, followed by mass spectrometry four 
constituents of the anaphase-promoting complex/cyclosome (APC/C), including APC3, APC4, 
APC5 and APC7, were identified as potential interaction partners of PTEN. Validation of the 
newly found APC/C interaction partners of PTEN revealed that the interactions were mediated 
by the C-terminal domain of PTEN, and not its N-terminal phosphatase domain. Binding of 
nuclear PTEN to APC/C constituents enhanced the E3 ligase activity of the APC/C complex by 
promoting the association of APC and its activator CDH1, which led to a proteasome-dependent 
reduction of APC/C targets, such as the oncoproteins polo-like kinase 1 (PLK1) and Aurora 
kinase. Interestingly, nuclear exclusion but not phosphatase inactivation of PTEN impaired the 
activation of the APC/C-CDH1 complex and resulted in a hypersensitivity to pharmacological 
inhibition of APC/C-CDH1 targets. Moreover, the reduction of APC/C-CDH1 activity after loss of 
nuclear PTEN could contribute to the induction of cellular senescence that has been observed 
in non-proliferating cells (Chen et al., 2005). 
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Another well studied aspect of PTEN is its role in the maintenance of genomic integrity, either 
by acting directly in the nucleus or indirectly by modulating the functions of nuclear proteins. An 
initial study by Puc et al. (Puc et al., 2005) found that Pten−/− mouse embryonic stem cells 
displayed a partially defective checkpoint activation in response to ionizing radiation (IR). This 
defect was due to phosphorylation-dependent inactivation of the checkpoint kinase 1 (CHK1), 
an essential kinase involved in the regulation of cell cycle progression and preservation of 
genomic stability. AKT could phosphorylate CHK1 at serine residue 280, and this 
phosphorylation was negatively regulated by PTEN. Furthermore, the phosphorylation of CHK1 
led to its monoubiquitination and sequestration to the cytosol. The sequestration of CHK1 
disrupts the G2–M cell cycle checkpoint and promotes genomic instability and the accumulation 
of DNA double strand breaks (DSBs) in tumors and PTEN-/- cells as evidenced by elevated 
levels of γ-H2A.X (Puc and Parsons, 2005). Although this finding did not identify a direct role for 
PTEN in the nucleus, Shen et al., observing a similar increase in γ-H2A.X in PTEN-/- cells, 
proposed a direct role for PTEN in the nucleus (Shen et al., 2007). Using immunofluorescence 
and co-immunoprecipitation experiments in Pten+/+ and Pten-/- MEFs, PTEN was shown to 
associate with centromeres by binding to the centromere protein CENP-C. CENP-C is a 
sequence-specific DNA-binding protein that binds exclusively to the centromere. It is an integral 
component of the inner kinetochore and is necessary for kinetochore action and accurate 
segregation during mitosis. The interaction between CENP-C and PTEN was facilitated by the 
N-terminal region of PTEN but was independent of its phosphatase-activity.  
The chromosomal instability and the increase in γ-H2A.X and DNA DSBs after loss of PTEN is 
thought to stem from a defect in DNA repair, specifically an impairment in homologous 
recombination-mediated repair (HR), which is facilitated by BRCA1, BRCA2, Rad51 and other 
proteins. The increase in DNA DSBs was accompanied by a decrease in Rad51 mRNA 
expression. Using chromatin immunoprecipitation (ChIP) experiments this decrease was shown 
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to be due to a loss of PTEN binding to the Rad51 promoter. Re-expression of PTEN in PTEN-/- 
cells could reverse chromosomal instability and restore levels of Rad51 and concomitantly DNA 
DSB repair. Overall, this study suggested that PTEN plays a fundamental role in the 
maintenance of chromosomal stability through the physical interaction with centromeres and the 
control of DNA repair. 
However, the results of this study could not fully be supported by Gupta et al. (Gupta et al., 
2009). Although both groups observed increased basal levels of γ-H2A.X and 53BP1 foci in 
Pten-/- cells, Gupta et al. could not find a difference in these levels after challenging Pten+/+ and 
Pten-/- cells with ionizing radiation (IR). They also failed to detect a difference in the 
phosphorylation levels of Ataxia Telangiectasia Mutated (ATM) as well as its effectors after IR, 
suggesting that PTEN deficient cells display a normal DNA damage response (DDR). PTEN 
deficient cells also displayed no defects in Rad51 expression or the DDR post irradiation. 
However, Gupta et al. found that Pten-/- cells are less sensitive to inhibition of the DNA-damage 
checkpoint response by caffeine. Caffeine treatment specifically increased IR-induced 
chromosome aberrations and the mitotic index in Pten+/+ cells, but not in Pten-/- cells, suggesting 
that Pten-/- cells possess defective checkpoints. This was corroborated by Pten-/- cells bypassing 
a taxol-induced mitotic arrest. Lastly, Gupta et al. could not confirm an interaction of PTEN with 
CENP-C, indicating that genomic instability in Pten-/- cells was not due to a lack of PTEN at 
centromeres. Overall, they proposed that the loss of PTEN does not result in defects in the 
DDR, but instead alters multiple cell cycle checkpoints, leaving cells less time for DDR and/or 
chromosome segregation. The different results obtained by the two studies could be explained 
by a number of reasons. Although both used MEFs for their experiments, it is possible that the 
MEFs originated from different mouse strains, were isolated in different ways or that one study 
used primary MEFs while the other one used immortalized MEFs. Moreover, differences in the 
reagents used in either study could account for inconsistencies of the results. For example, the 
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PTEN antibody that was used to confirm the interaction of PTEN and CENP-C is a non-
commercial PTEN antibody that is not available to other investigators. 
Despite the discrepancy of the two studies, further evidence for a role of nuclear PTEN in HR 
was provided by Bassi et al. (Bassi et al., 2013). They identified a ~75 kDa species of PTEN 
that could be SUMOylated at lysine 254. SUMOylation at this residue was important for the 
nuclear retention of PTEN and its role in the cellular response to DNA damage. Under normal 
conditions, SUMOylated PTEN was predominantly nuclear, but after exposure to DNA damage 
it was rapidly excluded from the nucleus. This was also dependent on the protein kinase ataxia 
telangiectasia mutated (ATM), which phosphorylates PTEN at threonine 398. A PTEN mutant 
that cannot be phosphorylated at threonine 398 resisted nuclear exclusion following genotoxic 
stress. Moreover, cells lacking nuclear SUMOylated PTEN were hypersensitive to DNA damage 
and displayed an impaired HR of DNA DSBs. 
These findings are in contrast with a study that found nuclear PTEN to be required for an 
adequate DDR in a glioblastoma model (Kang et al., 2017). In a murine model the combined 
inactivation of the XRCC4 non-homologous end-joining (NHEJ) DNA repair gene and p53 led to 
an increased expression of CK2. This kinase phosphorylates the PTEN C-terminal tail resulting 
in the DNA damage-resistant expression of cytoplasmic PTEN, and the attenuation of an 
appropriate DDR. CK2 inhibition or the over-expression of wild type PTEN or the PTEN4A 
mutant (S380A/T382A/T383A/S385A), which cannot be phosphorylated in the tail region, 
restored PTEN nuclear distribution and DNA repair activities and impaired tumor but not normal 
cell survival. Overall, Kang et al. hypothesized that after DNA damage active PTEN dimers 
accumulate in the nucleus and activate DNA repair pathways, particularly NHEJ. The nuclear 
exit of SUMOylated PTEN might play an integral role in the early ATM-mediated HR of DNA 
DSBs whereas dimeric PTEN could be an important upstream factor involved in activating the 
NHEJ DNA damage response and repair pathways. In summary, Bassi et al. (Bassi et al., 2013) 
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and Kang et al. (Kang et al., 2017) explore PTEN’s function in two different DNA repair 
pathways, and consequently it is possible that SUMOylated PTEN and dimeric PTEN have 
specific and unique roles in each pathway. 
Subsequently, several studies affirmed that loss of PTEN led to a reduction in Rad51 
expression, IR-induced Rad51 foci formation and HR across cell lines from different cancer 
types. Interestingly, the HR defect resulted in a sensitivity to inhibitors of the DNA repair enzyme 
poly(ADP‐ribose) polymerase (PARP). PARP is a nuclear protein and its main function consists 
in the detection of DNA single strand breaks (SSB) and the recruitment of the enzymatic 
machinery involved in DNA repair. PARP activation is an immediate cellular response to 
metabolic, chemical, or radiation-induced DNA SSB damage (Ame et al., 2004). The sensitivity 
to PARP inhibitors extended to PTEN deficient cell lines and tumors, including breast, prostate, 
bladder and brain cancer cell lines and xenografts (Mendes-Pereira et al., 2009), as well as 
primary murine astrocytes, human glioma lines (McEllin et al., 2010) and human endometrioid 
endometrial carcinoma cell lines (Dedes et al., 2010). Overall, these findings indicate that the 
use of PARP inhibitors in patients with PTEN deficient cancers may be therapeutically useful. 
 
Recent evidence uncovered a novel function of nuclear PTEN in transcriptional regulation 
through the control of chromatin remodeling (Chen et al., 2014). In Pten-/- MEFs the 
heterochromatic distribution of heterochromatin protein 1 alpha (HP1α) was altered. As a 
member of the heterochromatin protein 1 family (HP1) HP1α is a fundamental unit 
of heterochromatin packaging and is also involved in the regulation of euchromatic gene 
expression. Using affinity purification of tagged PTEN from HeLa nuclear extracts followed by 
mass spectrometry, the change in heterochromatin architecture was found to be due to a direct 
interaction of the C-terminal domain of PTEN with histone H1. H1 is a linker histone that is 
involved in chromatin compaction and it is located at the base of the nucleosome near the DNA 
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entry and exit. Loss of the H1-PTEN interaction reduced loading of HP1α onto chromatin, led to 
chromatin decondensation and induced acetylation of histone H4 at lysine 16 (H4K16ac). 
Moreover, by regulating H1’s distribution on chromatin and subsequent alteration of H4K16ac 
occupancy on gene promoters, PTEN modulated gene expression. 
This finding was corroborated by Gong et al. (Gong et al., 2015), who reported that loss of 
PTEN in MEFs, U2OS or MCF10A cells led to a decrease in the heterochromatin mark 
H3K9me3, decondensation of heterochromatin and a subsequent increase in transcription of 
highly repetitive satellite DNA elements. This was due to a direct interaction between PTEN and 
HP1α, which as mentioned above plays a key role in establishing and maintaining 
transcriptionally repressive heterochromatin. Loss of PTEN resulted in a reduction in HP1α 
protein stability and a subsequent decrease of compact heterochromatin. Both studies found 
that PTEN’s effect on heterochromatin structure was dependent on the PTEN C-terminus and 
independent of PTEN’s phosphatase activity. Interestingly, in cells expressing wild type PTEN a 
C-terminally truncated mutant, PTEN Y336*, localized predominantly to the nucleus. There it 
could bind to HP1α but did not protect it from degradation, suggesting that PTEN Y336* acts in 
a dominant-negative manner to alter PTEN function on heterochromatin. Moreover, the PTEN 
Y336* mutant did not function as a tumor suppressor and was sensitive to chemotherapeutic 
agents such as PARP inhibitors or DNA demethylating agents. 
 
PTEN in cancer 
The word cancer describes more than 100 related benign and malignant diseases. Today it is 
one of the leading causes of death in the world (Hanahan and Weinberg, 2000; Jemal et al., 
2011). High throughput sequencing technologies have enabled researches to sequence 
thousands of cancer genomes to explore the mutational landscape of the different types of 
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cancer in the hope to identify novel and actionable therapeutic targets. PTEN is emerging from 
these studies as one of the most frequently mutated tumor suppressors with alterations in 
almost 10% of cases across all cancer types (Lawrence et al., 2014; Shah et al., 2012). 
Moreover, for specific types of cancer, rates of genetic inactivation of PTEN can reach more 
than 40%, such as in glioblastoma and cancer of the prostate and more than 60%, such as in 
endometrial cancer (Cerami et al., 2012; Gao et al., 2013). In addition to DNA mutations, PTEN 
expression can also be affected by epigenetic silencing. Promoter silencing has been found to 
down-regulate PTEN expression in thyroid, breast, lung, endometrial, ovarian, gastric, and brain 
tumors (Hollander et al., 2011). To add even more complexity, in glioma, lung and prostate 
cancer PTEN expression can be decreased by the overexpression of several micro-RNAs 
including miRNA-21, miRNA 25a, miRNA22 or the miRNA 106b-25 cluster (Hollander et al., 
2011).  
The study of mouse models revealed that even small changes in PTEN expression can have 
profound effects on tumor susceptibility (Alimonti et al., 2010; Shen-Li et al., 2010). This 
suggests that PTEN can function as a haploinsufficient tumor suppressor and, unlike implied by 
the two-hit model (Knudson, 1971), even subtle reduction of PTEN levels are detrimental for its 
tumor suppressive function. Taken together it has become increasingly clear that the loss of 
PTEN in cancer is extremely common and accomplished in many different ways including 
genetic inactivation, epigenetic silencing, post-translational modifications or protein-protein 
interactions. 
Genetic alterations of the PTEN gene range from point mutations, which often encode unstable 
and/or catalytically inactive proteins, to large chromosomal deletions. The generation of Pten 
knock-out mice has recapitulated many of the phenotypes seen in humans. As Pten-/- mice die 
during embryonic development, Pten+/− mice have been studied extensively. These mice are 
viable and develop neoplasms of the breast, prostate, adrenal medulla, endometrium, and 
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intestine, as well as lymphomas. Moreover, tissue specific deletion of Pten results in cancers of 
the breast, prostate, lung, bladder, and pancreas (Hollander et al., 2011). Deletion of Pten from 
the tumor microenvironment can have pro-tumor effects on tumor cells, in which Pten was not 
deleted (Trimboli et al., 2009) 
As a lipid phosphatase of the second messenger PIP3, PTEN is part of the PI3K/AKT signaling 
pathway, which is regarded as a key regulator in many essential cellular processes, including 
cell survival, growth, and differentiation. PI3K is comprised of the regulatory subunit p85, 
encoded by the PIK3R1 gene and the catalytic subunit p110, encoded by the PIK3CA gene 
(Skolnik et al., 1991). Both genes are frequently mutated, with PIK3CA being the second most 
altered gene across all cancer types (<10% frequency) and PIK3R1 being mutated in more than 
4% of cases (Kandoth et al., 2013; Lawrence et al., 2014). A pan-cancer study found that while 
PIK3CA and PIK3R1 mutations are mutually exclusive, they can occur together with mutations 
of PTEN (Kandoth et al., 2013) suggesting that activating alleles of PI3K are not equivalent to 
the loss of PTEN. The PI3K/AKT upstream regulator Ras, which directly binds to and activates 
the catalytic subunit of PI3K, is also repeatedly altered in cancer (>5% across all cancer types) 
(Gupta et al., 2007; Kandoth et al., 2013; Lawrence et al., 2014). Moreover, certain growth 
factor receptor complexes such as HER2/HER3 and EGFR/GAB1, which are able to activate 
PI3K in a context-dependent manner, are frequently modified across cancer types (Laffargue et 
al., 1999; Wallasch et al., 1995). Specifically, activating mutations and gene amplifications of 
EGFR are found in nearly 30% of glioblastomas (Verhaak et al., 2010) and in xenografts derived 
from breast cancer patients (Eirew et al., 2015). HER2, which is encoded by the ERBB2 gene, 
is amplified or mutated in up to 30% of breast cancers and is generally a marker for increased 
disease recurrence and poor prognosis (Mitri et al., 2012; Moasser, 2007). The activation of 
AKT, a direct downstream mediator of PI3K, is oftentimes achieved by the loss of PTEN or the 
activation of PI3K. However, amplifications or mutations of AKT isoforms AKT1 and AKT2 are 
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frequently seen in breast and endometrial cancers (Kandoth et al., 2013; Lawrence et al., 2014) 
and uterine, pancreatic, breast and prostate cancers (Cerami et al., 2012; Gao et al., 2013). 
Taken together with mutations of PI3K/AKT downstream effectors such as PDK1, TSC1/2 and 
mTOR, all of which are mutated more sporadically, the PI3K/AKT pathway is the most 
commonly altered signaling pathway in cancer. This has led to extensive studies towards the 
discovery of pharmacological interventions. 
Designing anti-cancer therapeutics directed against the loss of PTEN as a tumor suppressor 
has proven difficult, mostly resulting in strategies utilizing inhibitors of kinases that lie at the level 
of PI3K or downstream. Several inhibitors targeting all PI3K isoforms (pan-PI3K) are currently in 
clinical trials, but despite being reasonably well tolerated by patients, they have shown limited 
efficacy as single agents. This could in part be due to the activation of several compensatory 
pathways that have been shown to drive resistance to PI3K inhibitors (Mayer and Arteaga, 
2016). To minimize adverse reactions to pan-PI3K inhibitors, latest efforts tried to develop PI3K 
isoform-selective inhibitors. This is supported by recent findings from preclinical studies that 
have emphasized the divergent roles of class I PI3K catalytic isoforms depending on the genetic 
context. While HER2/Neu- and KRAS-driven tumors have been shown to rely mainly on p110α 
(Castellano et al., 2013; Utermark et al., 2012), a body of evidence suggests that certain PTEN-
deficient cancer cells rely on the p110β isoform, which is thought to be activated primarily by G 
protein-coupled receptors (GPCRs), to drive phosphatidylinositol signaling (Jia et al., 2008; Ni et 
al., 2012; Wee et al., 2008). Clinical testing of p110β-specific inhibitors in patients with PTEN-
deficient cancers is continued, although it is known that PI3K isoforms are able to compensate 
for each other (Dillon and Miller, 2014; Stratikopoulos and Parsons, 2016). Moreover, targeting 
kinases acting downstream of PTEN and PI3K has been of limited use due to a variety of 
adaptive and compensatory responses to these drugs within the cancer cells. For example, 
24 
 
early preclinical studies showed that inhibition of mTOR leads to an up-regulation of insulin 
receptor substrate 1 (IRS1), resulting in aberrant PI3K/AKT activation (O'Reilly et al., 2006).  
While agents targeting receptor tyrosine kinases (RTK) upstream of PI3K, such as HER2, have 
shown remarkable activity in certain cancer patients, PTEN deficiency seems to be associated 
with resistance to RTK inhibitors. In vitro this makes sense because if a PI3K antagonist such 
as PTEN is defective, then less PI3K activation from RTKs should be required to drive 
PIP3 signaling. However, the significance of PTEN status in RTK-targeted therapy remains 
controversial in the clinic. Trastuzumab (Herceptin; Genentech), a monoclonal antibody that 
binds to the extracellular domain of HER2 on the cell surface and disrupts HER2-HER3 
heterodimers, has shown remarkable activity in HER2+ breast cancer patients (Piccart-Gebhart 
et al., 2005; Romond et al., 2005). In PTEN deficient tumors it was historically considered less 
effective regardless of whether this agent was administered in neoadjuvant, adjuvant, or 
metastatic settings (Dave et al., 2011; Esteva et al., 2010; Razis et al., 2011). However, one 
study found that PTEN loss was associated with improved response to neoadjuvant treatment 
with the EGFR/HER2 kinase inhibitor Lapatinib (Tykerb; GlaxoSmithKline) followed by 
Trastuzumab (Dave et al., 2011). Contrary to the results of these smaller studies, a more recent 
study with more than 1000 patients revealed that PTEN status did not have an impact on 
disease-free-survival in patients treated with adjuvant chemotherapy plus Trastuzumab (Perez 
et al., 2013). Taken together it has become evident that in most cases therapeutical intervention 
with a single agent will eventually result in the activation of feedback and compensatory 
pathways and that combination therapies should be considered. In fact, clinical trials are 
currently evaluating preclinical findings of synergism between PI3K inhibition and anti-estrogen 
therapy, as well as inhibitors against PARP, CDK4 and 6, and mitogen-activated protein kinase 
kinase (MEK) (Stratikopoulos and Parsons, 2016). For example, PTEN loss can lead to defects 
in HR (Bassi et al., 2013; Shen et al., 2007) and this seems to sensitize PTEN-deficient cells 
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and tumors to inhibition of PARP. This was first reported using cell lines and xenografts, 
including breast, prostate, bladder and brain cancer cell lines and xenografts (Mendes-Pereira 
et al., 2009), as well as primary murine astrocytes, human glioma lines (McEllin et al., 2010) and 
human endometrioid endometrial carcinoma cell lines (Dedes et al., 2010). Moreover, results 
from early clinical studies suggested that some PTEN-deficient cancers may be sensitive to 
PARP inhibition, including advanced cancers of the prostate, treated with Niraparib (MK-4827; 
Tesaro) (Ogilvie-Michie et al., 2013) as well as metastatic endometrial cancers, treated with 
Olaparib (Lynparza; AstraZeneca) (Forster et al., 2011).  
Moreover, therapeutic strategies have been proposed to increase PTEN expression and/or 
phosphatase activity. These strategies include the use of statins, which promote the activity of 
the transcription factor peroxisome proliferator-activated receptor-gamma (PPARγ) leading to an 
upregulation of PTEN mRNA levels (Teresi et al., 2006). Another study recommends the use of 
demethylating agents to reverse epigenetic silencing of PTEN by methylation (Phuong et al., 
2011). Furthermore, it was suggested to use the mRNA of the PTEN pseudogene PTENP1 to 
sequester miRNAs repressing PTEN translation (Poliseno et al., 2010). Finally, therapies 
targeting PREX2a may be useful to de-repress PTEN phosphatase activity (Dillon and Miller, 
2014). 
 
PTEN and gene expression signatures 
Alterations in gene expression profiles upon loss and to a lesser degree upon over-expression 
of PTEN have been described previously. This includes, but is not limited to, the following 
studies, which all used microarray data analysis to identify the outcomes of PTEN alterations on 
gene expression.  
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Over-expression of PTEN in a lung cancer cell line led to gene expression changes and resulted 
in the inhibition of lung cancer invasion (Hong et al., 2000). In endometrial cancer cell lines 
over-expression of PTEN decreased cell proliferation through cell cycle arrest and apoptosis 
and led to the induction of genes implicated in cell proliferation, differentiation, apoptosis, or cell 
cycle control (Matsushima-Nishiu et al., 2001). 
Conversely, Pten deletion in MEFs identified the growth factor pleiotrophin (Ptn) as one of the 
most upregulated genes. Downregulation of Ptn by siRNA resulted in the reduction of Akt and 
GSK-3β phosphorylation as well as the suppression of growth and tumorigenicity of Pten-/- 
MEFs (Li et al., 2006). shRNA knockdown of PTEN in three carcinoma cell lines led to Jun N-
terminal kinase (JNK) activation and subsequent activation of JNK associated genes and this 
activation might sensitize PTEN deficient cells to JNK inhibition (Vivanco et al., 2007). 
Microarray analysis of mouse prostate tissues identified a reciprocal downregulation of PTEN 
and androgen receptor. This reciprocal downregulation could be exploited by the combined 
pharmacologic inhibition of PI3K and AR signaling, which caused near-complete prostate 
cancer regression in a Pten-deficient murine prostate cancer model (Carver et al., 2011). 
Microarray analysis of human prostate tissue, which often experiences PTEN loss, found 
RAS/MAPK pathway activation suggesting that co-targeting of the PTEN/PI3K/AKT and 
RAS/MAPK pathways could be a highly effective therapeutic strategy in patients (Mulholland et 
al., 2012).  
Lastly, one of the most comprehensive microarray analyses was performed by Saal et al., who 
analyzed the gene expression profiles of 105 patient-derived breast cancer samples (Saal et al., 
2007). They identified a gene expression signature characterized by the loss of PTEN, which 
was correlated with poor prognosis for carcinoma patients. Moreover, loss of PTEN expression 
led to the upregulation of biological processes such as cell cycle progression, DNA replication, 
mRNA processing and metabolism. Saal et al. concluded that the signature or its components, 
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for example, stathmin could be exploited clinically for the stratification of patients for anti-
PTEN/PI3K/AKT pathway therapy and subsequently for monitoring therapeutic efficacy. 
The mechanism of PTEN affecting gene expression has mostly been thought to function 
through the PI3K/AKT pathway. However, other models have been proposed. Although PTEN 
was reported to be a downstream transcriptional target of p53 in mediating apoptosis (Backman 
et al., 2001), other studies suggest that PTEN may act upstream of p53 (Freeman et al., 2003; 
Mayo and Donner, 2002). It has been shown that PTEN can increase p53 stability and its DNA 
binding activity by direct binding to p53 (Freeman et al., 2003). The physical association 
between PTEN and p53 was confirmed by further studies (Flores-Delgado et al., 2007; Tang 
and Eng, 2006). Additional evidence for the cross talk between PTEN and p53 came from 
Bilbao et al., who found PTEN to physically interact with p300 in the nucleus. p300 is an 
acetyltransferase, which maintains p53 in a highly acetylated state in response to DNA damage 
(Bilbao et al., 2006). In summary, all these studies suggest that PTEN can affect gene 
expression partly through the modulation of expression and activity levels of the transcription 
factor p53. 
To get mechanistical insights into how PTEN affects gene expression, Tibarewal et al. explored 
microarray data obtained from cell lines over-expressing wild type or phosphatase mutant PTEN 
(Tibarewal et al., 2012). While wild type PTEN altered the expression of a large number of 
transcripts, PTEN G129E, a lipid phosphatase dead PTEN mutant, caused modest changes in 
the expression of a small number of transcripts. Interestingly, PTEN Y138L, which has lipid 
phosphatase activity but no protein phosphatase activity and therefore can suppress cellular 
PIP3 levels and AKT activity, affected a large set of transcripts that were also responsive to wild 
type PTEN. However, PTEN Y138L failed to alter the expression levels of a significant group of 
transcripts that were the most responsive to wild type PTEN. Transcript levels either responded 
similarly to wild type PTEN and PTEN Y138L or only to wild type PTEN, indicating that the 
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protein phosphatase activity of PTEN has a positive regulatory effect on its lipid phosphatase 
activity. Moreover, the protein phosphatase activity is required for the auto-dephosphorylation of 
threonine 366 in the PTEN Tail-domain and this auto-dephosphorylation is necessary for a fully 
functional lipid phosphatase activity.  
More recently two groups linked PTEN loss-mediated gene expression alterations to a direct 
interaction of PTEN with histones and subsequent chromatin remodeling (Chen et al., 2014; 
Gong et al., 2015). Chen et al. found that loss of PTEN increased levels of H4K16ac, indicative 
of transcriptionally active chromatin and induced global gene expression changes. The increase 
in H4K16ac was dependent on the dissociation of histone H1, a novel interaction partner of 
PTEN, from chromatin and the subsequent decondensation of chromatin. Gong et al. also 
observed a decondensation of heterochromatin upon loss of PTEN, which was concomitant with 
a decrease in the heterochromatin mark H3K9me3, and a subsequent increase in transcription 
of highly repetitive satellite DNA elements. 
 
Overall, the link between PTEN loss and gene expression alterations seems to be well 
established. However, the exact mechanism of PTEN affecting transcription remains elusive. 
Gene expression can be regulated on multiple levels, for example, through DNA and chromatin 
modifications, regulation of transcription, post-transcriptional modifications of RNA, mRNA 
degradation and translation. How chromatin modifications affect gene expression and how gene 





Histone modifications and their functions 
The human genome comprises ~35,000 protein coding genes, only double the amount found for 
example in the fruit fly Drosophila melanogaster. This raises the question whether it could be 
DNA alone that is responsible for storing the full range of information that ultimately gives rise to 
complex eukaryotic organisms, such as Homo sapiens. And in fact, epigenetics, a phenomenon 
that changes gene expression or a cellular phenotype in a potentially stable and sometimes 
heritable manner without changing the underlying DNA sequence, adds many layers of 
complexity. Epigenetics includes, but is not limited to, post-translational modifications of 
histones, small proteins that package and order the DNA into structural units called 
nucleosomes. In each nucleosome 146 base pairs (bp) of DNA wrap in 1.67 left-handed 
superhelical turns around a core histone octamer consisting of an H3-H4 tetramer and two H2A-
H2B dimers (Luger et al., 1997). Histones are small globular proteins with unstructured, charged 
N-termini (histone “tails”) that possess a large number of residues, most notably lysines that can 
be post-translationally modified. There are at least eight distinct types of post-translational 
modifications (PTMs) found on histones including acetylation, phosphorylation, methylation, 
deimination, ADP ribosylation, proline isomerization, ubiquitination and SUMOylation 
(Kouzarides, 2007). Overall, histone modifications are thought to function through two distinct 
mechanisms. The first mechanism affects the higher-order chromatin structure by disrupting 
contacts between adjacent nucleosomes or interactions between histones and DNA resulting in 
a more open and accessible chromatin fiber. The second mechanism is the recruitment of non-
histone proteins, which often times carry enzymatic activities that further modify chromatin. 
Moreover, the recruitment of additional non-histone proteins provides a means to tightly regulate 
the different stages of processes such as transcription, DNA replication and DNA repair that 
may require a distinct type of chromatin-remodeling activity as well as a different set of 




Histone acetylation is thought to neutralize the positive charges of the lysine residues within the 
histone tails thereby causing the nucleosome to unfold, which increases the access for 
chromatin binding proteins such as transcription factors (Lee et al., 1993). Acetylation of histone 
lysine residues is a highly dynamic process and is mediated by the opposing actions of two 
families of enzymes, histone acetyltransferases (HATs), which encompass two major classes 
(type-A and type-B HATs) and histone deacetylases (HDACs), which encompass four classes 
(classes I-IV) (Sterner and Berger, 2000; Yang and Seto, 2007). The main acetylation sites on 
histone H3 are lysines 9, 14, 18 and 27 (Thorne et al., 1990) and lysines 5, 8, 12 and 16 on 
histone H4 (Grunstein, 1997). Histone acetylation is generally associated with the activation of 
transcription; however, it has become evident that some acetylation events are important for 
histone deposition and nucleosome assembly during DNA replication and heterochromatin 
maintenance (Grunstein, 1997). For example, by disrupting the interaction of the histone H4 N-
terminal tail with the acidic patch of a H2A/H2B dimer of an adjacent nucleosome, H4K16ac can 
interfere with the formation of a compact higher-order chromatin structure in vitro (Robinson et 
al., 2008; Shogren-Knaak et al., 2006). Consistent with these findings in vitro, deacetylation of 
H4K16ac was also shown to be important in heterochromatin formation in budding yeast (Millar 
et al., 2004). 
Histone acetylation has also been found on cis-regulatory elements, such as enhancers, which 
play a central role in driving cell-type-specific gene expression. Enhancers are short DNA 
sequences that are capable of activating transcription of their target genes independent of their 
orientation or distance (Bonn et al., 2012; Bulger and Groudine, 2011; Ong and Corces, 2011). 
A key feature of enhancers is the ability to provide binding platforms for transcription factors 
(TF). TFs recognize specific DNA sequences within the enhancer DNA and can recruit co-
activator proteins that often lack sequence-specific DNA binding competency and function as 
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histone modifiers, ATP-dependent chromatin remodelers, or mediators of long-range crosstalk 
with the basal transcription machinery at promoters (Calo and Wysocka, 2013). Enhancers 
exhibit high sensitivity to DNA nucleases, such as DNAse I (Gross and Garrard, 1988), and can 
be associated with nucleosomes containing specialized histone variants H3.3 and H2A.Z 
(Goldberg et al., 2010; Jin et al., 2009). Moreover, enhancers are characterized by the presence 
of several histone marks including H3K4me1 and H3K27ac (Wang et al., 2008). H3K4me1 was 
the first histone modification linked to cis-regulatory elements (Heintzman et al., 2007). 
Moreover, H3K4 mono-methylation often precedes significant nucleosomal depletion and 
enhancer activation suggesting that H3K4me1 partakes in enhancer priming (Creyghton et al., 
2010; Rada-Iglesias et al., 2011; Zentner et al., 2011). H3K27ac on the other hand is associated 
with active enhancers (Creyghton et al., 2010; Heintzman et al., 2009) but is almost invariably 
acquired in the context of pre-existing H3K4me1 (Bonn et al., 2012). Its distribution throughout 
the genome shows a high degree of cell-type specificity. H3K27ac is thought to be acetylated by 
two highly homologous HATs, E1A binding protein p300 (p300) and CREB-binding protein 
(CBP), that are used for genome-wide enhancer mapping (Jin et al., 2011; Tie et al., 2009). 
More recently, genome-wide studies of H3K27ac distribution have led to the identification of 
super-enhancers, which are clusters of enhancers characterized by the binding of high levels of 
master transcription factors and the Mediator complex. They are thought to drive high-level 
expression of genes encoding key regulators of cell identity (Hnisz et al., 2013; Loven et al., 
2013; Whyte et al., 2013). The high levels of expression of genes associated with super-
enhancers render these genes particularly sensitive to disruptions, which may explain their 
sensitivity to transcription inhibition (Chipumuro et al., 2014; Christensen et al., 2014; 




Histone methylation does not change the charge of the histone protein and predominantly 
occurs on the side chains of lysines, which can be mono-, di- or tri-methylated (Martin and 
Zhang, 2005) and arginines, which can be mono-, symmetrically or asymmetrically di-
methylated (Bedford and Clarke, 2009). Histone methylation is a process with a relatively slow 
turnover compared to other PTMs and was originally thought to be irreversible (Byvoet et al., 
1972). There are at least  two families of enzymes that catalyze the addition of methyl groups 
donated from S-adenosyl methionine (Murray, 1964) to lysines, the SET domain containing 
proteins (Rea et al., 2000) and Dot1 like proteins (Feng et al., 2002). These histone 
methyltransferases are highly substrate specific and can methylate histones incorporated in 
chromatin, free histones and non-histone proteins (Huang and Berger, 2008). The removal of 
methyl groups from lysines is catalyzed by two families of demethylases that also show high 
substrate specificity, the amine oxidases (Shi et al., 2004) and Jumonji C (JmjC) domain 
containing iron-dependent dioxygenases (Cloos et al., 2006; Tsukada et al., 2006; Whetstine et 
al., 2006). The diverse array of methylation events provides exceptional regulatory power and 
depending on the sites of methylation, it can signal either activation or repression of processes 
like transcription, heterochromatin formation, RNA splicing, DNA repair and cell cycle control 
(Greer and Shi, 2012). 
As mentioned previously, H3K4me1 was the first histone modification globally linked to distal 
regulatory regions such as enhancers (Heintzman et al., 2007). However, H3K4me1 is not 
unique to enhancers, as it is widely distributed and generally covers substantially broader 
regions than the underlying genetic enhancer elements. It also coincides with large 5′ portions 




H3K4me3 is usually found at the 5’-end of active genes, where it is associated with initiated 
RNA polymerase II phosphorylated at serine 5 (Santos-Rosa et al., 2002). Moreover, there is a 
strong correlation between H3K4me3 and transcription rates, active RNA polymerase II 
occupancy, and histone acetylation (Ng et al., 2003; Schneider et al., 2004). In mammalian 
genomes the H3K4me3 mark generally consists of localized to punctate sites; however, a 
unique pattern of H3K4me3 can be found over developmental gene clusters like the Hox gene 
cluster, where large regions of continuous H3K4me3 spanning multiple genes and intergenic 
regions are common (Bernstein et al., 2005). 
Methylation at H3K9 is implicated in the silencing of euchromatic genes as well as the formation 
of silent heterochromatin, the condensed, transcriptionally inactive state of chromatin 
(Kouzarides, 2007). The repression is facilitated by H3K9me3 binding and recruitment of the 
heterochromatin protein 1 (HP1), the protein responsible for the spreading and maintenance of 
heterochromatin (Bannister et al., 2001; Lachner et al., 2001). HP1 in turn recruits methylating 
enzymes, including DNA methyltransferases 1 and 3b (Dnmt1 and Dnmt3b) (Fuks et al., 2003), 
and also brings in further H3K9-methylating activity that modifies nucleosomes on the daughter 
strand, thus ensuring the transmission of the H3K9me3 mark (Maison and Almouzni, 2004). 
Recently it was shown that HP1α, a member of the HP1 family can interact with PTEN (Chen et 
al., 2014; Gong et al., 2015). Loss of this interaction results in a reduction in HP1α protein 
stability, a decrease in H3K9me3 levels, de-condensation of heterochromatin and a subsequent 
increase in transcription of highly repetitive satellite DNA elements (Gong et al., 2015). 
Another mark commonly associated with transcriptional repression is H3K27me3. The 
methyltransferase responsible for H3K27 tri-methylation is enhancer of zeste homolog 2 
(EZH2). EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is 
well known for its repression of genes involved in development and differentiation (Cao et al., 
2002). It was shown that AKT can phosphorylate EZH2 at serine 21 leading to a suppression of 
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its methyltransferase activity by impeding EZH2 binding to histone H3. This results in a 
decrease in H3K27me3 and the de-repression of silenced genes (Cha et al., 2005). Moreover, 
phosphorylation of EZH2 can switch its function from a polycomb repressor to a co-activator of 
critical transcription factors including the androgen receptor (AR) (Xu et al., 2012).  
H3K36me3 is found in actively transcribed regions. It is enriched in exons compared to introns 
and there are lower levels of H3K36me3 in alternatively spliced exons than in constitutively 
spliced exons (Kolasinska-Zwierz et al., 2009). Moreover, H3K36me3 can be found associated 
with the elongating form of RNA polymerase II phosphorylated at serine 2 and it is believed that 
H3K36me3 can support the suppression of inappropriate transcription initiation of RNA 
polymerase II from cryptic start sites within the coding region (Carrozza et al., 2005; Keogh et 
al., 2005). 
Modification Genomic distribution Functional association 
H3K4me1 poised enhancers, promoters enhancer priming, transcriptional 
activation 
H3K4me3 active promoters transcriptional activation 
H3K27me3 inactive promoters transcriptional repression 
H3K27ac active enhancers, promoters transcriptional activation, 
H3K9me1 heterochromatin, enhancers transcriptional repression, 
heterochromatin formation 
H3K9me3 heterochromatin transcriptional repression, 
heterochromatin formation 
H3K36me3 gene bodies transcriptional activation, RNA 
splicing 





Table 1: Histone modifications and their functions 
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Transcription: An overview 
Transcription is a tightly controlled process in which RNA polymerases (RNAPs) produce RNAs 
complementary to one strand of DNA. In eukaryotes there are three RNAPs, each of which is 
dedicated to transcribing a unique set of genes. RNA Polymerase I (RNAPI) transcribes the 
genes coding for the 18S and 28S rRNAs, whereas RNA Polymerase III (RNAPIII) transcribes a 
range of genes coding for structural or catalytic RNAs like tRNAs, the 5S rRNA, the U6 snRNA 
and some small nucleolar RNAs (snoRNAs) like the 7SK snRNA. RNA Polymerase II (RNAPII) 
is responsible for transcribing all protein-coding genes into mRNAs, which makes it the 
polymerase that produces the largest group of distinct individual RNAs. Additionally it 
transcribes genes encoding small non-coding RNAs like snRNAs, snoRNAs and miRNAs 
(Alberts et al., 2002).  
The transcription cycle of the processively transcribing RNAPII is divided into 4 stages, pre-
initiation, initiation, elongation and termination. Successful initiation and completion of each 
stage are dependent on a multitude of transcription factors and other proteins, specific 
sequences in the DNA as well as posttranslational modifications, that all contribute to the 
precise regulation of the transcription cycle (Alberts et al., 2002).  
Although all three RNAPs have similarity in structure and subunit configuration, only RNAPII 
possesses a unique C-terminal repeat domain (CTD) on its largest subunit Rpb1. The CTD is 
evolutionary conserved in fungi, plants and animals and is comprised of 25 to 52 tandem heptad 
repeats with the consensus sequence Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (Y1S2P3T4S5P6S7). 
Despite this domain’s uniqueness and the lethality of a CTD deletion in vivo, it is not essential 
for the catalytic activity of RNAPII during RNA synthesis in vitro (Corden, 1990). This suggests a 
role for the CTD as a regulatory element and indeed it could be shown that the CTD serves as a 
binding platform for a multitude of proteins including transcriptional regulators, mRNA-
processing enzymes and histone modifiers. To couple and coordinate the actions of all these 
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CTD binding proteins with specific stages of transcription, a dynamic pattern of posttranslational 
modifications, referred to as the CTD code, is required (Phatnani and Greenleaf, 2006).  
As suggested by the sequence of the heptad repeats, the CTD can be highly phosphorylated 
and it is now clear that the phosphorylation state changes depending on RNAPII’s progress 
through the transcription cycle. It was discovered early on that the CTD of Rpb1 exists in two 
main forms that migrate differently on SDS PAGE: a hypophosphorylated form, designated IIa 
migrating faster, and a hyperphosphorylated form, designated IIo migrating slower on SDS 
PAGE. The hypophosphorylated form, IIa, preferentially associates with the pre-initiation 
complex at the promoter, and in fact phosphorylation of the CTD before this point prevents 
recruitment and initiation. Pre-initiation is followed by several phosphorylation events, resulting 
in a hyperphosphorylated CTD, which is required for promoter clearance and transcript 
elongation (Buratowski, 2009). The most studied and best understood phosphorylation sites are 
serines 2 and 5 (Ser2 and Ser5); however phosphorylation of serine 7 and more recently 
tyrosine 1 and threonine 4  have also been reported to play important roles in transcription 
regulation (Chapman et al., 2007; Heidemann and Eick, 2012). To add even more layers to the 
complexity of CTD posttranslational modifications, serine and threonine residues can be 
glycosylated (Ranuncolo et al., 2012), lysine and arginine residues of non-consensus repeats 
can be ubiquitinated (Li et al., 2007) or methylated (Sims et al., 2011), respectively, and 
cis/trans-isomerization of Pro3 and Pro6 can contribute to changes in the CTD structure.  
 
Ser2 and Ser5 phosphorylation 
The availability of monoclonal antibodies with phosphorylation pattern-dependent specificities 
and the advent of chromatin immunoprecipitation (ChIP) greatly facilitated the characterization 
of the role of CTD phosphorylation in gene expression. The first commercially available 
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antibodies were directed against Ser2 and Ser5, which makes these two sites the best studied. 
The first major findings using ChIP experiments revealed that Ser5 phosphorylation (Ser5P) 
primarily occurs in promoter regions (Komarnitsky et al., 2000), whereas Ser2 phosphorylation 
(Ser2P) predominates in the coding region and at the 3’- end of a gene (Morris et al., 2005). 
During initiation Ser5 and Ser7 are phosphorylated by the cyclin-dependent kinase 7 (CDK7) 
(Akhtar et al., 2009; Komarnitsky et al., 2000). CDK7 together with cyclin H and Mat1 comprises 
the trimeric kinase-complex that can associate with the 10 subunit core complex of the basal 
transcription factor IIH (TFIIH). Formation of a pre-initiation complex (PIC), facilitated by the 
mediator complex, which together with other general transcription factors recruits 
hypophosphorylated RNAPII to promoters, strongly stimulates TFIIH’s kinase activity. After 
phosphorylation at Ser5 and Ser7 RNAPII is released from the promoter and begins 
transcription. Ser5P is also required for the recruitment of the mRNA capping enzyme, which 
binds directly to Ser5P residues (Fabrega et al., 2003). The proximity of the CTD to the mRNA 
exit channel ensures the ideal positioning of the capping machinery for rapid modification of the 
5’- end of the emerging mRNA. Moreover, the Ser5P mark is recognized by several histone 
modifiers that use the changing phosphorylation pattern to distinguish promoter-proximal and -
distal regions (Hampsey and Reinberg, 2003). Unlike the Ser5P mark, the role of the Ser7P 
mark is less well understood. It is clear that it is placed during initiation and remains stable until 
RNAP II reaches the polyadenylation site and that it is responsible for the recruitment of the 
integrator complex, which is involved in the expression and processing of snRNAs (Egloff et al., 
2007). When RNAPII enters productive elongation and proceeds towards the 3’- end of a gene, 
levels of Ser5P drop and levels of Ser2P increase, which results in both marks overlapping 
within the coding region. This double mark is important for activation of in vitro splicing and 
polyadenylation, as shown by in vitro experiments using a CTD phosphorylated at Ser2 and 
Ser5 (Hirose and Manley, 1998; Hirose et al., 1999). The important process of removing the 
Ser5P mark is despite substantial efforts and two known Ser5P phosphatases, Rtr1 and Ssu72, 
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still incomplete. Rtr1 was shown to be responsible for the removal of the Ser5P mark within the 
coding region where Ser5P and Ser2P overlap (Mosley et al., 2009). For Ssu72 there is 
evidence showing that it is a bona fide Ser5 phosphatase (Krishnamurthy et al., 2004), but its 
exact role during the CTD cycle remains enigmatic. As part of the cleavage and polyadenylation 
factor (CPF), Ssu72 is located far from the region where most of Ser5 dephosphorylation is 
thought to occur. Moreover, Ssu72 mutants do not affect promoter-proximal Ser5P levels. 
Taken together this might point to Ssu72 as the phosphatase responsible for removal of Ser5P 
further downstream of the transcription start site (TSS), during termination.  
After the removal of Ser5P, the Ser2P mark rises downstream of the TSS and is the prevailing 
phosphorylation mark. Historically, this mark was long considered to be solely dependent on 
CDK9, the kinase subunit of the positive elongation factor (P-TEFb) (Buratowski, 2009). This is 
in disagreement with findings in yeast, which possesses two different Ser2 kinases, Ctk1 and 
Bur1. Ctk1 was the first Ser2 kinase to be discovered in yeast and it was thought to be 
responsible for the bulk of Ser2 phosphorylation in vivo. However, Ctk1 is non-essential and 
coexists with the essential kinase Bur1. Bur1 stimulates elongation and suppresses aberrant 
initiation of transcription by acting on non-CTD substrates, such as the elongation factor Spt5 
(Liu et al., 2009). It can also phosphorylate Ser2 of the CTD (Murray et al., 2001) thereby 
stimulating subsequent Ser2 phosphorylation by Ctk1 (Qiu et al., 2009). With the identification of 
two new metazoan Ser2 kinases, CDK12 and CDK13, it became clear that the division of 
function between Bur1 and Ctk1 kinases in yeast may have been retained in higher organisms. 
CDK12 and CDK13 display CTD kinase activity in vitro and are associated with cyclin K. 
Moreover, CDK12 can phosphorylate Ser2 in vivo and is associated with elongating RNAPII, 
implying that it is the metazoan orthologue of Ctk1 (Bartkowiak and Greenleaf, 2011; Bartkowiak 
et al., 2010). Depletion of CDK12 or cyclin K in human cells leads to a reduction in total Ser2P 
levels and expression of select genes, including several DNA damage response genes (Blazek 
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et al., 2011), but global RNAPII transcription is not affected detectably in CDK12/cyclin K-
depleted cells. The exact function of CDK13 remains obscure. CDK9 phosphorylates Ser2 as 
well as the transcription elongation factors Spt4 and Spt5 and is presumed to be the metazoan 
orthologue of yeast Bur1. 
Ser2 phosphorylation is thought to play a major role in overcoming an early elongation block. It 
marks RNAPII molecules that are competent for long-range elongation, which is necessary to 
produce most mRNAs. In fact, Ser2P is generally not seen on non-expressed genes, that 
otherwise can carry the Ser5P mark and display RNAPII occupancy at the promoter (Margaritis 
and Holstege, 2008). Moreover, Ser2P seems dispensable for elongation of snRNAs and 
replication-activated histones genes, encoding relatively short RNAs, which are neither spliced 
nor polyadenylated (Medlin et al., 2005). Additionally to its importance during elongation, Ser2P 
plays an essential role in the coordination of mRNA splicing and the assembly of splicing 
complexes (Hirose et al., 1999) as well as the polyadenylation of the newly synthesized mRNAs 
(Hirose and Manley, 1998; Hsin and Manley, 2012). mRNA polyadenylation is generally tightly 
linked to transcription termination, and two Ser2P-binding proteins have been implied in 
facilitating this coupling. One of them is Pcf11, an essential polyadenylation factor that may help 
to tether the polyA machinery to the elongating RNAPII (Licatalosi et al., 2002; Meinhart and 
Cramer, 2004). The other Ser2P-binding protein is Rtt103, a member of the Rat1/Xrn2 complex. 
This complex displays 5′-to-3′ exonuclease activity that, upon cleavage of the nascent mRNA at 
the polyA site, is required for rapid degradation of the downstream mRNA resulting in 
transcription termination by the “torpedo” model (Kim et al., 2004; West et al., 2004). 
The phosphatase responsible for the removal of Ser2P is thought to be TFIIF-associating CTD 
phosphatase 1 (Fcp1). Although ChIP experiments found that Fcp1 was present on active 
genes at 5′- and 3′-ends and was shown to be capable of dephosphorylating both Ser2P and 
Ser5P (Lin et al., 2002), global analyses located higher levels of Fcp1 primarily in promoter-
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distal regions indicating that Fcp1 prefers Ser2P (Cho et al., 2001). Taken together with the 
discovery that mutations in Fcp1 led to increased levels of Ser2 phosphorylation (Bataille et al., 
2012), it seems likely that Fcp1 is responsible for dephosphorylating Ser2P at the end of the 
transcription cycle, thereby restoring RNAPII to its hypophosphorylated state and making it 
available for the next round of transcription.  
 
(Hsin and Manley, 2012) 
Figure 1.3: Dynamic modification of the CTD during the transcription cycle. 
During transcription initiation, CDK7 phosphorylates the RNAPII CTD at Ser5 and Ser7. During 
elongation, CDK9 and most likely CDK12 phosphorylate the RNAPII CTD at Ser2, while the phosphate 
groups on Ser5 and Ser7 are gradually removed by phosphatases. Rtr1 and Ssu72 are the most likely 
phosphatases to remove Ser5P; Ssu72 also removes Ser7P. As RNAPII nears termination, the 
phosphatase Fcp1 dephosphorylates Ser2P regenerating hypophosphorylated RNAPII, which can be 
recycled for subsequent rounds of transcription. 
 
 
Regulation of transcription by TFIIH, P-TEFb and the super elongation complex 
The first step in gene expression is the formation of a PIC at the double-stranded promoter 
DNA. As part of the PIC hypophosphorylated RNAPII is guided to the promoter by several 
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general transcription factors that recognize specific DNA sequence elements within the core 
promoter, including TATA, initiator, and the downstream promoter element (DPE). After binding 
of the double-stranded promoter DNA, transcription is initiated by the local melting of the 
promoter DNA. This melting is facilitated by the large multi-subunit complex TFIIH, which 
contains ATP-dependent helicases that open the double-stranded DNA so that is accessible for 
RNAPII to initiate RNA synthesis at the +1 transcription start site. However, this synthesis is 
initially inefficient and often leads to the production of short, aborted RNAs. For RNAPII to enter 
the main body of the gene and produce a full-length transcript, promoter clearance is required. 
This depends on the phosphorylation of the RNAPII CTD by TFIIH-associated kinase CDK7 and 
other general transcription factors such as the mediator complex (Buratowski, 2009).  
CDK7 is an interesting and multifarious kinase that, as a CDK-activating kinase (CAK) and as 
part of TFIIH, plays an essential role in both the regulation of the cell cycle as well as 
transcription. CDK7 can exert its kinase function in a minimal complex together with cyclin H, 
and the RING-finger protein Mat1 (Devault et al., 1995; Tassan et al., 1995), but it is also found 
in quaternary complexes with the DNA helicase XPD/ERCC2 and in the 10-subunit TFIIH 
complex (Serizawa et al., 1995; Shiekhattar et al., 1995). In vitro CDK7 can phosphorylate the 
activation loops of many cell cycle CDKs including the three interphase CDKs, CDK2, CDK4 
and CDK6 and the mitotic CDK, CDK1 (Malumbres and Barbacid, 2009). This ability allows 
CDK7 to regulate the timing of activation and cyclin-binding preferences of different CDKs 
during the cell cycle in vivo. During transcription, CDK7 functions as both a positive regulator of 
transcription by phosphorylating RNAPII CTD and CDK9 in the P-TEFb complex and as a 
negative regulator responsible for the recruitment of the negative elongation factor (NELF) 
(Fisher, 2005, 2012).  
Historically, transcription regulation was thought to mainly occur during the recruitment step of 
the transcription cycle and the formation of a PIC. However, this model has to be reconsidered 
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after recent findings in metazoan systems revealed that much of the transcription regulation 
occurs well after the recruitment of RNAPII to promoters through the control of pausing and the 
efficiency of early elongation (Adelman and Lis, 2012). In fact, it has now become clear that on 
many developmentally regulated genes RNAPII arrests just after promoter clearance, typically 
∼30–40 nucleotides downstream of the transcription start site (TSS) (Levine, 2011). Promoter-
proximal pausing is mediated by the action of pause factors, including 5,6-dichloro-1-β-d-
ribofuranosylbenzimidazole (DRB) sensitivity-inducing factor (DSIF) and NELF (Yamaguchi et 
al., 1999), the recruitment of which is promoted by TFIIH kinase activity. Release of the paused 
RNAPII from the proximal promoter to start productive elongation requires the kinase activity of 
P-TEFb (Marshall and Price, 1995). P-TEFb phosphorylates NELF and Spt5, a component of 
DSIF, causing NELF to dissociate from RNAPII and transforming DSIF to a state that promotes 
RNAPII elongation (Yamada et al., 2006). Furthermore, P-TEFb phosphorylates serine residues 
within the RNAPII CTD, creating a platform for binding of RNA-processing factors and 
chromatin-modifying factors (Peterlin and Price, 2006). The active P-TEFb complex contains the 
kinase CDK9 as a catalytic subunit and cyclin T1 or cyclin T2 as regulatory subunits (Peng et 
al., 1998). P-TEFb can be part of several multi-subunit complexes including the super 
elongation complex (SEC). The SEC contains the ELL family members ELL1, ELL2 and ELL3, 
AF4/FMR2 family member 1 (AFF1), AF4/FMR2 family member 4 (AFF4), eleven-nineteen 
leukaemia (ENL), ALL1-fused gene from chromosome 9 (AF9), and the RNAPII elongation 
factor P-TEFb (Lin et al., 2010). AFF4 is the scaffold for assembling the SEC and it mediates 
the interactions between P-TEFb, ENL, AF9 and ELL. AFF4 belongs to the mammalian AFF 
family, with additional members AFF1, AFF2 (also known as FMR2) and AFF3 (also known as 
LAF4). All members of the family share conserved functional domains, including an N-terminal 
homology domain, a C-terminal homology domain, an AF4/LAF4/FMR2 (ALF) domain, 
mediating the interaction with SIAH ubiquitin ligases, as well as a serine-rich transactivation 
domain involved in transcriptional activation (Luo et al., 2012).  
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The activity of P-TEFb is tightly regulated and the first level of control is accomplished by the 
differential expression of the P-TEFb subunits. Moreover, to achieve full enzymatic activity of P-
TEFb, CDK7 phosphorylates threonine 186 located in the activation loop (T loop) of CDK9 
(Larochelle et al., 2012). Interestingly, phosphorylation of the T loop also facilitates binding to 
the inhibitory 7SK snRNA, which is transcribed by RNAPIII and builds the core of the 7SK small 
nuclear ribonulceoprotein (7SK snRNP) (Nguyen et al., 2001; Yamada et al., 2006; Yang et al., 
2001). Additional components of this inhibitory complex are hexamethylene bisacetamide-
inducible proteins 1 and 2 (HEXIM1 and HEXIM2), which form homo- or heterodimers that 
undergo a conformational change upon binding to 7SK snRNA enabling them to bind P-TEFb 
(Byers et al., 2005; Yik et al., 2003). The inactive complex between HEXIM, P-TEFb, and 7SK 
snRNA predominates in many cells. Although the exact mechanism of P-TEFb release from this 
complex is not known it is interesting to note that P-TEFb can be released when transcription is 
dramatically inhibited, for example, when cells are treated with UV light, actinomycin D, or P-





CHAPTER 2: PTEN, gene expression and chromatin modifications 
Introduction 
Conserved in all organisms, gene expression is the universal process by which information 
stored in the DNA is used in the synthesis of functional gene products. These are often proteins, 
but can also be functional RNAs, for example rRNAs or tRNAs. If the end product is a protein, 
gene expression is divided into the following tightly regulated steps; transcription, in which DNA 
is transcribed into mRNA, followed by mRNA processing and export and finally translation, in 
which the mature mRNA is translated into a protein (Alberts et al., 2002). Although the entire 
process from DNA to protein is referred to as gene expression, in this chapter we use the term 
gene expression when discussing the production of mRNA.  
Gene expression can be controlled through a multitude of mechanisms including the regulation 
of DNA and chromatin modifications, transcription, post-transcriptional modifications of RNA, 
mRNA degradation, or the regulation of translation (Alberts et al., 2002). Chromatin 
modifications are post-translational modifications (PTMs) found on histones, which form the 
basis for epigenetic regulation. Epigenetics is a phenomenon that changes gene expression or 
a cellular phenotype in a potentially stable and sometimes heritable manner, but without 
changing the underlying DNA sequence. There are at least eight distinct types of PTMs found 
on histones including acetylation, phosphorylation, methylation, deimination, ADP ribosylation, 
proline isomerization, ubiquitination and SUMOylation (Kouzarides, 2007). The best studied and 
understood modifications occur on the tails of histones H3 and H4 and include lysine acetylation 
and methylation. Overall, histone modifications are thought to influence gene expression 
through two distinct mechanisms. They can recruit non-histone proteins such as transcription 
factors and histone modifiers, which carry enzymatic activities that further modify chromatin. 
Moreover, they can influence the higher-order chromatin structure. For example by disrupting 
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contacts between adjacent nucleosomes or interactions between histones, histone modifications 
can render DNA more open and accessible to the transcription machinery (Kouzarides, 2007). 
As lipid phosphatase of the second messenger PIP3, PTEN is part of the PI3K/AKT pathway, 
which is regarded as a key regulator of many essential cellular processes including cell survival, 
growth, and differentiation. It is well established that activation of the pathway after loss of 
PTEN leads to gene expression alterations (Carver et al., 2011; Li et al., 2006; Mulholland et al., 
2012; Vivanco et al., 2007), which can be summarized in distinct PTEN loss signatures (Saal et 
al., 2007). However, effects of PTEN loss on gene expression independent of the PI3K/AKT 
pathway are less well studied. However, the protein phosphatase activity of PTEN seems to be 
necessary for its full effect on gene expression as a phosphatase dead mutant of PTEN does 
not affect gene expression to the same degree as wild type PTEN (Tibarewal et al., 2012). More 
recently two studies linked PTEN loss mediated gene expression alterations to a direct 
interaction of PTEN with histone proteins and subsequent chromatin remodeling (Chen et al., 
2014; Gong et al., 2015). Loss of PTEN, either by increasing the activating histone mark 
H4K16ac or decreasing the heterochromatin mark H3K9me3, led to a decondensation of 
chromatin resulting in an increase of gene expression. However, the exact mechanism of how 
PTEN affects gene expression remains elusive. 
 
In this chapter, we will establish a genetically unbiased model system to study the effects of 
PTEN loss on gene expression and chromatin modifications. In doing so, we hope to better 
understand PTEN’s PI3K/AKT-dependent as well as PI3K/AKT-independent functions in the 






Pten can be deleted in primary mouse embryonic fibroblasts 
To study the effects of PTEN loss we first wanted to identify a suitable model organism. There 
are a number of cell lines from which isogenic pairs have been derived that only differ in their 
PTEN genotype. However, most of these cell lines are cancer cell lines that have been 
passaged many times and in addition to the PTEN deletion are likely to contain many other 
genetic alterations, which could interact with or mask the effects of PTEN loss. We therefore 
decided to establish an unbiased model system without underlying genetic alterations, in which 
we could easily ablate PTEN expression. We choose primary mouse embryonic fibroblasts 
(MEFs) that were not immortalize and that were passaged less than 8 times. MEFs were 
isolated from Ptenfl/fl mice, which possess loxP sites flanking exon 5 of the endogenous locus of 
Pten (Lesche et al., 2002) (Fig. 2.1 A). After extracting the Ptenfl/fl embryos, we isolated 
fibroblasts and grew them as adherent cells. Addition of CMV-Cre-recombinase led to the 
recombination of the loxP sites, which deleted exon 5 of Pten thereby preventing Pten 
expression resulting in Pten-/- MEFs (Fig 2.1 A and B). Addition of a CMV-Null virus, which does 
not contain a functional Cre-recombinase enzyme, does not affect the endogenous locus of 
Pten, resulting in Pten WT MEFs, which we use as our control cells (Fig 2.1 A and B). 
Moreover, as we derived Pten WT and Pten-/- MEFs from the same embryo we created isogenic 
cell lines that only differ in their PTEN genotype. 
The Adeno-virus system displayed very high efficiency of Pten deletion as shown by western 
blot data. We found that almost 100% of Pten was no longer expressed as early as one 
passage after addition of the Cre-recombinase virus and was undetectable three passages after 
infection (Fig 2.2 A). In immunofluorescence (IF) experiments, cytosolic Pten was lost one 
passage after infection. Nuclear Pten remained visible in more than 50% of the cells at one 
passage, but this signal was undetectable after three passages (Fig 2.2 B). This finding 
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prompted us to perform experiments using Pten WT and Pten-/- MEFs that had been passaged 
at least 3 times after infection, to allow for the complete depletion of nuclear Pten. 
qRT-PCR revealed a 50% reduction in Pten mRNA transcript levels as early as one passage 
after infection and mRNA levels did not decrease further in later passages (Fig 2.2 C). It is 
possible that, despite deleting exon 5 of Pten, transcription of alternative mRNA transcript still 
occurs. These transcripts could be detected by qRT-PCR primers targeting a sequence located 
in exon 6 of the endogenous Pten locus. However, as exon 5 encodes the important 
phosphatase domain of PTEN and we did not detect any Pten protein expression, we were 
confident that the mRNA we detected is not translated into functional Pten protein. 
 
Pten deletion leads to gene expression alterations 
As discussed in the introduction (see Chapter 1, “PTEN and gene expression”) it has been well 
documented that loss of PTEN leads to gene expression alterations. To gain further insights into 
these changes, we generated microarray expression data from four isogenic pairs of Pten WT 
and Pten-/- MEFs. The array consisted of 24758 probes, of which 3477 were significantly 
upregulated and 3998 were significantly downregulated in the Pten-/- MEFs. The top 25 up and 
down-regulated genes are summarized in Fig 2.3 A. 
To ensure the reproducibility of our microarray data we verified the expression changes of two 
up- and two downregulated genes (Agtr2 and Apod were upregulated and Maob and Irs2 were 
downregulated in Pten-/- MEFs) in an independent pair of Pten WT and Pten-/- MEFs using qRT-




Gene set enrichment analysis (GSEA) 
To identify pathways as well as biological processes that are altered in Pten-/- MEFs we 
performed gene set enrichment analysis (GSEA) (Subramanian et al., 2005). As a good first 
characterization, we performed GSEA using pre-defined hallmark gene sets (Liberzon et al., 
2015). This is a collection of 50 gene sets which are part of “the Molecular Signature Database” 
(MSigDB) maintained by the GSEA team. These gene sets were generated by computational 
methodology based on gene set overlaps to summarize and represent specific well-defined 
biological states or processes.  
While in the Pten WT MEFs only one gene set (“APICAL_JUNCTION”) was significantly 
enriched, we find 23 out of 50 gene sets significantly enriched in the Pten-/- MEFs. These gene 
sets include cell cycle checkpoints (“G2M_CHECKPOINT” and “MITOTIC_SPINDLE”), 
pathways commonly altered in cancer (“E2F_TARGETS”, “MYC_TARGETS_V1 and V2”, 
“MTORC1_ SIGNALING”, “IL6_JAK_STAT3_SIGNALING”, “TNFA_SIGNALING_VIA_NFKB”, 
“KRAS_SIGNALING_UP” and “P53_PATHWAY”) but also metabolism (“GLYCOLYSIS”) and 
DNA repair (“DNA_REPAIR”) (Fig 2.3 C). The majority of these pathways and biological 
processes are altered in human cancers indicating that MEFs provide a good model system that 
can recapitulate disease-related processes occurring in humans. 
Moreover, we found an important PTEN loss signature significantly enriched in our Pten-/- MEFs 
(Fig 2.4 A). The signature was generated from 105 patient-derived breast cancer samples and 
is associated with poor prognosis in patients (Saal et al., 2007). This validated the strength of 
our model system even further, making us confident that the model system we choose, despite 
originating from a different organism, reflects gene expression changes seen in human 
samples. 
Furthermore, we performed in-depth analysis of our expression data using gene ontology (GO) 
enrichment analysis. GO-terms are divided into three domains, “cellular component”, “molecular 
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function” and “biological process”. Using the “molecular function” domain, which encompasses 
activities of gene products at the molecular level, for example binding or catalysis, we found 
GO-terms including translational repression (“TRANSLATION_REPRESSOR_ACTIVITY”, 
“TRANSLATION_REGULATORY_ACTIVITY”) and GO-terms related to phosphatidylinositide-
kinase activity (“PHOSPHATIDYLINOSITOL_KINASE_ACTIVITY”, “PHOSPHATIDYL-
INOSITOL_PHOSPHATE_KINASE_ACTIVITY” and “PHOSPHATIDYLINOSITOL_3_PHOS-
PHATE_BINDING”) significantly enriched in the Pten WT MEFs (Fig 2.4 B upper panel). In the 
Pten-/- MEFs significantly enriched GO-terms included gene sets related to DNA binding, 
replication and repair (“SINGLE_STRANDED_DNA_BINDING”, “HELICASE_ACTIVITY”, 
“ENDODEOXYRIBO-NUCLEASE_ACTIVITY”, “NUCLEASE_ACTIVITY”, “DAMAGED_DNA_ 
BINDING”, “ENDONUCLEASE_ACTIVITY”, “NUCLEOTIDYLTRANSFERASE_ACTIVITY”). We 
also found the GO-term “NUCLEOSOME_BINDING” significantly enriched in our Pten-/- MEFs, 
suggesting that the loss of Pten could affect chromatin (Fig 2.4 B lower panel).  
More evidence linking PTEN, gene expression and chromatin modifications was provided by Xu 
et al. (Xu et al., 2012). EZH2, the catalytic subunit of the polycomb repressive complex 2 
(PRC2) is primarily known for its function in silencing gene transcription by trimethylating lysine 
27 on histone H3 (Cao et al., 2002). However, upon phosphorylation of EZH2 at serine 21, 
mediated by AKT, a functional switch occurs in EZH2 resulting in its transition from a 
transcriptional repressor to a co-activator of critical transcription factors and other genes. As 
loss of PTEN typically increases AKT activity we were not surprised to find the gene set “EZH2-




Pten affects the expression of a subset of genes in a PI3K/AKT-independent 
manner 
To separate the influence of Pten loss on gene expression into PI3K-dependent and 
independent effects, we generated mRNA-Seq expression data from three isogenic pairs of 
Pten WT and Pten-/- MEFs that were treated with 1 µM of GDC-0941 or DMSO for 12h. 
Immunoblotting analysis of lysates taken from treated and untreated cells confirmed the 
efficiency of the Pten deletion and showed an increase in phosphorylated AKT at Ser473 in 
Pten-/- MEFs compared to Pten WT MEFs. GDC-0941 treatment abolished the phosphorylation 
of AKT at Ser473 completely in Pten WT MEFs and lowered phosphorylation levels to nearly 
undetectable levels in Pten-/- MEFs (Fig 2.5 A). 
To isolate PI3K-dependent genes we identified 716 transcripts that were significantly 
upregulated by more than 15% in DMSO treated Pten-/- MEFs compared to DMSO treated Pten 
WT MEFs. Of these 716 genes, 208 genes were significantly downregulated in GDC-0941-
treated PTEN-/- MEFs compared to DMSO treated PTEN-/- MEFs. We used the list of 208 PI3K-
dependent genes for GO-term enrichment analysis using the “biological process” domain and 
found GO-terms related to DNA replication (“DNA replication initiation”, “DNA replication” and 
“DNA-dependent DNA replication”), protein transport (“nucleo-cytoplasmic transport”, “nuclear 
transport” and “protein import”), and cell cycle (“cell cycle”) significantly enriched (Fig 2.5 B). 
To isolate PI3K-independent genes we identified 885 transcripts that were significantly 
upregulated by more than 15% in GDC-0941-treated Pten-/- MEFs compared to DMSO treated 
Pten WT MEFs.  
Overall, we observed fewer upregulated genes in DMSO treated Pten-/- MEFs (716 genes) than 
in GDC-0941-treated Pten-/- MEFs (885 genes) and this discrepancy was mainly due to 182 
genes that were significantly upregulated by the GDC-0941 treatment alone. 
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Of the 885 transcripts that were upregulated in GDC-0941-treated Pten-/- MEFs, 653 were not 
significantly affected by GDC-0941. We used those 653 transcripts to compile a list of PI3K-
independent genes and performed GO-term enrichment analysis using the “biological process” 
domain. We found GO-terms related to general cellular processes (“cell adhesion”, 
“developmental process”, “regulation of signal transduction”, “sensory perception” and “cell 
differentiation”) but also gene expression (“regulation of gene expression”, “regulation of RNA 
biosynthetic process”, “regulation of transcription, DNA-templated” and “regulation of 
transcription from RNA polymerase II promoter”) significantly enriched (Fig 2.5 C). This 
indicates that there is a component of PTEN regulation of gene expression that is independent 
of its role in the PI3K/AKT pathway. 
 
Pten deletion does not affect chromatin modifications globally 
Gene expression can be regulated by histone modifications. We therefore examined whether 
loss of Pten in MEFs affects chromatin modifications globally. We choose several antibodies 
raised against chromatin marks, which we thought to represent a good cross-section of the 
different functional groups of chromatin modifications; H3K4me3 marks active promoters, 
H3K36me3 marks gene bodies of actively transcribed genes, H3K27me3 is found on silenced 
chromatin, H3K27ac marks promoters and active enhancers, and H4K16ac marks 
transcriptional activation but can also be found to silence certain genomic regions. We took 
whole cell lysates of one pair of Pten WT and Pten-/- MEFs for four consecutive passages 
starting with the first passage after infection and analyzed these lysates for their levels of 
H3K4me3, H3K36me3, H3K27me3, H3K27ac and H4K16ac by immunoblotting. Overall, we 
found no gross difference in the levels of these chromatin marks between Pten WT and Pten-/- 
MEFs (Fig 2.6 A), indicating that the loss of Pten in early passage MEFs does not lead to global 
changes in these chromatin modifications. 
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It has previously been reported that loss of Pten in MEFs leads to a reduction in the 
heterochromatin mark H3K9me3 (Gong et al., 2015). To determine if we could make similar 
observations in our model system we took whole cell lysates from three different isogenic pairs 
of Pten WT and Pten-/- MEFs that had been passaged 4 times after infection. Immunoblotting 
analysis of H3K9me3 and H3K9me1, a precursor of H3K9me3, did not show a difference in the 
H3K9me1 mark between Pten WT and Pten-/- MEFs, but revealed a slight increase in the 
H3K9me3 mark in two of the three Pten-/- MEF samples (Fig 2.6 B). 
 
Native ChIP-Seq 
The absence of global differences in chromatin marks raised the question whether the deletion 
of Pten could result in a loss or gain of histone marks at a few key genes or genomic regions. 
To answer this question we performed native chromatin immunoprecipitation followed by 
massively parallel DNA sequencing (native ChIP-Seq). Native ChIP-Seq does not rely on the 
cross-linking of chromatin. This leads to greater antibody specificity and chromatin recovery 
efficiency and allows for very small amounts of input material compared to conventional ChIP. 
However, native ChIP can only be used for proteins that covalently bind to chromatin, such as 
histone modifications. We used a native ChIP protocol adapted from Umlauf et al. (Umlauf et al., 
2004), which is outlined in Figure 2.7. First, we harvested cells by trypsinization, followed by 
gentle cell lysis and isolation of nuclei by differential centrifugation through a sucrose cushion. 
Obtaining chromatin fragments of one to five nucleosomes in length is a critical step in the 
native ChIP protocol as optimal sequencing results using the Illumina technology are dependent 
on the process of cluster generation, which in turn is dependent on the size of the DNA 
fragments. In general, shorter fragments amplify more efficiently than longer fragments and 
longer library inserts generate larger, more diffuse clusters (Head et al., 2014).  
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We used the enzyme micrococcal nuclease (MNase) to shear the chromatin and obtain optimal 
fragment length for sequencing. MNase is an endonuclease that digests any DNA, but used at 
specific concentrations will preferentially cut the most accessible chromatin, which is the linker 
DNA connecting the nucleosomes thereby releasing DNA fragments of about 150 bp. To obtain 
chromatin fragments of, on average, one to five nucleosomes in length, we optimized the 
amount of MNase units used per µg of chromatin by performing partial MNase digestions using 
increasing amounts of the MNase enzyme. With increasing amounts of MNase units per µg of 
chromatin the ratio of mono-nucleosomes to poly-nucleosomes increased in a similar manner 
for Pten WT and Pten-/- MEFs (Fig 2.8 A and  B). Using 0.05 units of MNase/µg, poly-
nucleosomes were the predominant species, which as mentioned above are not optimal for 
sequencing. On the other hand, 0.08 units of MNase/µg of chromatin led to an over-digestion of 
the chromatin resulting in DNA fragments that are too short for sequencing. We, therefore, 
choose an intermediate amount of MNase of 0.065 units/µg of chromatin for Pten WT and Pten-/- 
MEFs for all native ChIP experiments performed in this research study. 
After MNase digestion the native ChIP protocol is identical to conventional ChIP protocols with 
the exception that no reverse-crosslinking is required (Fig 2.7). Using two isogenic pairs of Pten 
WT and Pten-/- MEFs we performed IPs with antibodies raised against chromatin marks 
H3K4me1, H3K4me3, H3K36me3, H3K27me3 and H3K9me3 and H3K27ac. All IPs yielded 
sufficient amounts of DNA for library preparation and subsequent massively parallel 
sequencing. For all histone marks high depth sequencing coverage was obtained for one 
isogenic pair of MEFs, termed “discovery data set”. To validate our findings we obtained lower 
depth sequencing coverage for the second isogenic pair of MEFs, termed “validation data set”. 
“Bowtie”, an ultrafast, memory-efficient short read aligner (Langmead et al., 2009) was used to 
align reads that passed quality control to the mouse genome (NCBI37/mm9). The numbers of 
sequenced and processed reads for each histone mark for the discovery as well as the 
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validation data sets are summarized in Figure 2.9 A. The discrepancy of sequenced and aligned 
reads varied for each condition and this was mainly due to the removal of reads that could not 
be mapped uniquely. 
IP efficiency as well as antibody specificity can be assessed by analyzing the relative 
distribution of mapped reads across the genome. In the Input sample, which should represent a 
random cross-section through the genome, reads predominantly mapped to intergenic and 
repeat regions, and less than 25% of reads mapped to introns and exons (Fig 2.9 B 1st panel). 
H3K27me3, H3K9me3, and H3K27ac samples showed a similar distribution as the Input sample 
(4th, 5th, and last panel). H3K27me3 is a repressive broad chromatin mark that does not form 
sharp peaks but rather extends over large genomic areas from inactive promoters far into 
intergenic regions. H3K9me3 also represents a repressive, broad chromatin mark, which is 
found on heterochromatin. H3K27ac is usually found in sharp peaks on active promoters and 
enhancers, which oftentimes lie in intergenic regions. Moreover, the H3K27ac antibody 
displayed a higher background signal, which could account to some extend for the abundance 
of reads mapping to repeat and intergenic regions. In the H3K4me3 and H3K36me3 samples 
approximately 40% of reads mapped to introns and exons (2nd and 3rd panel). H3K4me3 is 
mainly found on active promoters, which lie in or near genes and H3K36me3 is mostly found on 
active gene bodies. In the H3K4me1 samples approximately 30% of reads mapped to introns 
and exons (Fig 2.9 B 6th panel). H3K4me1 marks active and poised enhancers, and is therefore 
predominantly found near promoters of transcriptionally active and inactive genes. Overall, we 
established sufficient antibody specificity and IP efficiency resulting in high quality data for 
subsequent analysis. 
Although, we have demonstrated the high efficiency of our Cre-recombinase-based Pten 
deletion system using immunoblotting and immunofluorescence experiments (Fig 2.2 A and B), 
we additionally ascertained Pten deletion on a genomic level. Examination of the H3K36me3 
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mark at the endogenous Pten locus (Fig 2.9 C) confirmed the absence of H3K36me3 reads at 
exon 5 in the Pten-/- MEF sample, indicating that Cre-recombinase had deleted the DNA at the 
genomic locus (Fig 2.9 D). 
 
Pten loss alters histone marks at select genes 
To analyze our native ChIP-Seq data, we first determined whether the expression levels of 
select genes correlated with the ChIP-Seq enrichment profiles of RNAPII, H3K4me3, 
H3K36me3, H3K27ac and H3K4me1. Based on our microarray data we selected Dpt, which is 
the most upregulated gene and Fam150a, which is the most downregulated gene in Pten-/- 
MEFs for analysis. In accordance with their expression levels, Dpt had higher levels of 
H3K4me3, H3K36me3 and H3K27ac in the Pten-/- MEFs, whereas Fam150a had higher levels 
of these histone marks and H3K4me1 in the Pten WT MEFs (Fig 2.10 A and B). We also 
analyzed the histone profiles of two genes, E2f1 and Myc, which represent two of the top gene 
lists that were enriched in our Pten-/- MEF microarray data (Fig 2.3 C). For E2f1 levels of RNAPII 
and all histone marks were comparable between Pten WT and Pten-/- MEFs (Fig 2.10 C). For 
Myc we observed significantly higher levels of RNAPII and slightly increased levels of H3K4me3 
and H3K36me3 in the Pten-/- MEFs and slightly higher levels of H3K27ac in Pten WT MEFs (Fig 
2.10 D). Overall, our data suggest that the Pten status of a cell can affect levels of histone 
marks and RNAPII on certain genes.  
 
Pten loss increases levels histone marks H3K36me3, H3K27me3 but not 
H3K9me3 
We analyzed the data for each histone mark using two different approaches. Using software 
designed for peak calling we identified areas in the genome that showed enrichment of aligned 
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reads when compared to the Input control. By comparing peaks called with a certain 
significance cut-off between Pten WT and Pten-/- MEFs, unique regions and their associated 
genes could be determined. However, it has to be noted that unique peaks represent peaks that 
were called significant in one genotype without reaching significance level in the other genotype, 
which does not imply a complete absence of the peak in the latter genotype. 
In the second approach we compared profiles of the average enrichment of reads for each 
histone mark over a given set of genes or otherwise defined genomic regions. Based on RNA-
Seq data, we obtained from 4 pairs of isogenic Pten WT and Pten-/- MEFs, we classified genes, 
for which 2 rpkm, or more, were reported as expressed. Genes, for which less than 2 rpkm were 
reported were classified as not expressed. Expressed genes were then ranked from most 
upregulated to most downregulated in Pten-/- MEFs and subdivided into quartiles resulting in 
upregulated genes (first quartile), unchanged genes (second quartile) and, downregulated 
genes (third quartile). We created bed-files based on these classifications, which were then 
used to generate profiles of the average enrichment of reads for each histone mark. 
SICER, an algorithm designed to call peaks, also referred to as islands, for broad histone 
marks, identified almost 13000 H3K36me3 islands with a significance cut-off of -log(p-value) > 4 
in the Pten WT and Pten-/- MEFs. Out of these, 533 islands were significantly decreased and 
2211 islands were significantly increased in the Pten-/- MEFs. The expression levels of genes 
associated with decreased islands correlated with an upregulation in Pten WT MEFs (Spearman 
correlation p-value < 0.0001), and the expression levels of genes associated with increased 
islands correlated with an upregulation in Pten-/- MEFs (Spearman correlation p-value = 0.0012). 
GO enrichment analysis of genes associated with decreased islands in Pten-/- MEFs showed 
GO-terms related to development and cell morphogenesis significantly enriched (Fig 2.11 B left 
panel). Genes associated with increased islands in Pten-/- MEFs were significantly enriched for 
GO-terms related to metabolic processes, cell cycle, gene expression, DNA repair and DNA 
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replication (Fig 2.11 B right panel). The enrichment profiles of H3K36me3 showed slightly higher 
signals in the Pten-/- MEFs at expressed genes in the discovery as well as the validation data 
set (Fig 2.11 A). Overall, the data suggest higher levels of the H3K36me3 mark in Pten-/- MEFs, 
which correlated with an increase in transcription of genes involved in cell cycle control, gene 
expression, DNA repair and DNA replication. 
SICER called approximately 12000 H3K27me3 islands with a significance cut-off of -log(p-
value) > 2 in Pten WT and Pten-/- MEFs. Out of these, 1209 islands were significantly decreased 
and 2023 islands were significantly increased in Pten-/- MEFs. The H3K27me3 mark is 
associated with genes that are not expressed making a correlation with expression levels 
difficult. In the discovery as well as the validation data sets, the enrichment profiles of 
H3K27me3 showed slightly higher signals in the Pten-/- MEFs at expressed genes and markedly 
higher signals in Pten-/- MEFs around the TSS of genes that are not expressed (Fig 2.11 C). 
Overall, we found an increase in the H3K27me3 mark in Pten-/- MEFs, which did not seem to 
correlate with a decrease in gene expression in these cells. 
SICER identified 7155 H3K9me3 islands in Pten WT MEFs and 6800 H3K9me3 islands in Pten-
/- MEFs. Overall, the enrichment profiles of H3K9me3 showed slightly higher signals in Pten WT 
MEFs at islands called in Pten WT or Pten-/- MEFs (Fig 2.11 D), suggesting a slight decrease of 
the H3K9me3 mark in Pten-/- MEFs. However, at genomic regions containing satellite DNA, we 
found slightly higher signals in Pten-/- MEFs (Fig 2.11 E), indicating a slight repression of 
satellite DNA in Pten-/- MEFs. This might result in fewer transcripts, originating from genomic 




The effect of Pten loss on histone mark H3K4me3 is inconclusive 
The first narrow histone mark we analyzed, H3K4me3 displayed inconsistencies between the 
two biological replicates. Enrichment profiles of H3K4me3 showed markedly higher signals in 
Pten-/- MEFs around the TSS of expressed genes, as well as up- and downregulated genes in 
the discovery data set (Fig 2.12 A upper panels). In contrast, in the validation data set 
enrichment profiles of H3K4me3 at the same genes showed noticeably higher signals in Pten 
WT MEFs (Fig 2.12 A lower panels). These inconsistencies led us to exclude H3K4me3 from 
further analysis. 
 
Deletion of Pten changes the enhancer landscape 
Enhancers can broadly be classified as inactive, primed, poised or active (Ernst and Kellis, 
2010). Inactive enhancers are devoid of transcription factor binding and histone modifications, 
whereas primed enhancers are closely bound by sequence-specific transcription factors and are 
found at nucleosome-free regions of open chromatin. Poised enhancers are similar to primed 
enhancers. They require additional cues including the recruitment of co-activators to transition 
to active enhancers. Poised enhancers are marked by H3K4me1, but lack H3K27ac which is the 
distinguishing mark of active enhancers (Creyghton et al., 2010; Heinz et al., 2015). Moreover, 
H3K27ac can be found on super-enhancers, which are groups of enhancers in close proximity 
to each other (typically 12.5 kb or less) that are bound by unusually high levels of transcription 
factors (Pott and Lieb, 2015). Genes associated with super-enhancers typically are highly 
expressed and are often pivotal for controlling and defining cell identity (Hnisz et al., 2013; 
Whyte et al., 2013). 
Using MACS2, an algorithm designed for calling narrow histone mark peaks, with a significance 
cut-off of -log(q-value) > 10, we identified 16069 H3K4me1 peaks in the Pten WT MEFs and 
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15835 H3K4me1 peaks in the Pten-/- MEFs. 15130 peaks were common to both genotypes. The 
enrichment profiles of H3K4me1 around the TSS of expressed genes, as well as around the 
TSS of up- and downregulated genes showed slightly higher signals in Pten WT MEFs in the 
discovery data set (Fig 2.12 B upper panels) and slightly higher signals in Pten-/- MEFs in the 
validation data set (Fig 2.12 B lower panels). Overall, these findings suggest that loss of Pten 
does not affect the H3K4me1 mark in early passage MEFs. 
Using MACS2 with a significance cut-off of -log(q-value) > 5 we identified 12213 H3K27ac 
peaks in the Pten WT MEFs and 10137 H3K27ac peaks in the Pten-/- MEFs. 9743 peaks were 
common to both genotypes. The enrichment profiles of H3K27ac showed markedly higher 
signals in Pten WT MEFs, around the TSS of expressed genes, as well as around the TSS of 
up- and downregulated genes in the discovery data set (Fig 2.12 C upper panels) and the 
validation data set (Fig 2.12 C lower panels). Overall, this does not suggest a significant loss or 
gain of enhancer elements after deletion of Pten, but rather a decrease in the peak height at 
existing enhancers, perhaps indicating a weakening of these enhancer elements. 
Does the increase in the H3K27ac mark in Pten WT MEFs affect the distribution of poised and 
active enhancers? Using MACS2 with the “bdgdiff” option, designed for differential peak 
detection, we divided peaks identified within 5 kb of a protein-coding TSS into two classes. 
Peaks that were marked by H3K4me1 were classified as poised enhancers and peaks that were 
marked by H3K4me1 and H3K27ac were classified as active enhancers. We found 4011 poised 
and 7157 active enhancers in Pten WT MEFs and 5691 poised and 5641 active enhancers in 
Pten-/- MEFs (Fig 2.13 A). 3067 of the poised and 5118 of the active enhancers were shared 
between the two genotypes (Fig 2.13 A). Moreover, poised enhancers unique to Pten-/- MEFs 
and active enhancers unique to Pten WT MEFs shared 1169 of the associated genes. GO 
enrichment analysis of genes associated with these 1169 genes showed GO-terms related to 
metabolic processes and regulation of signaling significantly enriched (Fig 2.13 B). Genes 
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associated with active enhancers unique to Pten WT MEFs were significantly enriched for GO-
terms related to metabolic processes, gene expression, cell cycle, RNA processing and 
translation (Fig 2.13 B). Genes associated with poised enhancers unique to Pten-/- MEFs were 
significantly enriched for GO-terms related to metabolic processes, gene expression, protein 
targeting and RNA processing (Fig 2.13 B). We created profile plots of the average signal of 
H3K4me1, H3K27ac and RNAPII for each of the groups of enhancers (Fig 2.13 C). Overall, 
H3K4me1 signals were slightly higher in Pten WT MEFs but did not differ significantly between 
poised and active enhancers for either genotype (Fig 2.13 C, dotted lines). As shown previously, 
H3K27ac signals were significantly higher in Pten WT MEFs on all enhancers (Fig 2.13 C, solid 
lines). As expected, signals for H3K27ac were markedly increased on active enhancers (Fig 
2.13 C, solid lines in the lower panels). RNAPII occupancy around the TSS of genes associated 
with poised and active enhancers was increased in Pten-/- MEFs (Fig 2.13 C, faded, solid lines). 
RNAPII occupancy was markedly increased on genes associated with active enhancers for Pten 
WT and Pten-/- MEFs (Fig 2.13 C, faded, solid lines in the lower panels), which correlates with 
the increased transcriptional activity of genes associated with active enhancers. Further detailed 
analysis of RNAPII occupancy will be discussed in Chapter 3. 
Lastly, does the increase in H3K27ac in Pten WT MEFs affect the super-enhancer landscape? 
We analyzed the H3K27ac data using the ROSE software package (Loven et al., 2013; Whyte 
et al., 2013) and identified 822 super-enhancers in the Pten WT MEFs and 573 super-
enhancers in the Pten-/- MEFs (Fig 2.13 D). Profile plots of H3K27ac enrichment across super-
enhancers showed higher signals in Pten WT MEFs at super-enhancers identified in Pten WT or 
Pten-/- MEFs (Fig 2.13 D). Interestingly, H3K27ac signals around the TSS of super-enhancer 
associated genes did not differ between expressed genes and super-enhancer associated 
genes (Fig 2.13 E, dotted lines). Furthermore, we confirmed that RNAPII occupancy around the 
TSS of genes associated with super-enhancers was markedly increased compared to 
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expressed genes in Pten WT and Pten-/- MEFs (Fig 2.13 E, solid lines). However, despite the 
higher H3K27ac signal on enhancers and super-enhancers in Pten WT MEFs, RNAPII 
occupancy was higher in Pten-/- MEFs indicating that the increase in enhancer strength in Pten 





In this chapter we made the following observations: 1) Pten can be efficiently deleted in MEFs 
carrying loxP sites flanking exon 5 of the endogenous Pten locus; 2) MEFs provide a suitable 
model system to study the effects of Pten loss on gene expression; 3) Loss of Pten affects gene 
expression in a PI3K/AKT-dependent and -independent manner; 4) Loss of Pten does not 
change chromatin modifications globally but affects histone modifications found at enhancers. 
In accordance with the literature, which is discussed in detail in Chapter 1, we found that Pten 
loss affects expression levels of a subset of genes. For example, we found the growth factor 
pleiotrophin (Ptn) to be significantly upregulated in our Pten-/- MEFs. Ptn was also identified by 
Li et al. (Li et al., 2006) as one of the most upregulated genes after Pten deletion in MEFs. 
Furthermore, an important PTEN loss signature, generated from 105 patient-derived breast 
cancer samples that is associated with poor prognosis (Saal et al., 2007), was significantly 
enriched in our Pten-/- MEFs. The correlation of our MEF data with data derived from human 
samples indicates that the MEF model system, despite originating from a different organism, 
reflects gene expression changes observed in human samples and can recapitulate processes 
seen in human cancers. 
Interestingly, we also identified 653 transcripts that were upregulated after Pten deletion in a 
PI3K/AKT-independent manner. A similar observation was made by Tibarewal et al. (Tibarewal 
et al., 2012), who reported that over-expression of a lipid phosphatase-dead PTEN mutant 
caused modest changes in the expression of a small number of transcripts. PI3K/AKT-
independent genes were not only enriched for genes involved in general cellular processes but 
also for genes involved in gene expression and regulation of gene expression. This indicates 
that there is a component of PTEN regulation of gene expression that is independent of its role 
in the PI3K/AKT pathway. 
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Gene expression can be influenced by histone modifications. We therefore compared Pten WT 
and Pten-/- MEFs for their protein levels of several histone modifications. Overall, we found no 
difference in H3K4me3, H3K36me3, H3K27me3, H3K27ac or H4K16ac levels by 
immunoblotting. However, early passage, primary Pten-/- MEFs displayed a slight increase in the 
repressive histone mark H3K9me3. Analysis of native ChIP-Seq data for H3K9me3 revealed 
marginally fewer, significantly called islands in the Pten-/- MEF, which overall exhibited slightly 
lower average read density for H3K9me3. On the other hand, at genomic regions associated 
with satellite DNA, average read densities in Pten-/- MEFs were higher than in Pten WT MEFs, 
which might implicate fewer transcripts originating from genomic regions associated with 
satellite DNA. These results are partly in discordance with findings by Gong et al. (Gong et al., 
2015), who reported a decrease in the H3K9me3 mark after loss of Pten and a subsequent 
increase in transcription of satellite DNA including major and minor satellite DNA. Some of the 
differences might be explained as follows; although both studies used MEFs it is possible that 
they originated from different mouse strains. We derived primary MEFs, which were not 
passaged more than 4 times after infection, from mice bred in the C57/bl6 background. 
Moreover, Gong et al. might have been using immortalized MEFs, which could have been 
passaged many times. Perhaps early passage MEFs display high levels of H3K9me3 
immediately after Pten loss, and these levels decrease over time when cells adapt to the Pten 
deletion. 
Gong et al. also reported a decondensation of heterochromatin after loss of Pten, which was 
supported by Chen et al. (Chen et al., 2014). However, partial MNase digestion of chromatin 
derived from our primary MEFs did not show an increased sensitivity to MNase in the Pten-/- 
MEFs suggesting that loss of Pten in our early passage MEFs does not affect chromatin 
condensation. Overall, we conclude from these findings that the relationship between loss of 
Pten and heterochromatin formation remains inconclusive. 
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As Pten loss did not seem to alter histone modifications globally, we determined whether it 
could affect histone marks at a subset of genes. In Pten-/- MEFs we identified a subset of genes 
with elevated levels of H3K36me3. The transcript levels of most of these genes were 
upregulated in the Pten-/- MEFs and, as shown by GO enrichment analysis, were enriched for 
genes involved in cell cycle control, gene expression, DNA repair and DNA replication. As 
H3K36me3 marks active gene bodies, an increase of this mark at over-expressed genes is in 
accordance with the literature. 
Furthermore, we found that the enhancer mark H3K27ac, but not the enhancer mark H3K4me1, 
was markedly increased in Pten WT MEFs at enhancers and super-enhancers. H3K4me1 
marks poised enhancers, which lack H3K27ac. It is also found on active enhancers together 
with H3K27ac. We observed a gain of ~2600 active enhancers in Pten WT MEFs and a gain of 
~2000 poised enhancers in Pten-/- MEFs. However, the lists of genes associated with these 
enhancers shared a large overlap. The algorithm used to identify peaks that are marked by both 
H3K4me1 and H3K27ac uses a certain significance cut-off. In the Pten-/- MEFs the H3K27ac 
mark was overall lower resulting in fewer significant peaks. However, this does not mean that 
the peaks are absent in this genotype, they just did not meet the significance cut-off. It is 
therefore unclear whether the poised enhancers in the Pten-/- MEFs are truly poised enhancers 
or if the associated H3K27ac signal simply was not called significant.  
When comparing the RNAPII occupancy on genes associated with poised or active enhancers, 
we observed higher RNAPII signals in Pten-/- MEFs on all enhancers. We made similar 
observations when comparing super-enhancers. Although the number of super-enhancers and 
the associated H3K27ac signals were elevated in Pten WT MEFs, RNAPII occupancy on the 
TSS of super-enhancer associated genes was lower in Pten WT MEFs. Overall, these data 
suggest that the increase in enhancer strength is not translated into elevated RNAPII binding at 
TSS, and does not result in greater transcript levels of the enhancer-associated genes. 
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These paradoxical results might be explained as follows; perhaps loss of PTEN positively 
affects gene expression in a manner that renders Pten-/- MEFs independent of strong enhancers 
to activate transcription. For example, loss of PTEN could enhance RNAPII recruitment to 
promoters in an enhancer-independent way. On the other hand, perhaps a decrease in 
enhancer strength is a feedback loop that counteracts the increase in transcriptional activity. 
Moreover, a gain in RNAPII occupancy could imply an increase in the activity of RNAPII-
containing transcription complexes (Alberts et al., 2002) but it could also indicate an increase in 
RNAPII promoter-proximal pausing, an important widespread mechanism of transcription 
regulation in higher eukaryotes (Adelman and Lis, 2012). We will discuss the implications of 
elevated RNAPII occupancy on the TSS in more detail in Chapters 3 and 4. In summary, we can 
only speculate on the exact functions of the decreased enhancer strength in Pten-/- MEFs. 
However, we believe it to be essential to verify these findings in an additional model system, for 
example, in a different set of isogenic cell lines or mouse tissues. 
Overall, we established a genetically unbiased model system to study the effects of PTEN loss 
on gene expression and chromatin modifications. Deletion of PTEN decreased the transcript 
levels of a subset of genes and increased the transcript levels of a different subset of genes in a 
PI3K/AKT-dependent as well as -independent manner. The upregulated genes were enriched 
for genes involved in DNA binding, replication and repair, but also for regulation of gene 
expression. Moreover, although loss of PTEN did not affect histone modifications globally, it 
altered levels of H3K27me3 and H3K36me3 at a subset of genes. Furthermore, in Pten-/- MEFs 
levels of H3K27ac at enhancers and super-enhancers were markedly decreased. However, 
RNAPII occupancy on the associated genes did not decrease, suggesting that the alteration of 




Figure 2.1: Generation of isogenic pairs of Pten WT and Pten-/- mouse embryonic 
fibroblasts (MEFs).  
(A) Schematic representation of the genomic structure of the Pten locus with exon 5 boxed. 
Exon 5 is flanked by loxP sites and can be deleted upon Cre-recombinase addition. (B) 
Schematic of making mouse embryonic fibroblasts. Embryos of Ptenfl/fl mice in a C57/bl6 
background were harvested 14.5 days after mating. Fibroblasts were isolated and cultured in 
DMEM growth media supplemented with 10% FBS and 2 mM L-Glutamine (total 6 mM L-
Glutamine). To generate an isogenic pair, cells were split into two plates and each plate was 
infected with Adeno-virus containing CMV-Cre-recombinase or CMV-Null. 
 
Figure 2.2: Pten is efficiently deleted from MEFs by addition of Adeno-virus particles 
containing Cre-recombinase. 
(A) Whole cell lysates of Pten WT and Pten-/- MEFs were taken 1 or 3 passages after infection 
with Adeno-virus. They were analyzed for PTEN protein levels by immunoblotting. (B) Pten WT 
and Pten-/- MEFs were fixed 1 or 3 passages after infection with Adeno-virus and analyzed for 
PTEN protein levels using immunofluorescence stainings. The quantification of PTEN protein 
levels is shown in the table below. n = 20. (C) The relative amount of PTEN mRNA over GAPDH 
was measured in one isogenic pair of Pten WT and Pten-/- MEFs 3 passages after infection 
using qRT-PCR. Error bars represent standard deviations from n = 3. The delta-delta-Ct method 
was used to analyze the data, with the Pten WT sample set to 1. 
 
Figure 2.3: Significantly altered genes and pathways in Pten-/- MEFs. 
Microarray gene expression analysis was performed on 4 isogenic pairs of Pten-/- (labeled 
“Null”) and Pten WT (labeled WT) MEFs. (A) Heat map of the top 25 up- and downregulated 
genes in MEFs. (B) The relative amount of the indicated transcripts normalized to GAPDH was 
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measured in one isogenic pair of Pten WT and Pten-/- MEFs using qRT-PCR. Error bars 
represent standard deviations from n = 3. The delta-delta-Ct method was used to analyze the 
data, with each gene’s Pten WT sample set to 1. (C) Gene set enrichment analysis was 
performed using pre-defined “hallmark” gene sets. The top enriched gene sets upregulated in 
Pten-/- MEFs (upper panel) or Pten WT MEFs (lower panel) are shown, along with the 
normalized enrichment score (NES), nominal p-value (NOM p-value), and the false discovery 
rate q-value (FDR q-value). 
 
Figure 2.4: Significantly enriched gene signatures and “molecular functions” in Pten-/- 
MEFs. 
(A-C) Gene set enrichment analysis was performed on microarray expression data from Pten-/- 
and WT MEFs. GSEA-supplied normalized enrichment score (NES), nominal p-value (NOM p-
value), and the false discovery rate q-value (FDR q-value) are given. (A) GSEA of the up-
regulated Saal et al. PTEN loss signature genes. (B) GO enrichment analysis was performed 
with the “molecular function” domain gene sets using the GSEA software. (C) GSEA of “EZH2-
stimulated” genes identified by Xu et al. (Xu et al., 2012). 
 
Figure 2.5: Significantly altered genes and pathways in Pten-/- MEFs treated with GDC-
0941. 
mRNA-Seq analysis was performed on 3 isogenic pairs of Pten WT and Pten-/- MEFs treated 
with 1 µM of GDC-0941 or DMSO for 12 h. (A) Whole cell lysates of GDC-0941-treated or 
DMSO-treated cells were analyzed for protein levels of PTEN and p-AKT Ser473 using 
immunoblotting. (B and C) GO enrichment analysis using the “biological process” domain was 
performed using the Gene Ontology Consortium web-based tool. (B) Gene sets that were 
significantly enriched in the PI3K-dependent gene list are shown, along with the p-values. (C) 
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Gene sets that were significantly enriched in the PI3K-independent gene list are shown, along 
with the p-values. 
 
Figure 2.6: Pten loss does not affect chromatin modifications globally. 
(A) Whole cell lysates of one isogenic pair of Pten WT and Pten-/- MEFs were taken 1, 2, 3 and 4 
passages after infection and analyzed for protein levels of PTEN, H3K4me3, H3K36me3, 
H3K27ac, H3K27me3 and H4K16ac by immunoblotting. (B) Whole cell lysates of three isogenic 
pairs of Pten WT and Pten-/- MEFs were taken 4 passages after infection and analyzed for 
protein levels of PTEN, H3K9me1 and H3K9me3 by immunoblotting. 
 
Figure 2.7: Schematic of native ChIP protocol, MNase digestion and ChIP-Seq data 
analysis workflows. 
(A) Native ChIP protocol workflow. Cells are harvested by trypsinization and nuclei are isolated 
by differential centrifugation through a sucrose cushion. Chromatin is then digested using the 
enzyme micrococcal nuclease (MNase). Sheared chromatin is subjected to immuno-
precipitations. Precipitated DNA is extracted and libraries are prepared for sequencing on a 
NextSeq sequencing machine. (B) MNase digestion workflow. Isolated nuclei were incubated 
with pre-determined amounts of MNase. After centrifugation the pellet is resuspended in 0.5 M 
NaCl and centrifuged again. The supernatant from the high-salt extraction is used for immuno-
precipitations. (C) Data analysis workflow. Reads were aligned using the Bowtie ultrafast, short 
sequence aligner. Significant peaks were called utilizing the MACS2 software using either the 
narrow or broad peak options. Downstream analysis including differential peak analysis, peak 
annotation and super-enhancer analysis is performed using Galaxy deepTools, bedtools or the 




Figure 2.8: Pten WT and Pten-/- MEFs are not differentially affected by MNase digestion. 
Chromatin isolated from Pten WT and Pten-/- MEFs was digested with increasing amounts of 
MNase and was then analyzed using a High Sensitivity DNA ChIP on an Agilent Bioanalyzer. 
(A) Chromatograms of MNase digested chromatin samples are shown. (B) Gel-like 
representations of MNase digested chromatin samples are shown. 
 
Figure 2.9: Native ChIP-Seq quality control. 
(A) Table summarizing sequenced and aligned reads of each histone mark for (upper panel) the 
discovery data set and (lower panel) the validation data set.  (B) Reads were classified into 
“Intergenic region”, “Repeat region”, “Intron” or “Exon” according to the location in the genome 
they mapped to. Pie charts of the mapped reads’ distribution across the genome are shown. (B) 
Capture of the UCSC genome browser (NCBI37/mm9) showing the ChIP-Seq profiles for 
H3K36me3 for the Pten locus in Pten WT and Pten-/- MEFs. The Pten gene with exons 1-9 is 
displayed below with the arrow head indicating the direction of transcription. (C) Magnification of 
the capture of the UCSC genome browser (NCBI37/mm9) showing the ChIP-Seq profiles for 
H3K36me3 for the Pten locus in Pten WT and Pten-/- MEFs. The Pten gene with exons 4 and 5 
is displayed below with the arrow head indicating the direction of transcription. 
 
Figure 2.10: Pten loss alters histone marks at select genes 
(A-D) Captures of the UCSC genome browser (NCBI37/mm9) showing the ChIP-Seq profiles for 
RNAPII, H3K4me3, H3K36me3, H3K27ac and H3K4me1. Genomic positions are indicated 
above the tracks. The exons and introns of each gene are shown below the tracks. The arrow 
heads indicate the direction of transcription. The genomic loci for (A) Dpt, (B) Fam150, (C) E2f1 




Figure 2.11: Pten loss increases the levels of histone marks H3K36me3, H3K27me3 but 
not H3K9me3. 
(A-D) Native ChIP-Seq experiments using antibodies raised against H3K36me3, H3K27me3 
and H3K9me3 were performed using Pten WT and Pten-/- MEFs. (A) Profiles of the average 
enrichment of H3K36me3 (bin size 50 bp) in the (left panel) discovery data set and (right panel) 
validation data sets were generated at expressed genes. Gene bodies were scaled to 4 kb. 
Regions 1 kb upstream of the TSS and 4 kb downstream of the TES are shown unscaled. (B) 
GO enrichment analysis using the “biological process” domain was performed using the Gene 
Ontology Consortium web-based tool. Gene sets that were significantly enriched in (left panel) 
genes associated with H3K36me3 islands increased in Pten WT MEFs and (right panel) genes 
associated with H3K36me3 islands increased in Pten-/- MEFs are shown, along with the p-
values. (C) Profiles of the average enrichment of H3K27me3 (bin size 50 bp) in the (upper 
panels) discovery data set and (lower panels) validation data set were generated at (right 
panels) not expressed genes and (left panels) expressed genes. 10 kb upstream and 
downstream of the TSS are shown unscaled. (D) Profiles of the average enrichment of 
H3K9me3 (bin size 50 bp) were generated at islands identified in (left panel) Pten WT MEFs 
and (right panel) Pten-/- MEFs. Islands were scaled to 1 kb. 1 kb upstream of the island start site 
and 1 kb downstream of the island end site are shown unscaled. (E) Profiles of the average 
enrichment of H3K9me3 (bin size 50 bp) were generated at annotated satellite DNA. Satellite 
DNA regions were scaled to 500 bp. 1 kb upstream of the satellite DNA region start site and 1 
kb downstream of the satellite DNA region end site are shown unscaled. 
 
Figure 2.12: Loss of Pten affects histone marks H3K4me3, H3K27ac and H3K4me1. 
(A-C) Native ChIP-Seq experiments using antibodies raised against H3K4me3, H3K27ac and 
H3K4me1 were performed using Pten WT and Pten-/- MEFs. (A) Profiles of the average 
enrichment of H3K4me3 (bin size 50 bp) in the (upper panels) discovery data set and (lower 
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panels) validation data set were generated at (left panels) expressed genes, (middle panels) 
upregulated genes, and (right panels) downregulated genes. 1 kb upstream and 1 kb 
downstream of the TSS are shown unscaled. (B) Profiles of the average enrichment of H3K27ac 
(bin size 50 bp) in the (upper panels) discovery data set and (lower panels) validation data set 
were generated at (left panels) expressed genes, (middle panels) upregulated genes, and (right 
panels) downregulated genes. 2 kb upstream and 2 kb downstream of the TSS are shown 
unscaled. (C) Profiles of the average enrichment of H3K4me1 (bin size 50 bp) in the (upper 
panels) discovery data set and (lower panels) validation data set were generated at (left panels) 
expressed genes, (middle panels) upregulated genes, and (right panels) downregulated genes. 
2 kb upstream and 4 kb downstream of the TSS are shown unscaled. 
 
Figure 2.13: Loss of Pten alters the enhancer landscape. 
(A-C) H3K4me1 peaks within 5 kb of a protein-coding TSS were defined as poised enhancers if 
they did not coincide with a H3K27ac peak and as active enhancer if they did coincide with a 
H3K27ac peak. (A) Venn diagram of (left panel) poised and (right panel) active enhancers 
identified in Pten WT and Pten-/- MEFs. (B) GO enrichment analysis using the “biological 
process” domain was performed using the Gene Ontology Consortium web-based tool. 
Significantly enriched gene sets for genes associated with active enhancers in Pten WT MEFs 
and poised enhancers in Pten-/- MEFs or genes associated with active enhancers unique to Pten 
WT MEFs or genes associated with poised enhancers unique to Pten-/- MEFs are shown, along 
with the p-values. (C) Profiles of the average enrichment of H3K4me1, H3K27ac and RNAPII 
(bin size 50 bp) were generated around the TSS of genes associated with (upper panels) poised 
enhancers and (lower panels) active enhancers. 2 kb upstream and 4 kb downstream of the 
TSS are shown unscaled. Profiles are shown for genes associated with poised or active 
enhancers that are (left panels) common in Pten WT and Pten-/- MEFs, (middle panels) unique 
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in Pten WT MEFs or (right panels) unique in Pten-/- MEFs. (D) Profiles of the average 
enrichment of H3K27ac signal over genomic regions identified as super-enhancers in (left 
panel) Pten WT MEFs and (right panel) Pten-/- MEFs were generated using a bin size of 50 bp. 
Super-enhancers were scaled to 2 kb. 2 kb upstream and downstream of the super-enhancer 
region are shown unscaled. (E) Profiles of the average enrichment of H3K27ac and RNAPII (bin 
size 50 bp) were generated around the TSS of (left panel) expressed genes, or genes 
associated with (middle panel) super-enhancers called in Pten WT MEFs or (right panels) 











































































CHAPTER 3: PTEN’s role in transcription regulation 
Introduction 
In the previous chapter we showed that loss of PTEN leads to gene expression alterations, and 
discussed how these alterations might be based on changes in the landscape of post-
translational histone modifications. However, chromatin modifications are only one mode by 
which gene expression can be regulated. Another mechanism is the regulation of transcription 
itself. As described in Chapter 2, RNA-Seq experiments in GDC-0941-treated MEFs revealed 
the PI3K/AKT-independent upregulation of gene sets related to “regulation of transcription, 
DNA-templated” and “regulation of transcription from RNA polymerase II promoter” after the loss 
of PTEN (Fig 2.5 C), implicating a role of PTEN in the regulation of transcription. 
The term “transcription” describes the tightly controlled process in which RNA polymerases 
(RNAPs) produce RNAs complementary to one strand of DNA. Although in eukaryotes there are 
three RNAPs, each of which is dedicated to transcribing a unique set of genes, in this chapter 
when discussing transcription we refer to the process in which RNAPII generates mRNAs. 
RNAPII is a 550 kDa protein complex consisting of 12 subunits and, uniquely among the 
RNAPs, it possesses a C-terminal repeat domain (CTD) on its largest subunit Rpb1. The CTD is 
highly evolutionary conserved and is comprised of up to 52 tandem heptad repeats with the 
consensus sequence Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (Y1S2P3T4S5P6S7). Highly 
phosphorylatable, the CTD is a regulatory element that serves as a binding platform for a 
multitude of proteins including transcriptional regulators, mRNA-processing enzymes, and 
histone modifiers. To couple and coordinate these CTD binding proteins with the four specific 
stages of transcription, which are pre-initiation, initiation, elongation and termination, a dynamic 
pattern of posttranslational modifications referred to as the CTD code is required (Phatnani and 
Greenleaf, 2006). The most studied and best understood posttranslational modification of the 
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RNAPII CTD is phosphorylation, specifically phosphorylation of serines 2 and 5 (Ser2 and 
Ser5). During initiation Ser5 and Ser7 are phosphorylated by the cyclin-dependent kinase 7 
(CDK7), which together with cyclin H and Mat1 comprises the trimeric kinase-complex that can 
associate with the 10 subunit core complex of the basal transcription factor IIH (TFIIH) (Akhtar 
et al., 2009; Komarnitsky et al., 2000). CDK7 activity can be inhibited by the covalent inhibitor 
THZ1, which by targeting a remote cysteine residue outside of the canonical kinase domain has 
the unique ability to achieve high selectivity for CDK7 (Kwiatkowski et al., 2014). Furthermore, 
THZ1 has been shown to be highly effective in inhibiting transcription of genes associated with 
super-enhancers (SE) (Chipumuro et al., 2014; Christensen et al., 2014; Kwiatkowski et al., 
2014; Wang et al., 2015). Super-enhancers are groups of enhancers in close proximity to each 
other (typically 12.5 kb or less) that are bound by unusually high levels of transcription factors 
such as the Mediator complex (Pott and Lieb, 2015). They are frequently identified near genes 
that are central for controlling and defining cell identity and thus can be used for the 
identification of genes important for cell type specification (Hnisz et al., 2013; Whyte et al., 
2013). In tumor cells, super-enhancers are often found to be associated with genes vital for 
driving tumorigenicity; this, together with their high levels of expression, is what makes super-
enhancer-associated genes especially vulnerable to transcriptional inhibitors such as THZ1 
(Chipumuro et al., 2014; Christensen et al., 2014; Kwiatkowski et al., 2014; Wang et al., 2015). 
Another inhibitor targeting transcription initiation is Triptolide, a natural product isolated from a 
traditional Chinese medicinal plant. Triptolide covalently binds to XPB, a subunit of TFIIH, and 
has been shown to inhibit its DNA-dependent ATPase activity, thereby inhibiting transcription 
and potentially nucleotide excision repair (Titov et al., 2011).  
To release the paused RNAPII from the proximal promoter and to enter productive elongation, 
Ser5P and Ser7P are removed and Ser2 is phosphorylated by CDK9 (Marshall and Price, 1995) 
and potentially CDK12 and CDK13 (Bartkowiak and Greenleaf, 2011; Bartkowiak et al., 2010). 
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CDK9 is the kinase subunit of the positive elongation factor (P-TEFb) (Peng et al., 1998), which 
in addition to Ser2 phosphorylation is also responsible for phosphorylating positive as well as 
negative elongation factors such as negative elongation factor (NELF) and elongation factor 
Spt5 (Yamada et al., 2006). Moreover, mediated by AFF4, a member of the mammalian AFF 
family, P-TEFb can associate with multi-subunit complexes including the super elongation 
complex (SEC), which was found to aid in the regulation of the transcriptional elongation 
checkpoint (Luo et al., 2012).  
CDK9 kinase activity can be inhibited by a number of more or less specific small molecule 
inhibitors including Flavopiridol and LCD000067. Flavopiridol is an anti-cancer therapeutic agent 
currently in clinical trials, which has inhibitory effects towards CDK1, CDK2, and CDK4, and less 
potently towards CDK7. Moreover, Flavopiridol is a potent P-TEFb inhibitor and as such is not 
competitive with ATP. In cells, Flavopiridol reduces RNAPII Ser2 phosphorylation and blocks 
RNAPII-mediated transcription (Chao et al., 2000). LCD000067 is a small molecule inhibitor 
based on a 2,4-aminopyrimidine scaffold with a selectivity for CDK9 over other CDKs between 
55-fold to over 230-fold; it is thought to be more specific than other CDK9 inhibitors including 
Flavopiridol (Albert et al., 2014). 
In this chapter, we will explore how transcription might be regulated by nuclear PTEN. 
Additionally, we will determine whether the loss of PTEN sensitizes cells to transcription 
inhibition and whether the use of inhibitors directed against transcription could provide an 





Nuclear PTEN can associate with chromatin 
As described in the previous chapter, we used primary MEFs that have loxP sites flanking exon 
5 of Pten inserted into the endogenous Pten locus. Addition of Adeno-virus containing CMV-
Cre-recombinase resulted in Pten-/- MEFs whereas addition of Adeno-virus containing CMV-Null 
resulted in Pten WT MEFs. Immunoblotting shows that almost 100% of Pten was no longer 
expressed as early as one passage after addition of the Adeno-virus containing CMV-Cre-
recombinase and was undetectable three passages after infection (Fig 3.1 A). 
Immunofluorescence (IF) experiments show that cytosolic Pten was lost one passage after 
infection. Interestingly, nuclear Pten remained visible in more than 50% of the cells at one 
passage, and this signal was undetectable after three passages (Fig 3.1 B), indicating that there 
is a nuclear pool of Pten that is distinct from the cytosolic pool. To allow for the complete 
depletion of nuclear Pten we only performed experiments using Pten WT and Pten-/- MEFs that 
had been passaged at least 3 times after infection. 
To further characterize the nuclear pool of Pten we performed cellular fractionation experiments 
of Pten WT and Pten-/- MEFs. While the majority of Pten resided in the cytosolic fraction, a small 
amount of Pten could be found in the nuclear fraction. Interestingly, after a high salt extraction of 
the nuclear proteins we did not detect Pten in the soluble nucleoplasm, but rather in the 
insoluble nuclear fraction that contains the nuclear lamina and chromatin (Fig 3.1 C). We further 
corroborated this finding using a different fractionation protocol (Fig 3.1 D). Starting with isolated 
MEF nuclei we performed partial digestion with micrococcal nuclease (MNase) followed by a 
high-salt extraction to obtain chromatin fragments of, on average, one to five nucleosomes in 
length. This resulted in three fractions, one containing the most accessible chromatin with 
associated proteins and nuclear proteins that do not bind to chromatin (low salt soluble fraction), 
one containing transcriptionally active chromatin as evidenced by the high levels of 
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phosphorylated RNAPII (high-salt soluble fraction) and one containing the least accessible, 
higher order chromatin and associated proteins (high-salt insoluble fraction). The majority of 
Pten was present in the low salt soluble fraction, which contains soluble nuclear proteins that do 
not bind chromatin or bind chromatin only weakly, and in the high salt insoluble fraction, which 
contains the least accessible, higher order chromatin (Fig 3.1 E). However, some Pten was 
present in the high salt soluble fraction, which contains transcriptionally active chromatin (Fig 
3.1 E) suggesting that there is a pool of nuclear PTEN that could associate with the transcription 
machinery. 
 
The 7SK snRNA, a negative regulator of the P-TEFb complex, is upregulated in 
Pten-/- MEFs 
We generated genome-wide mRNA expression data for four isogenic pairs Pten WT and Pten-/- 
MEFs and analyzed the transcript levels of non-coding polyadenylated RNAs. We identified 612 
expressed and annotated non-coding polyadenylated RNAs, 139 of which were significantly 
upregulated in the Pten WT MEFs (Fig 3.2 A left panel). 71 transcripts were significantly 
upregulated in the Pten-/- MEFs including the 7SK snRNA (Fig 3.2 A right panel) and we 
confirmed this finding in three isogenic pairs of Pten WT and Pten-/- MEFs using qRT-PCR (Fig 
3.2 B). The upregulation of the 7SK snRNA, which is a negative regulator of the P-TEFb 
complex (Nguyen et al., 2001; Yang et al., 2001), suggests a connection between PTEN and 
transcription regulation, and more evidence for this hypothesis was provided by our mRNA-Seq 
data generated from GDC-0941-treated MEFs. As mentioned in Chapter 2 we identified genes 
that were significantly upregulated in Pten-/- MEFs in a PI3K/AKT-independent manner. GO-term 
enrichment analysis of these genes using the “biological process” domain revealed significantly 
enriched GO-terms related to general cellular processes (“cell adhesion”, “developmental 
process”, “regulation of signal transduction”, “sensory perception and cell differentiation”). 
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However, more importantly, we found gene sets related to gene expression and regulation of 
gene expression (“regulation of gene expression”, “regulation of RNA biosynthetic process”, 
“regulation of transcription, DNA-templated” and “regulation of transcription from RNA 
polymerase II promoter”) significantly enriched (Fig 3.2 C), supporting a potential role for PTEN 
in transcription regulation. 
 
PTEN co-migrates with components of the transcription machinery 
If PTEN can regulate transcription it might do so through a direct association with transcription 
complexes. To explore this possibility we applied nuclear extracts, which were prepared under 
conditions conducive to the stability of large transcription complexes, to size exclusion 
chromatography. Size-exclusion chromatography is a method employed to separate proteins 
and protein complexes by their size. Generally, smaller molecules are trapped in the pores of 
the adsorbent material of the chromatography column resulting in a slower migration time and 
elution in later fractions. Molecules such as multi-subunit protein complexes that are too large to 
be trapped in the adsorbent pores, simply pass by the pores making them migrate through the 
column more quickly and elute in the early fractions. As transcription complexes are some of the 
largest multi-subunit complexes found in cells most of their components are expected to migrate 
through a size-exclusion column quickly and elute in very early fractions. We analyzed HeLa 
nuclear extracts by their application to size exclusion chromatography, followed by Western blot 
analysis. These studies indicate that while most PTEN elutes around 50 kDa corresponding to 
free, unbound PTEN, a small portion of PTEN elutes in fractions corresponding to 2 MDa and 
669 kDa (Fig 3.3 A). Within this size range, large transcription complexes elute that contain 
RNAPII, RNAPII phosphorylated at Ser2 or Ser5, Spt5, BRD4 and phosphorylated BRD4 as 
well as components of the TFIIH complex (CDK7, Cyclin H) and the super elongation complex 
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(AFF4 and P-TEFb components CDK9 and Cyclin T1) (Fig 3.3 A). This raises the possibility that 
PTEN could be part of these large complexes in vivo. 
To confirm the specificity of our PTEN antibodies, we compared results from size exclusion 
chromatography experiments using PTEN WT HeLa nuclear extracts and PTEN-/- HeLa nuclear 
extracts (Fig 3.3 B). Clonal PTEN-/- HeLa cell lines were created employing the CRISPR/Cas9 
system using a guide RNA targeting exon 3 and a small part of the downstream intron of the 
endogenous PTEN locus. Western blot analysis of PTEN-/- HeLa fractions showed no bands at 
the 50 kDa size, where PTEN is expected to migrate (Fig 3.3 B). However, we observe some 
bands in the input samples when probing with different PTEN antibodies. These bands do not 
migrate at the expected PTEN size and we postulate that they are background bands due to 
long exposures of the western blots.  
Next, we wanted to ask whether the loss of PTEN affects the composition of transcription 
complexes as evidenced by a change in their migration time through the size exclusion 
chromatography column. When we compare the elution fractions of PTEN WT HeLa nuclear 
extracts and PTEN-/- HeLa nuclear extracts for their protein contents of RNAPII, RNAPII Ser2P, 
RNAPII Ser5P, Cyclin T1, AFF4, CDK9, BRD4, phosphorylated BRD4, Spt5, CDK7 and Cyclin 
H we observe that most of these proteins elute in corresponding fractions suggesting that PTEN 
loss does not grossly disturb the overall composition of the large transcription complexes these 
proteins are part of (Fig 3.3 A and B). 
 
Loss of PTEN affects RNAPII occupancy on TSS 
The co-migration of PTEN with transcription complexes in size exclusion chromatography raised 
the question of potential consequences on the transcriptional behavior of these complexes. We 
performed chromatin immunoprecipitation sequencing (ChIP-seq) using an antibody raised 
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against total RNAPII in two pairs of isogenic Pten WT and Pten-/- MEFs, averaged the aligned 
reads for each genotype, and used the merged files for further analysis (Fig 3.4 A). Genes that 
we had previously classified as expressed in MEFs using RNA-Seq had slightly higher RNAPII 
occupancy around the transcription start site (TSS) (Fig 3.4 B left and right panels) and subtly 
higher RNAPII occupancy in the 3’-UTR (Fig 3.4 B left panel) in the Pten-/- MEFs. These cells 
also displayed elevated levels of phosphorylated RNAPII Ser2 and Ser5 when compared to 
Pten WT MEFs (Fig 3.4 C). We next called significant regions of RNAPII enrichment (from here 
on referred to as “RNAPII peaks” or “peaks”) using MACS2 with a significance cut-off of -log(q-
value) > 10 that were located within 5 kb of the TSS of a protein-coding gene. 5114 peaks were 
shared between the Pten WT and Pten-/- MEFs, 317 peaks were unique in the Pten WT MEFs, 
and 2410 peaks were unique in the Pten-/- MEFs (Fig 3.4 D). As described before, unique peaks 
represent peaks that were called significant in one genotype without reaching significance in the 
other genotype, which does not imply a complete absence of the peak in the latter genotype. 
GO enrichment analysis for the genes associated with uniquely called peaks identified GO-
terms related to metabolic processes significantly enriched in Pten WT MEFs (Fig 3.4 E upper 
panel). In Pten-/- MEFs significantly enriched GO-terms included those related to cellular 
metabolic processes, sensory perception, gene expression, protein modification processes, 
transcription and RNA processing (Fig 3.4 E lower panel). We then generated profile plots for 
RNAPII occupancy on genes associated with called peaks. Genes that were classified as 
common between Pten WT and Pten-/- MEFs had slightly higher occupancy of RNAPII around 
the TSS (Fig 3.4 F upper panel, left and right panels) in the Pten-/- MEFs. Genes that were 
unique to Pten WT MEFs had slightly higher occupancy of RNAPII around the TSS in Pten WT 
MEFs (Fig 3.4 F middle panel), and genes that were unique to Pten-/- MEFs had considerably 
higher occupancy of RNAPII around the TSS and throughout the gene body and the 3’-UTR 
Pten-/- MEFs (Fig 3.4 F lower panel). 
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To corroborate our findings and to assess whether the increase in RNAPII occupancy after loss 
of PTEN is dependent on PI3K/AKT pathway activation we performed ChIP-Seq experiments 
using an antibody raised against total RNAPII in two mouse breast tumor lines, one expressing 
the H1047R Pik3ca mutation (MycOE Pik3ca Mut), which  increases Pik3ca catalytic activity 
resulting in enhanced downstream signaling, and one harboring a Pten deletion (MycOE Pten 
Null) (Stratikopoulos et al., 2015). In accordance with our findings in MEFs, the MycOE Pten 
Null cell line displayed increased levels of phosphorylated RNAPII Ser2 and Ser5 when 
compared to the MycOE Pik3ca Mut cells (Fig 3.5 A). We called significant peaks from our high 
coverage sequencing data (Fig 3.5 B) (significance cut-off: -log(q-value) > 20) that were located 
within 5 kb of the TSS of a protein-coding gene. We identified 6530 peaks that were common 
between the MycOE Pik3ca Mut and MycOE Pten Null cell lines, 1097 peaks that were unique 
in the MycOE Pik3ca Mut cell line and 1054 peaks that were unique in the MycOE Pten Null cell 
line (Fig 3.5 C). GO enrichment analysis for the genes associated with uniquely called peaks did 
not identify distinct GO-terms for MycOE Pik3ca Mut or MycOE Pten Null cells (Fig 3.5 D). 
Moreover, gene sets that were significantly enriched in both cell lines represented a cross-
section of GO-terms identified for genes associated with uniquely called RNAPII peaks in Pten 
WT and Pten-/- MEFs. We then generated profile plots for RNAPII occupancy for genes 
associated with the called peaks. Genes that were common between MycOE Pik3ca Mut and 
MycOE Pten Null cells as well as genes that were unique to MycOE Pten Null cells showed 
higher occupancy of RNAPII at the TSS and throughout the gene body and 3’-UTR in the 
MycOE Pten Null cells (Fig 3.5 E, upper and lower panels). Genes associated with MycOE 
Pik3ca Mut cells unique peaks showed higher RNAPII occupancy at TSS and a comparable 




In summary, in two different Pten Null cell lines RNAPII occupancy on expressed genes was 
higher than in the corresponding Pten WT cell lines suggesting an increase in transcription 
complex activity after the loss of PTEN at least on a subset of genes. Moreover, this was not 
mimicked by a Pik3ca mutation since expression of a Pik3ca activating mutation did not affect 
RNAPII occupancy on TSS. 
 
PTEN interacts with components of the transcription machinery in vitro 
Having shown that PTEN can co-migrate with transcription complexes in size exclusion 
chromatography experiments we next wanted to ask whether it does so by directly binding to 
components of the transcription machinery. We performed a yeast-2-hybrid (Y2H) screen using 
the PTEN C2TAIL as the bait fragment against a library of prey-fragments of the human fetal 
brain and identified AFF4, a member of the super-elongation complex as a potential interaction 
partner of PTEN. We confirmed this interaction using co-immunoprecipitation experiments from 
HEK293 cell lysates co-expressing the PTEN C2TAIL-fragment and the V5-tagged AFF4 
fragment, AFF4(aa 615-784)-V5 (Fig 3.6 A and B). Next we purified full-length GST-PTEN from 
E.coli and used this protein to immunoprecipitate endogenous AFF4 from DBTRG and HEK293 
cells (Fig 3.6 C). 
PTEN is comprised of several domains that have various functions and have been shown to 
interact with a multitude of potential and verified interaction partners (see Chapter 1 for a 
summary). To identify the specific PTEN domain required for the interaction with AFF4, we 
expressed and purified GST-PTEN deletion constructs (full-length GST-PTEN, GST-PDC2, 
GST-PD, GST-C2 and GST-TAIL) in E.coli and used these proteins for immunoprecipitation 
experiments in HEK293 cells (Fig 3.6 D and E). We confirmed the interaction of full-length GST-
PTEN with AFF4 and identified interactions between GST-PDC2, GST-PD and GST-C2 with 
endogenous AFF4 (Fig 3.6 F). This suggests more than one interaction interface between 
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PTEN and AFF4, as both the C2-domain and the PD-domain constructs can bind to AFF4 
independently. The decreased interaction we observed with the PD-domain alone can most 
likely be attributed to the decreased protein stability of the PD-domain. Interestingly, when we 
probed the immunoprecipitated lysates for other proteins of the transcription machinery, we 
observed interactions of endogenous RNAPII, Cyclin T1, CDK9 and CDK7 with GST-PTEN, 
GST-PDC2, GST-PD and GST-C2 (Fig 3.6 F). The GST-TAIL construct only weakly interacted 
with Cyclin T1, suggesting that the PTEN Tail-region is not essential for binding to proteins of 
the transcription machinery. In summary, using immunoprecipitation and GST pull down 
experiments we showed that PTEN can interact with AFF4 as well as additional components of 
the transcription machinery, including RNAPII, Cyclin T1, CDK9, and CDK7, and that this 
interaction is most likely facilitated by protein interfaces located in the PD and C2 domains. 
 
PTEN can be phosphorylated by CDK9 and CDK7 in vitro 
PTEN binding to CDK9 and CDK7 in vitro raised an interesting possibility. Could the interaction 
be translated into PTEN being a substrate for CDK9 or CDK7? To answer this question we 
performed in vitro kinase assays with purified and activated kinase complexes CDK9/Cyclin T1 
or CDK7/Cyclin H/Mat1 and GST-PTEN constructs. Using equal amounts of GST-PTEN, GST-
PDC2, GST-TAIL and GST (Fig 3.6 A+B lower panels) we detected moderate to low levels of 
phosphorylation for all constructs using either of the CDK9 or CDK7 kinase complexes (Fig 3.7 
A and B). We found the highest levels of phosphorylation in the GST-TAIL construct indicating 
that the phosphorylation site is located in the Tail-region of PTEN. The Tail-region harbors 
multiple residues (Thr366, Ser370, and a cluster containing Ser380, Thr382, Thr383, and 
Ser385), any of which could be potential substrates for CDK9 or CDK7. This was supported by 
the GST-PDC2 construct, which is missing the Tail-region, being phosphorylated at the lowest 
level. However, this also suggests that there might be an additional phosphorylation site outside 
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the Tail-region. In sum, we show that purified full-length as well as several GST-PTEN 
constructs can be phosphorylated by CDK9/Cyclin T1 or CDK7/Cyclin H/Mat1 kinase complexes 
in vitro. 
 
Endogenous PTEN interacts with RNAPII, Cyclin T1, CDK9 and CDK7 
Since our previous findings were based on the over-expression and use of purified proteins, we 
next wanted to confirm the interactions between PTEN and components of the transcription 
machinery in cells expressing endogenous levels of these proteins. Proximity ligation assay 
(PLA) is a method used to investigate potential interactions of endogenous proteins using fixed 
cells. The protocol we applied requires cells fixed on cover slides and employs two primary 
antibodies that recognize the proteins of interest and were raised in different species. The 
species-specific constant regions of the primary antibodies can be bound by secondary 
antibodies (termed PLA probes), which are attached to a short, unique DNA nucleotide 
sequence. When the PLA probes are in close proximity of each other (40 nm or less) and 
appropriate enzymes are added the DNA strands can be ligated and participate in rolling circle 
DNA synthesis. The amplified DNA is recognized by complimentary, fluorescently-labeled 
oligonucleotide probes and can be visualized using fluorescence microscopy. This method is 
especially useful for the detection of endogenous protein complexes that are expressed at low 
levels or interact only weakly. 
To determine whether endogenous PTEN can interact with components of the transcription 
machinery, we performed PLA experiments using a PTEN antibody raised in rabbit and 
antibodies against RNAPII, Cyclin T1, CDK9, or CDK7 raised in different species. We took 
images with a fluorescence confocal microscope and analyzed the cell nuclei for their content of 
fluorescent spots. In a PLA a positive interaction is represented by a distinct fluorescent spot if 
the two target proteins are located less than 40 nm from each other. For all antibodies tested, 
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we could detect significantly more fluorescent spots in PTEN WT HeLa cells than compared to 
PTEN-/- HeLa cells, which were used as a negative control (Fig 3.8 A-D). As an additional 
control we used either antibody alone and detected only non-specific background signals (Fig 
3.8 A-D). As there was no AFF4 antibody available that is raised in mouse and is suitable for 
immunofluorescence we could not determine the interaction of endogenous PTEN and AFF4. 
Overall, these data suggest that nuclear PTEN can interact with endogenous RNAPII, Cyclin T1, 
CDK9 and CDK7. 
 
Increased sensitivity of certain PTEN-/- cell lines to transcription inhibition 
The increase in transcriptional activity in cells that lost PTEN raised two vital questions. Does 
the loss of PTEN make cells more vulnerable to transcription inhibition? And can we exploit the 
dependency on transcription of these cells by specifically targeting transcription? We chose two 
paths of transcription inhibition, one targeting transcription initiation by inhibition of CDK7 or 
TFIIH and one targeting transcription elongation by inhibiting CDK9. CDK7 kinase activity can 
be effectively inhibited by the covalent CDK7 inhibitor THZ1 (Kwiatkowski et al., 2014) and 
TFIIH activity can be inhibited by Triptolide, a drug that targets XPB, a subunit of TFIIH, and 
inhibits its DNA-dependent ATPase activity (Titov et al., 2011). CDK9 kinase activity can be 
inhibited by Flavopiridol (Chao et al., 2000) or LCD000067 (Albert et al., 2014). 
To describe the sensitivity of a cell line to an inhibitor we use the parameter “growth inhibition of 
50%” (GI50), which is the inhibitor concentration that has to be applied to achieve a 50% 
reduction in cell proliferation. The GI50 can be determined by performing dose-response 
titrations. Increasing concentrations of each inhibitor were added to cells and cell proliferation 
was measured using the IncuCyte ZOOM® live-cell imaging and analysis system. The drug 
concentration required to achieve 50% of maximal growth in the cell line was then calculated by 
linear interpolation adapted from the Nature analysis of the NCI60 panel (Shoemaker, 2006).  
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We found that isogenic pairs of Pten WT and Pten-/- MEFs, a pair of mouse breast tumor cell 
lines (MycOE Pik3ca Mut and MycOE Pten Null) and an isogenic pair of PTEN WT and PTEN-/- 
HCT116 (Lee et al., 2004) responded differentially to THZ1 or Triptolide. In all three cell line 
systems the PTEN Null cells were more sensitive to THZ1 or Triptolide when compared to their 
PTEN WT counterparts as shown by the lower GI50s (Fig 3.9 A and B). Similarly, application of 
CDK9 inhibitors Flavopiridol or LCD000067 in the same three cell systems resulted in lower 
GI50s in the PTEN Null cells (Fig 3.9 C and D) indicating that loss of PTEN sensitizes cells to 
transcription inhibition. 
As CDK7 is an important CAK during the cell cycle (Fisher, 2012) we examined whether the 
sensitivity of PTEN Null cell lines to CDK7 inhibition is partly due to the inhibition of the cell 
cycle. When comparing Pten WT and Pten-/- MEFs, MycOE Pik3ca Mut cells and MycOE Pten 
Null cells and HCT116 PTEN WT and HCT116 PTEN-/- cells we find no difference in their 
sensitivity to the cell cycle inhibitor Palbociclib (Fig 3.9 E), suggesting that the loss of PTEN 
does not result in an increased sensitivity to cell cycle inhibition. 
  
Over-expression of PTEN desensitizes cells to transcription inhibition 
If loss of PTEN sensitizes cells to transcription inhibition, does over-expression of PTEN rescue 
this phenotype? And is PTEN’s phosphatase activity necessary to do so? To answer these 
questions we over-expressed wild type PTEN (PTEN WT) or phosphatase-dead PTEN (PTEN 
C124S) in MycOE Pten Null cells. Initially, expression of high levels of PTEN WT reduced cell 
proliferation but did not decrease the sensitivity to transcription inhibition by THZ1 or 
Flavopiridol (data not shown). However, stable expression of PTEN WT is not well tolerated by 
MycOE Pten Null cells and over time PTEN WT expression is downregulated. The resulting cell 
population expressing PTEN WT at a medium level displayed a decreased sensitivity to 
treatment with THZ1 or Flavopiridol (Fig 3.10 A and B). Over-expression of PTEN C124S did 
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not affect cell proliferation or the cells’ response to the THZ1 treatment, but did result in a 
slightly increased sensitivity to Flavopiridol treatment (Fig 3.10 A and B). Moreover, analysis of 
whole cell lysates revealed that expression of PTEN WT but not PTEN C124S decreased levels 
of p-AKT Ser473 as well as RNAPII Ser2P and Ser5P (Fig 3.10 C), suggesting that the 
phosphatase activity of PTEN is important for its role in transcription regulation. 
 
Knock-down of PTEN sensitizes cells to transcription inhibition 
If complete loss of PTEN sensitizes cells to transcription inhibition, does a reduction in PTEN 
protein levels have the same effect? To answer this question we transduced HCT116 cells with 
six different pools of lentiviral particles containing shRNAs targeting PTEN (termed PTEN 
shRNA #1, #2, #3, #4, #5 and #6), or with lentiviral particles containing an off-target shRNA as 
our control (control or shRNA “C”). The knock-down efficiency varied between the different 
shRNAs, with PTEN shRNA #1 reducing PTEN protein levels by 80%, shRNAs #2 and #3 
reducing PTEN protein levels by 30%, shRNAs #4 and #5 reducing PTEN protein levels by 40% 
and shRNA #6 reducing PTEN protein levels by 20% (Fig 3.10 D). Surprisingly, the two shRNAs 
(#1 and #5), which decreased PTEN protein levels the most, did not increase levels of p-AKT 
Ser473 and shRNA #1 also did not increase levels of RNAPII Ser5P. However, infection with 
any other shRNA increased levels of p-AKT Ser473, RNAPII Ser2P and Ser5P (Fig 3.10 D). We 
next tested these knock-down cell lines for their sensitivity to transcription inhibition by THZ1 
and Flavopiridol. 5 out of 6 and 4 out of 6 knock-down cell lines showed a significant increase in 
their sensitivity to THZ1 and Flavopiridol, respectively (Fig 3.10 E and F). Interestingly, the 
response to transcription inhibition did not seem to increase with greater reduction in PTEN 
levels, as shRNA #1, which showed the highest reduction in PTEN levels, was not differentially 
affected by transcription inhibition when compared to the control cells. However, we suspect 
that shRNA #1 is expressed at very high levels, making it efficient at reducing PTEN protein 
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levels but also causing off-target effects. In fact, a relatively moderate decrease in PTEN levels 
of 30-40% and even a 20% reduction was sufficient to elicit an increased response to 
transcriptional inhibitors. 
 
Increased sensitivity of TNBC cell lines to transcription inhibition 
Having shown that PTEN status can affect cells’ response to transcription inhibition we next 
wanted to explore the mechanism of how PTEN influences transcription. Wang et al (Wang et 
al., 2015) screened a panel of breast cancer cell lines including 6 triple negative breast cancer 
(TNBC) cell lines and 4 ER/PR+ cell lines and found an exceptional sensitivity to CDK7 
inhibition in response to THZ1 treatment in the TNBC cell lines (Fig 3.11 A). Interestingly, 5 out 
of the 6 TNBC lines tested are negative for PTEN protein expression as evidenced by 
immunoblotting, whereas all ER/PR+ cell lines express varying levels of PTEN protein (Fig 3.11 
A). RNA-Seq experiments comparing the two TNBC lines BT549 and MDA-MB-468, both 
harboring frameshift mutations, with the two ER/PR+ cell lines T47D, which expresses wild type 
PTEN, and ZR-75-1, which expresses the PTEN L108R mutant, identified a subset of genes 
that is over-expressed in TNBC and especially sensitive to transcription inhibition. This subset of 
genes, which comprises 451 genes, is significantly enriched in our Pten-/- MEF microarray data, 
which is described in Chapter 2 (Fig 3.11 B). A subset of vital genes within this gene set 
encodes transcriptional regulators and signaling factors and is referred to as the “Achilles 
cluster”. This “Achilles cluster” gene set is significantly enriched in our Pten-/- MEF microarray 
data (Fig 3.11 C) suggesting that genes from this gene set could be important in conferring 




Loss of Pten does not grossly disturb the super-enhancer landscape in MEFs 
Interestingly, 40% of the “Achilles cluster” genes are associated with super-enhancers (SE), 
which are often found near genes that are highly expressed and especially vulnerable to 
transcription inhibition (Chapuy et al., 2013; Hnisz et al., 2013; Kwiatkowski et al., 2014; Loven 
et al., 2013; Whyte et al., 2013). Super-enhancers are groups of enhancers typically located 
12.5 kb or less from each other displaying the histone mark H3K27ac. We analyzed our 
H3K27ac ChIP-Seq data to identify potential differences in the super-enhancer landscape in 
Pten WT and Pten-/- MEFs. As described in Chapter 2 we obtained high coverage ChIP-Seq 
data sets (discovery data set, Fig 3.12 A) for the H3K27ac mark in Pten WT and Pten-/- MEFs. 
We analyzed these data sets using the ROSE software package (Loven et al., 2013; Whyte et 
al., 2013) and identified 822 super-enhancers in the Pten WT MEFs, 496 of which were unique 
to this genotype and 573 super-enhancers in the Pten-/- MEFs, 247 of which were unique to this 
genotype (Fig 3.12 B left and right panels). Profile plots of H3K27ac score distributions across 
super-enhancers showed higher H3K27ac signals in Pten WT MEFs for super-enhancers that 
were identified in Pten WT or Pten-/- MEFs (Fig 3.12 C). This finding was confirmed by our low 
coverage validation data set (Fig 3.12 A and C). Overall this suggests that the loss of PTEN in 
early passage MEFs does not result in a gain of super-enhancers, but rather a slight overall 
decrease of super-enhancer strength when compared to Pten WT MEFs. We therefore 
hypothesize that the over-expression of “Achilles cluster” genes, which seems to confer 
sensitivity to transcription inhibition in the Pten-/- MEFs is not due to a change in the super-
enhancer landscape after loss of PTEN but might be due to a direct interaction of PTEN with 






In this chapter we made the following observations: 1) There is a nuclear pool of Pten that can 
associate with chromatin; 2) The loss of PTEN increases the transcriptional activity in cells while 
simultaneously upregulating 7SK snRNA, a negative regulator of transcription and a component 
of the P-TEFb complex; 3) Nuclear PTEN can directly interact with CDK7, CDK9, Cyclin T1, 
AFF4 and RNAPII; 4) PTEN status correlates with cells’ sensitivity to transcription inhibition; 5) 
Loss of PTEN upregulates the expression of “Achilles cluster” genes, thought to confer 
sensitivity to transcription inhibition to cells, without grossly altering cells’ super-enhancer 
landscape. 
We conclude from these findings that there is a nuclear pool of PTEN that by binding to 
components of the transcription machinery exerts a negative influence on cells’ transcriptional 
activity. 
Although we did not observe an overall increase in transcription of satellite and con-coding DNA 
elements in Pten-/- MEFs as reported before (Gong et al., 2015) we did find an upregulation of 
the non-coding, regulatory 7SK snRNA. The 7SK snRNA builds the core of the negative 
regulatory 7SK small nuclear ribonucleoprotein complex (7SK snRNP) (Nguyen et al., 2001; 
Yang et al., 2001). The inactive complex, which contains the 7SK snRNA, P-TEFb and HEXIM1 
or HEXIM2 predominates in many cell lines (Byers et al., 2005; Yik et al., 2003); however, P-
TEFb can be released from the complex when transcription is dramatically inhibited, for 
example when cells are treated with UV light, actinomycin D, or P-TEFb inhibitors (Byers et al., 
2005; Nguyen et al., 2001). We propose that a similar reverse feedback loop exists in Pten-/- 
MEFs, in which the negative regulator 7SK snRNA is upregulated to counteract the increased 
transcriptional activity after loss of PTEN. 
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Binding of PTEN to CDK7, CDK9, Cyclin T1, AFF4 or RNAPII, all of which can be part of large 
transcription complexes has not been reported before but raises the intriguing question of how 
PTEN affects the composition and/or activity of these complexes. Size exclusion 
chromatography of PTEN WT or PTEN-/- HeLa nuclear extracts showed no gross difference in 
the composition of transcription complexes. However, in two different Pten Null cell lines RNAPII 
occupancy on expressed genes was higher than in the corresponding Pten WT cell lines. 
Moreover, this increase did not seem dependent on PI3K/AKT pathway activation as expression 
of a Pik3ca mutation did not positively affect RNAPII occupancy on TSS. 
As phosphorylation events play an important role in the regulation of transcription, it would be 
an exciting possibility if PTEN were a protein phosphatase for one or more of the proteins of the 
transcription machinery, such as the RNAPII CTD. 
In turn, phosphorylation of the Tail-domain of PTEN by CDK7 or CDK9 might serve to negatively 
regulate PTEN’s activity. The main phosphorylation sites in the C-terminal tail are Thr366, 
Ser370, and a cluster containing Ser380, Thr382, Thr383, and Ser385 (Miller et al., 2002; 
Vazquez et al., 2000). Phosphorylation of these residues is important for an intramolecular 
interaction between the C-terminal tail and the catalytic region of PTEN and results in a ‘closed’ 
PTEN conformation that restricts PTEN recruitment to the plasma membrane and PIP3 
access (Rahdar et al., 2009; Tibarewal et al., 2012). Moreover, phosphorylation of the C-
terminal tail increases the half-life of PTEN, but inhibits its phosphatase activity (Vazquez et al., 
2000). 
We found that the loss of Pten increases expression of a specific set of “Achilles cluster” genes, 
which were previously identified to be upregulated and sensitive to transcription inhibition in the 
TNBC cell lines BT549 and MDA-MB-468 (Wang et al., 2015). The “Achilles cluster” gene set 
contains a striking number of genes involved in signaling and transcription regulation and is 
thought to confer sensitivity to transcription inhibition. 40% of the “Achilles cluster” genes were 
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associated with super-enhancers, which in tumor cells are often found to be associated with 
genes vital for driving tumorigenicity that are especially vulnerable to transcriptional 
inhibitors (Chapuy et al., 2013; Hnisz et al., 2013; Kwiatkowski et al., 2014; Loven et al., 2013; 
Whyte et al., 2013). As the “Achilles cluster” was identified by comparing two TNBC cell lines 
harboring frameshift mutations in the PTEN gene to two ER/PR+ cell lines expressing WT PTEN 
and PTEN L108R, respectively, we expected to find an altered super-enhancer landscape after 
loss of PTEN. We found that in MEFs 20-30% (30% in Pten WT and 20% in Pten-/- MEFs) of the 
“Achilles cluster” genes were associated with super-enhancers, but we did not see a substantial 
difference in the super-enhancer landscape between Pten WT and Pten-/- cells. In fact, in early 
passage primary MEFs loss of PTEN resulted in a slight decrease of the H3K27ac mark at 
super-enhancers indicating a decrease in super-enhancer strength. This decrease in H3K27ac 
could be a response to the increased transcriptional activity of PTEN-/- cells as evidenced by the 
increased occupancy of RNAPII on expressed genes and elevated levels of RNAPII Ser2P and 
Ser5P. Perhaps cells with increased transcription initiation and/or elongation do not need to rely 
on strong enhancers, or perhaps the downregulation of super-enhancers is a means to 
counteract the increase in transcriptional activity. 
We hypothesize that the upregulation of genes including “Achilles cluster” genes after loss of 
PTEN is not due to a change in the super-enhancer landscape but rather to the ablation of an 
inhibitory effect PTEN exerts on transcriptional complexes. We can only speculate on the exact 
mechanism of how PTEN’s interaction with components of the transcription machinery affects 
their transcriptional output, but our data suggest that direct binding of PTEN to proteins of the 
transcription machinery has an inhibitory effect. Upon loss of PTEN, phosphorylation of Ser2 
and Ser5 of the RNAPII CTD increases along with the transcription rate and this effect requires 
PTEN’s phosphatase activity. 
106 
 
We showed that loss of PTEN sensitizes cells to transcription inhibition. Pten-/- MEFs, PTEN-/- 
HCT116 and MycOE Pten Null cells were more sensitive to transcriptional inhibitors such as 
THZ1, Triptolide, Flavopiridol and LCD00067 than their PTEN WT counterparts. In HCT116 WT 
cells knockdown of PTEN by shRNAs increased the cells’ response to treatment with THZ1 or 
Flavopiridol. Moreover, over-expression of wild type PTEN but not a phosphatase dead mutant 
PTEN decreased the sensitivity to transcription inhibition in MycOE Pten Null cells. Wang et al 
(Wang et al., 2015) screened a panel of breast cancer cell lines including six triple negative 
breast cancer (TNBC) cell lines and four ER/PR+ cell lines. All six TNBC cell lines, 5 of which do 
not express PTEN protein, showed an exceptional sensitivity to CDK7 inhibition in response to 
THZ1 treatment (Fig 3.11 A). Of the four ER/PR+ cell lines, which were all less responsive to 
THZ1 treatment than the TNBC cell lines, one expressed WT PTEN, one the PTEN L108R 
mutant, one the PTEN C136Y and one is heterozygous with one allele harboring a frameshift 
mutation and one allele harboring the D92H mutation. It is unclear whether and to which degree 
these mutations affect PTEN phosphatase activity. However, keeping our PTEN over-
expression data in mind, which suggested that the phosphatase activity of PTEN is required for 
its role in transcription regulation, we hypothesize that the mutants retain a certain level of 
phosphatase activity. 
It is possible that inhibition of CDK7 by THZ1 not only affects transcription but also cell cycle 
regulation (Fisher, 2005). CDK7 is a CDK-activating kinase (CAK) and in this capacity can 
phosphorylate the T-loop of a number of CDKs including the cell cycle CDKs, CDK1, CDK2, 
CDK4 and CDK6 (Malumbres and Barbacid, 2009). We therefore tested whether loss of PTEN 
sensitizes cells to cell cycle inhibition using the small molecule inhibitor Palbociclib, which 
inhibits CDK4 and CDK6 that play important roles during the G1 phase of the cell cycle. We did 
not see a difference in the response of three different PTEN WT and PTEN-/- cell line systems to 
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treatment with Palbociclib, suggesting that loss of PTEN does not sensitize these cells to cell 
cycle inhibition. 
Overall our data suggest that loss of PTEN leads to an increase in gene expression and an 
upregulation of genes, previously shown to sensitize cells to transcription inhibition. We propose 
that through a direct interaction with the transcription machinery, PTEN exerts a negative 
regulatory effect on the activity of transcription complexes. Upon loss of PTEN the negative 
regulatory effect is eliminated and transcription of a subset of genes, sensitizing cells to 
transcription inhibition increases. Therefore it would be interesting to see whether the use of 







Figure 3.1: Nuclear Pten associates with chromatin. 
(A) Whole cell lysates of Pten WT and Pten-/- MEFs were taken 1 or 3 passages after infection 
with Adeno-virus and were analyzed for PTEN expression levels by immunoblotting. (B) Pten 
WT and Pten-/- MEFs were fixed 1 or 3 passages after infection with Adeno-virus and were 
analyzed for PTEN protein levels using immunofluorescence stainings. (C) Pten WT and Pten-/- 
MEFs were subjected to subcellular fractionation. PTEN protein levels in each fraction were 
determined by immunoblotting. (D) Schematic representation of the MNase/high-salt 
fractionation protocol. Isolated nuclei are incubated with pre-determined amounts of MNase. 
After centrifugation the supernatant (low salt soluble fraction) was collected and the pellet was 
resuspended in 0.5 M NaCl. Subsequent centrifugation separates the supernatant (high salt 
soluble fraction) and the pellet (high salt insoluble fraction). (B) Partial MNase digestion followed 
by high-salt extraction was performed on nuclei extracted from Pten WT and Pten-/- MEFs. Total 
RNAPII, EZH2, Cyclin T1, PTEN, CDK9 and CDK7 protein levels in each fraction were 
determined by immunoblotting. 
 
Figure 3.2: Loss of Pten alters expression of non-coding RNAs such as the 7SK snRNA. 
(A) Non-coding RNA expression levels were determined based on mRNA-Seq data of 3 
isogenic pairs of Pten WT and Pten-/- MEFs. Top up- (left panel) and downregulated (right 
panel) non-coding RNAs are shown, along with the log2(fold change) and p-value. (B) The 
relative amount of 7SK snRNA over Gapdh was measured in 3 isogenic pairs of Pten WT and 
Pten-/- MEFs using qRT-PCR. Error bars represent standard deviations from n = 3. The delta-
delta-Ct method was used to analyze the data, with the MEF1 Pten WT sample set to 1. (C) GO 
enrichment analysis using the “biological process” domain was performed using the Gene 
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Ontology Consortium web-based tool. Gene sets that were significantly enriched in the PI3K-
independent gene list are shown, along with the p-values. 
 
Figure 3.3: Nuclear PTEN co-migrates with large transcription complexes but does not 
affect the overall composition of theses complexes. 
(A+B) HeLa nuclear extracts were subjected to size exclusion chromatography on a Superose 6 
10/300 column. The protein content of the eluted fractions was analyzed by immunoblotting. 
Fractions corresponding to 2 MDa, 669 kDa and 75 kDa are indicated with arrowheads. (A) Size 
exclusion chromatography of nuclear extracts from PTEN WT HeLa cells. (B) Size exclusion 
chromatography of nuclear extracts from PTEN-/- HeLa cells. 
 
Figure 3.4: Loss of Pten affects RNA Polymerase II occupancy at TSS in MEFs. 
(A, B, D, E and F) ChIP-Seq experiments using an antibody raised against total RNAPII were 
performed using two isogenic pairs of Pten WT and Pten-/- MEFs. The data for each genotype 
was averaged and merged files were used to generate profiles of the average enrichment of 
RNAPII occupancy (bin size 50 bp). (B and F) (Left panels) Gene bodies were scaled to 6 kb. 
Regions 4 kb upstream of the TSS and 10 kb downstream of the TES are shown unscaled. 
(Right panels) 1 kb upstream and 1 kb downstream of the TSS are shown unscaled. (A) Table 
summarizing ChIP-Seq depth of coverage. (B) Occupancy of RNAPII is shown at expressed 
genes (genes with > 2 rpkm). (C) Whole cell lysates of two isogenic pairs of Pten WT and Pten-/- 
MEFs were analyzed for levels of RNAPII Ser2P and Ser5P by immunoblotting. The ratio of the 
phospho-protein band over the loading control by densitometry was calculated for each sample. 
These values were then normalized to the ratio of the Pten WT band of each pair and are 
shown below the corresponding phospho-protein band. (D) Venn diagram of RNAPII peaks 
called with a significance cut-off of -log(p-value) > 10 that were classified as common in Pten 
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WT and Pten-/- MEFs, unique in Pten WT or unique in Pten-/- MEFs. (E) GO enrichment analysis 
for genes associated with uniquely called peaks was performed with the Gene Ontology 
Consortium web-based tool using the “biological process” domain. (Upper panel) Significantly 
enriched gene sets in the Pten WT MEFs and (lower panel) significantly enriched gene sets in 
the Pten-/- MEFs are shown along with the software provided p-values. (F) Occupancy of 
RNAPII is shown at genes associated with peaks that are (upper panels) common in Pten WT 
and Pten-/- MEFs, (middle panel) unique in Pten WT MEFs and (lower panel) unique in Pten-/- 
MEFs. 
 
Figure 3.5: Loss of Pten affects RNA Polymerase II occupancy at TSS in mouse breast 
tumor cell lines. 
(A) Whole cell lysates of MycOE Pik3ca Mut cells and MycOE Pten Null cells were analyzed for 
levels of RNAPII Ser2P and Ser5P by immunoblotting. The ratio of the phospho-protein band 
over the loading control by densitometry was calculated for each sample. These values were 
then normalized to the ratio of the MycOE Pik3ca Mut cells band of each pair and are shown 
below the corresponding phospho-protein band. (B-E) ChIP-Seq experiments using an antibody 
raised against total RNAPII were performed using MycOE Pik3ca Mut and MycOE Pten Null 
cells. (B) Table summarizing ChIP-Seq depth of coverage. (C) Venn diagram of RNAPII peaks 
called with a significance cut-off of -log(p-value) > 20 that were classified as common in MycOE 
Pik3ca Mut and MycOE Pten Null cells, unique in MycOE Pik3ca Mut cells or unique in MycOE 
Pten Null cells. (D) GO enrichment analysis of genes associated with uniquely called peaks was 
performed with the Gene Ontology Consortium web-based tool using the “biological process” 
domain. Significantly enriched gene sets in the MycOE Pik3ca Mut cells and MycOE Pten Null 
cells are shown along with the software provided p-values. (E) Profiles of the average 
enrichment of RNAPII occupancy (bin size 50 bp) were generated and gene bodies were scaled 
to 6 kb. Regions 4 kb upstream of the TSS and 10 kb downstream of the TES are shown 
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unscaled. Occupancy of RNAPII is shown at genes associated with peaks that are (upper panel) 
common in MycOE Pik3ca Mut and MycOE Pten Null cells, (middle panel) unique in MycOE 
Pik3ca Mut cells and (lower panel) unique in MycOE Pten Null cells. 
 
Figure 3.6: Purified PTEN interacts with components of the transcription machinery. 
(A-C) A Yeast-2-Hybrid screen identified AFF4 as a potential binding partner of PTEN. (A) 
Representative illustration of full-length PTEN and AFF4. Fragments used in the Y2H screen as 
bait or prey-fragments are indicated. (B) HEK293 cell lysates co-expressing the V5-tagged prey-
fragment (AFF4) and the FLAG-tagged bait-fragment (PTEN) were incubated with anti-V5 
agarose beads. Pulled-down protein complexes were analyzed by immunoblotting. (C) HEK293 
or DBTRG cell lysates were incubated with recombinant GST control, GST-PTEN or control 
sepharose beads. Pulled-down protein complexes were analyzed by immunoblotting. (D-F) 
Immunoprecipitation experiments were used to show the interaction between PTEN and 
components of the transcription machinery. (D) Representative illustration of recombinant full-
length GST-PTEN and GST-PTEN deletion mutants used for immunoprecipitation experiments. 
(E) A coomassie stain of recombinant full-length GST-PTEN and GST-PTEN deletion constructs 
purified from BL21(DE3) pLyseE bacterial cells using glutathione sepharose beads was used for 
protein quantification. (F) HEK293 cell lysates were incubated with recombinant GST control, 
GST-PTEN, GST-PDC2, GST-PD, GST-C2 or GST-TAIL sepharose beads. Pulled-down protein 
complexes were analyzed by immunoblotting. 
 
Figure 3.7: PTEN can be phosphorylated by CDK9/Cyclin T1 and CDK7/Cyclin H/Mat1 in 
vitro. 
(A-B) In vitro kinase assays were performed with bacterially purified GST control, GST-PTEN, 
GST-PDC2 or GST-TAIL and recombinant activated kinase complexes CDK9/Cyclin T1 or 
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CDK7/Cyclin H/Mat1 in the presence of 5 μCi of radioisotope labeled ATP (γ-32P). Incorporation 
of (γ-32P)-ATP was analyzed using autoradiography. In the upper panel a representative 
exposure of two independent experiments is shown. In the lower panel coomassie stains of the 
corresponding gels are shown. 
 
Figure 3.8: Endogenous PTEN interacts with proteins of the transcription machinery. 
(A-D) Proximal ligation assays were performed in PTEN WT and PTEN-/- HeLa cells according 
to the manufacturer’s protocol. For each condition the PTEN antibody (Cat #9559, Cell 
Signaling) was incubated with either a total RNAPII, Cyclin T1, CDK9 or CDK7 antibody. Images 
were taken with a “Zeiss LSM 880 with Airyscan” confocal microscope using a 63x objective 
with oil immersion. Representative images are shown. As a control each antibody was 
incubated individually. Foci number was quantified with the Image J “analyze particles” plugin. 
The quantification for each condition is shown in the bar graphs below each panel. ±SD, n = 20. 
 
Figure 3.9: PTEN loss increases cells’ sensitivity to transcription inhibition. 
(A-D) Cell proliferation assays with isogenic pairs of Pten WT and Pten-/- MEFs, MycOE Pik3ca 
Mut and MycOE Pten Null mouse breast lines and an isogenic pair of PTEN WT and PTEN-/- 
HCT116 cells were performed using the IncuCyte ZOOM® live-cell imaging and analysis 
system. Cells were treated with increasing concentrations of (A) THZ1, (B) Triptolide, (C) 
Flavopiridol, (D) LCD000067 or (E) Palbociclib. GI50s were calculated using linear interpolation 
and are shown. ±SD, n = 3. 
 
Figure 3.10: PTEN status correlates with sensitivity to transcription inhibition. 
(A+B) Cell proliferation assays with MycOE Pten Null mouse breast lines expressing EV control, 
PTEN WT or PTEN C124S were performed using the IncuCyte ZOOM® live-cell imaging and 
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analysis system. Cells were treated with increasing concentrations of (A) THZ1 or (B) 
Flavopiridol. GI50s were calculated using linear interpolation and are shown. ±SD, n = 3. (C) 
Whole cell lysates of MycOE Pten Null mouse breast lines expressing EV control, PTEN WT or 
PTEN C124S were analyzed for protein levels of PTEN, total RNAPII, p-AKT Ser473 and 
RNAPII Ser2P and Ser5P using immunoblotting. The ratio of each phospho-protein band over 
the loading control by densitometry was calculated for each sample. These values were then 
normalized to the ratio of the MycOE Pten Null EV phospho-protein band over the control band 
and are shown below each phospho-protein band. (D) Whole cell lysates of HCT116 cell lines 
expressing control shRNA (labeled “C”) or shRNAs (labeled “#1-6”) targeting PTEN were 
analyzed for protein levels of PTEN, total RNAPII, p-AKT Ser473 and RNAPII Ser2P and Ser5P 
using immunoblotting. The ratio of each PTEN or phospho-protein band over the loading control 
by densitometry was calculated for each sample. These values were then normalized to the 
ratio of the HCT116 control shRNA PTEN band or phospho-protein band over the control band 
and are shown below each band. (E+F) Cell proliferation assays with HCT116 cell lines 
expressing control shRNA (labeled “C”) or shRNAs (labeled “#1-6”) targeting PTEN were 
performed using the IncuCyte ZOOM® live-cell imaging and analysis system. Cells were treated 
with increasing concentrations of (E) THZ1 or (F) Flavopiridol. GI50s were calculated using 
linear interpolation and are shown. ±SD, n = 3. 
 
Figure 3.11: TNBC cell lines show an exceptional sensitivity to transcription inhibition 
most likely conferred by the over-expression of “Achilles cluster” genes. 
(A) Table summarizing sensitivity to THZ1 treatment (from Wang et al (Wang et al., 2015)), 
PTEN genotype and PTEN protein expression levels for 6 TNBC and 4 ER/PR+ cell lines. (B 
and C) Gene set enrichment analysis was performed on microarray expression data from Pten-/- 
and WT MEFs. GSEA-supplied normalized enrichment score (NES), nominal p-value (NOM p-
value), and the false discovery rate q-value (FDR q-value) are given. (B) GSEA of “TNBC 
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upregulated and THZ1 sensitive” genes identified by Wang et al (Wang et al., 2015). (C) GSEA 
of “Achilles cluster” genes identified by Wang et al (Wang et al., 2015). 
 
Figure 3.12: Loss of Pten does not grossly affect the super-enhancer landscape in MEFs. 
(A-D) ChIP-Seq experiments using an antibody raised against the histone mark H3K27ac were 
performed in two isogenic pairs of Pten WT and Pten-/- MEFs. (A) Table summarizing ChIP-Seq 
depth of coverage for the discovery and validation data sets. (B) The “Rank ordering of super-
enhancer” (ROSE) software was used to call super-enhancers in (left panel) Pten WT and (right 
panel) Pten-/- MEFs using default settings. Stitched enhancers and super-enhancers are ranked 
by their RANKING_BAM signal. Their ranks are shown along the x-axis and the corresponding 
RANKING_BAM signal is shown on the y-axis. (C and D) Profiles of the average enrichment of 
H3K27ac signal over genomic regions identified as super-enhancers in (left panels) Pten WT 
MEFs and (right panels) Pten-/- MEFs were generated using a bin size of 50 bp. Super-
enhancers were scaled to 2 kb. 2 kb upstream and downstream of the super-enhancers are 
shown unscaled. (C) Enrichment profiles generated based on sequencing data from the 
discovery data set. (D) Enrichment profiles generated based on sequencing data from the 

































































CHAPTER 4: Conclusions 
 
Phosphatase and tensin homologue deleted on chromosome ten (PTEN) is a dual-specificity 
phosphatase that, by converting the lipid second messenger PIP3 back to PIP2, antagonizes 
the PI3K/AKT signaling pathway. It is considered one of the most frequently mutated tumor 
suppressors in human cancers. In this research study, we investigated the effects of PTEN loss 
on gene expression and transcription regulation. Although a number of studies have 
investigated gene expression alterations after loss of PTEN the exact mechanism remains 
elusive. 
In Chapter 2 we established a suitable model system that helped us study the effects of PTEN 
loss on gene expression. We showed that PTEN deletion affected the expression of a number 
of genes in a PI3K/AKT-dependent and -independent manner. Gene expression can be 
regulated by a number of mechanisms for example through histone modifications. Using native 
ChIP-Seq experiments we showed that loss of PTEN altered the levels of H3K36me3 and 
H3K27me3 on a subset of genes and decreased levels of H3K27ac at most enhancers as well 
as super-enhancers. 
In Chapter 3 we identified a nuclear pool of Pten that could associate with chromatin. Loss of 
PTEN increased the transcriptional activity of cells while simultaneously upregulating 7SK 
snRNA, a negative regulator of the P-TEFb complex and transcription. Furthermore, we showed 
a direct interaction between nuclear PTEN and components of the transcription machinery 
including CDK7, CDK9, Cyclin T1, AFF4 and RNAPII. PTEN deletion resulted in the 
upregulation of genes, previously shown to confer sensitivity to transcription inhibition. We 
propose that this sensitivity of PTEN deficient cells to inhibitors of transcription could be 
harnessed for targeted therapeutic interventions in cancer patients. 
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In sum, we conclude that there is a nuclear pool of PTEN that by binding to components of the 
transcription machinery exerts a negative influence on transcription.  
 
 
Figure 4.1: PTEN negatively regulates transcription by binding to transcription 
complexes. 
(A and B) PTEN can interact with (A) CDK7 and RNAPII as well as (B) CDK9, Cyclin T1, AFF4 and 
RNAPII, thereby exerting a negative regulatory effect on transcription. This interaction might also facilitate 
the phosphorylation of the PTEN Tail-domain by (A) CDK7 or (B) CDK9. Upon release of PTEN the 
inhibitory effect is eliminated and (A) Ser2P and (B) Ser5P levels increase along with the subsequent 




We propose a model, in which PTEN binds to CDK7, CDK9, Cyclin T1, RNAPII and/or AFF4 
thereby exerting a negative regulatory effect on the activity of transcription complexes. In 
reverse the binding also seems to facilitate the phosphorylation of the Tail-domain of PTEN. 
Upon loss of PTEN the negative regulatory effect is eliminated and phosphorylation of Ser2 and 
Ser5 of the RNAPII CTD increases along with the transcription rate, including transcription of 
“Achilles cluster” genes. It is most likely genes from the “Achilles cluster” gene set that confer 
sensitivity to transcription inhibition by THZ1, Triptolide, Flavopiridol or LCD000067 to PTEN 
deficient cells. 
Although we believe that this study provides compelling evidence to support our model, 
questions remain. For example, what are the dynamics of PTEN binding to components of the 
transcription machinery? Does PTEN bind to CDK9 and Cyclin T1 together with RNAPII and 
AFF4 or are there different complexes, PTEN can be part of? Furthermore, does PTEN interact 
with CDK7 that is bound to RNAPII or are these proteins in separate complexes? First answers 
to these questions could be provided by in vitro co-immunoprecipitation experiments using 
purified proteins. These purified proteins can also be used for phosphatase assays to answer 
the intriguing question of whether PTEN can be a protein phosphatase for components of the 
transcription machinery. Moreover, immunoprecipitation experiments from nuclear lysates 
potentially followed by mass spectrometry could be useful to confirm interactions of PTEN with 
transcription complexes and to identify interaction partners, we have not described here. 
What function does the phosphorylation of the PTEN Tail-domain by CDK7 or CDK9 serve? 
Could it negatively regulate PTEN’s phosphatase activity? There are several phosphorylation 
sites in the C-terminal tail of PTEN including Thr366, Ser370, and a cluster containing Ser380, 
Thr382, Thr383, and Ser385 (Miller et al., 2002; Vazquez et al., 2000). Phosphorylation of any 
of these residues can impact an intramolecular interaction between the C-terminal tail and the 
catalytic region of PTEN and results in a ‘closed’ PTEN conformation. This restricts PTEN 
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recruitment to the plasma membrane and PIP3 access (Rahdar et al., 2009; Tibarewal et al., 
2012) and inhibits PTEN’s phosphatase activity (Vazquez et al., 2000). De-phosphorylation of 
the Tail-domain, in particular Thr366, is most likely mediated by PTEN’s own protein 
phosphatase activity and this auto-dephosphorylation is necessary for a fully functional lipid 
phosphatase activity (Tibarewal et al., 2012). Whether phosphorylation of residues in the Tail-
domain can also negatively affect PTEN’s protein phosphatase domain, remains to be seen. To 
test whether phosphorylation of the PTEN tail does affect its phosphatase activity, phosphatase 
assays with wild type and phospho-mimicking PTEN mutants can be performed.  
The PTEN protein sequence contains additional phosphorylation sites and we propose that 
identification of the residues targeted by CDK7 or CDK9 could help in understanding the precise 
function of PTEN phosphorylation by these kinases. To identify the exact phosphorylation sites, 
kinase assays with PTEN mutants that cannot be phosphorylated at specific sites or mass 
spectrometry can be used. 
Furthermore, does loss of PTEN, in fact, increase the activity of RNAPII-containing transcription 
complexes? The increase in phosphorylation at Ser2 and Ser5 of the RNAPII CTD after loss of 
PTEN and the decrease of phosphorylation at Ser2 and Ser5 after re-introduction of PTEN 
would support this hypothesis. It is clear that phosphorylation of the RNAPII CTD plays an 
important role in the regulation of its activity and different phosphorylation states predominate at 
each stage of transcription. For example, during initiation Ser5 and Ser7 are phosphorylated. 
This releases RNAPII from the promoter and transcription begins. When RNAPII enters 
productive elongation and proceeds towards the 3’- end of a gene, levels of Ser5P drop and 
levels of Ser2P increase. Ser2 phosphorylation is thought to play a major role in overcoming an 
early elongation block and marks RNAPII molecules that are competent for the long-range 
elongation necessary to produce most mRNAs (Buratowski, 2009). Overall, an increase in 
phosphorylation of the RNAPII CTD translates into higher transcriptional activity. 
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Additionally, the gain in RNAPII occupancy, we observe on the TSS of expressed genes in 
PTEN deficient cells, could imply an increase in the activity of RNAPII-containing transcription 
complexes. Our findings could indicate that more RNAPII molecules are bound to promoters of 
expressed genes in PTEN deficient cells. It has been shown that the same DNA can 
simultaneously be transcribed by many molecules of RNAPII thereby significantly increasing 
transcript levels originating from that DNA (Alberts et al., 2002).  
However, a gain in RNAPII occupancy can also indicate an increase in promoter-proximal 
pausing of RNAPII, a phenomenon that has recently been recognized as an important 
widespread regulatory mechanism of transcription regulation in higher eukaryotes. As 
mentioned before RNAPII, together with a host of accessory factors, goes through a series of 
distinct stages: it binds to promoters, initiates RNA synthesis and then pauses in early 
elongation, 20-40 nucleotides downstream of the TSS. Paused RNAPII is associated with 
phosphorylated NELF and DSIF, which help establish the paused elongation complex. It 
remains stably associated with the nascent RNA and is fully capable of resuming elongation, as 
soon as appropriate signals elicit the transition to productive elongation. Paused RNAPII is 
especially high at genes associated with developmentally- and environmentally-responsive 
pathways. It is thought to be required for establishing permissive chromatin, as a pausing 
framework for rapid or synchronous induction of important genes, and/or as a checkpoint for 
coupling elongation and RNA processing (Adelman and Lis, 2012). To identify paused RNAPII 
several methods can be useful including ChIP-Seq experiments with antibodies raised against 
different phosphorylation states of the RNAPII CTD. Moreover, nuclear run-on assays or Global 
Run On (GRO)-Seq can be performed, which detect elongation-competent RNA polymerase 
through their ability to incorporate a label into nascent RNA. Another approach is short, capped 
RNA (scRNA) analysis followed by high-throughput sequencing (scRNA-Seq), a method in 
which short RNA species are isolated from nuclei with subsequent degradation of RNA species 
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lacking a cap. Any of these methods can also aid in measuring the overall activity level of 
RNAPII-containing transcription complexes.  
We showed that loss of PTEN sensitized cells to transcription inhibition. However, in three 
PTEN WT and PTEN-/- cell line systems we did not see a correlation of PTEN status and the 
response to the cell cycle inhibitor Palbociclib. CDK7 is a CDK-activating kinase (CAK), which 
can phosphorylate the T-loops of a number of CDKs thereby activating these CDKs. Among the 
substrates for CDK7 are the three interphase CDKs, CDK2, CDK4 and CDK6 and the mitotic 
CDK, CDK1 (Malumbres and Barbacid, 2009). Regulation of each phase of the cell cycle 
according to the classical model has long been considered to rely on specific CDKs and their 
association with specific cyclins. For example, during G1 phase mitogenic signals are first 
recognized by the expression of D-type cyclins (D1, D2 and D3) that bind and activate CDK4 
and CDK6, two kinases that can be inhibited by Palbociclib. G1 phase is followed by S phase, in 
which the expression of E-type cyclins (E1 and E2), which bind and activate CDK2 is tightly 
controlled and limited to the early stages of DNA synthesis. The CDK2-cyclin E complexes drive 
the G1/S transition and CDK2 is subsequently activated by cyclin A2 during the late stages of 
DNA replication to drive the transition from S phase to G2 phase (Malumbres and Barbacid, 
2009). As CDK7 can activate CDK2, it would be interesting to determine if the PTEN status of 
cells alters the response to CDK2 inhibition, for example by the inhibitor Roscovitine. Finally, 
CDK1 is activated by A-type cyclins at the end of interphase to enable the beginning of mitosis 
(Hochegger et al., 2008). More recently the basic concept of cell cycle progression, in which 
each phase of the cell cycle is driven by specific CDKs, has been challenged. Individual 
knockouts of CDK2, CDK4 or CDK6 in mice disturbed the cell cycle in a few highly specialized 
cell types but did not lead to major cell cycle defects in the majority of cell types, suggesting that 
these kinases are not essential for cell cycle progression of most cell types (Malumbres and 
Barbacid, 2009). Only knockout of CDK1 caused general cell cycle arrest, indicating that CDK1 
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alone can drive the cell cycle in mammalian cells. This result suggests a conservation of cell 
cycle regulation in mammalian cells and yeast (Malumbres and Barbacid, 2009). CDK1 can be 
phosphorylated by CDK7, which raises the question whether CDK1 inhibitors elicit different 
responses in PTEN WT and PTEN-/- cells. Moreover, it implicates that cell cycle inhibition by 
Palbociclib targeting CDK4 and CDK6, or by Roscovitine targeting CDK2 could be compensated 
by CDK1. For this reason and based on our current data, we cannot be certain if the PTEN 
status of cells in fact influences their response to cell cycle inhibition, or whether in specific cell 
types cell cycle CDKs can compensate for each other. 
Loss of PTEN sensitized cells to transcription inhibition and this effect could be reversed by 
over-expressing wild type PTEN but not by over-expressing the phosphatase dead mutant of 
PTEN (PTEN C124S). However, we do not currently know whether PTEN’s protein or lipid 
phosphatase activity is needed to do so. To answer this question, we are conducting 
experiments, in which we over-express PTEN mutants that are protein phosphatase-dead 
(PTEN Y138L) or lipid phosphatase dead (PTEN G129E) in Pten Null cells. Moreover, it would 
be interesting to perform RNAPII ChIP-Seq experiments in these cells to determine whether 
RNAPII occupancy on TSS decreases after re-introduction of wild type PTEN, PTEN G129E or 
PTEN Y138L. 
What are potential implications of the over-expression experiments? If PTEN’s protein 
phosphatase activity is required for its role in transcription regulation we propose an intriguing 
model where PTEN is directly de-phosphorylating components of the transcription machinery. 
As mentioned before phosphatase assays with purified proteins could identify potential targets 
of PTEN in the nucleus. 
But what could be the function of PTEN’s lipid phosphatase activity in the nucleus? Although 
PI3Ks were found to reside in the nuclear compartment (Irvine, 2003; Watt et al., 2004) together 
with nuclear pools of PIP2 and PIP3 bound to the nuclear matrix (Lindsay et al., 2006; Martelli et 
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al., 2004) suggesting a role of nuclear PTEN similar to its function in the cytoplasm, nuclear 
membrane-bound pools of PIP3 were shown to be insensitive to PTEN phosphatase activity 
(Lindsay et al., 2006). However, in addition to the presence of phosphoinositides on the inner 
nuclear envelop, PIP2 has also been found in detergent-treated nuclei devoid of their 
membrane (Vann et al., 1997). In addition, lipid-modifying enzymes responsible for non-
membranous PIP2 metabolism were found in the nucleus (Barlow et al., 2010) indicating that 
similar to cytosolic signaling, lipid second messengers could be generated to affect nuclear 
events. However, despite these findings the function of PIP2 in this cellular compartment 
remains poorly defined in part because few nuclear effector proteins have been identified. One 
group of PIP2-binding proteins are members of the NR5A subfamily of nuclear receptors, 
steroidogenic factor 1 (NR5A1; also known as SF-1) and liver receptor homolog 1 (NR5A2; also 
known as LRH-1), which are transcription factors that can bind to DNA as monomers (Krylova et 
al., 2005). SF-1 orchestrates endocrine tissue development and controls steroid biosynthesis, 
whereas LRH-1 is essential in early development and regulates bile acid synthesis and 
cholesterol transport (Krylova et al., 2005). Moreover, LRH-1 has been shown to regulate 
specific subsets of genes involved in cell proliferation in anti-estrogen-sensitive and -resistant 
breast cancer cells. In patients the LRH-1 transcriptional program is greatly associated with a 
signature of poor outcome and high-grade breast cancer tumors (Bianco et al., 2014). SF-1-
bound PIP2 can be converted to PIP3 by the lipid kinase inositol polyphosphate multikinase 
(IMPK) thereby increasing SF-1 activity (Blind et al., 2012). Interestingly, PTEN can 
dephosphorylate SF-1-bound PIP3 converting it back to PIP2 (Blind et al., 2012) suggesting that 
PTEN could negatively affect the transcriptional activity of NR5A nuclear receptors.  
Lastly, can the sensitivity of PTEN deficient cells to transcription inhibition be exploited in the 
clinic? Transcription is an important universal process in non-malignant as well as malignant 
cells and tissues and has therefore long been considered difficult to target in cancer therapy. As 
135 
 
general pharmacologic inhibition of the transcriptional machinery might lack selectivity for 
cancer cells it was thought to cause intolerable toxicity. However, recent studies using small-
molecule inhibitors have challenged this paradigm. Expression of certain genes has been 
shown to be extremely sensitive to transcription inhibition and these genes, often encoding 
oncogenic drivers, display a strong dependence on continuous active transcription, permitting 
high selectivity before ‘‘global’’ downregulation of transcription is achieved. One such small-
molecule inhibitor is JQ1. It targets bromodomain and extra-terminal proteins (BET) family 
members, such as BRD4, and exploits the dependence of certain cancers on the transcription of 
critical driver oncogenes (Delmore et al., 2011). Another inhibitor targeting transcription is THZ1, 
a highly selective covalent inhibitor of cyclin-dependent kinase CDK7. It has been shown to 
effectively inhibit the growth of certain cancers including T cell acute lymphoblastic leukemia 
(Kwiatkowski et al., 2014), MYCN-amplified neuroblastoma (Chipumuro et al., 2014), small-cell 
lung cancer (Christensen et al., 2014), and triple-negative breast cancer (Wang et al., 2015). 
TNBC is an extremely heterogeneous and aggressive disease with limited targeted therapies. 
However, Wang et al. (Wang et al., 2015) found that TNBC cell lines responded exceptionally 
well to transcription inhibition with THZ1. Interestingly, 5 out of the 6 TNBC cell lines tested did 
not express any PTEN protein and this together with our findings in three different cell line 
systems suggests an increased sensitivity of PTEN deficient cells to transcription inhibition. It 
would be essential to test this hypothesis in mouse models xenografted with PTEN deficient 
cells or patient-derived tissues. Ultimately, we hope that the increased sensitivity of PTEN 
deficient cells to inhibitors directed against transcription could provide an effective, clinical 






Plasmids and constructs 
Bacterial expression plasmids encoding GST-PTEN domains have been reported previously 
(Hodakoski et al., 2014). The MSCVneo-PTEN vector and the pIRES-FLAG-C2-Tail vector were 
previously described (Fine et al., 2009). The PTEN phosphatase-domain point mutants were 
generated using the QuikChange II XL Site-Directed mutagenesis kit (Agilent) as per 
manufacturer’s instructions utilizing the MSCVneo-PTEN as a template. The AFF4 bait-fragment 
was cloned into the pcDNATM3.1/V5-His vector using the TOPO® TA Expression Kit (Invitrogen) 
via topoisomerase ligation of Taq-Polymerase generated PCR purified fragments using full 
length AFF4 as a template. 
 
Antibodies 
Protein Target Purpose Company Catalogue # Type Concentration 















RNAPII (8WG16) WB Abcam ab817 mouse 
monoclonal 
1:1000 
RNAPII (N-20) ChIP-Seq Santa Cruz Sc-899 rabbit 
polyclonal 
5 ug/ChIP 










WB Abcam ab5408 mouse 
monoclonal 
1:5000 
H3  WB Abcam ab1791 rabbit 
polyclonal 
1:10000 












Vinculin WB Sigma-Aldrich V9131 mouse 
monoclonal 
1:5000 




















H3K4me3  ChIP-Seq Abcam ab8580 rabbit 
polyclonal 
3 µg/ChIP 
H3K4me1  ChIP-Seq Abcam ab8895 rabbit 
polyclonal 
3 µg/ChIP 
H3K27Ac  ChIP-Seq Abcam ab4729 rabbit 
polyclonal 
3 µg/ChIP 
H3K27me3 ChIP-Seq Millipore 07-449 rabbit 
polyclonal 
3 µg/ChIP 
H3K36me3 ChIP-Seq Abcam ab9050 rabbit 
polyclonal 
3 µg/ChIP 
H3K9me1 ChIP-Seq Abcam ab8896 rabbit 
polyclonal 
3 µg/ChIP 
H3K9me3 ChIP-Seq Abcam ab8898 rabbit 
polyclonal 
3 µg/ChIP 





Cyclin H WB Abcam ab92376 Rabbit 
polyclonal 
1:1000 
Hexim WB Abcam ab25388 rabbit 
polyclonal 
1:1000 
CDK9 WB Santa Cruz sc-484 rabbit 
polyclonal 
1:1000 
CDK9 WB, PLA Santa Cruz sc-484-G goat 
polyclonal 
1:1000, 1:100 
Cyclin T1 WB, PLA Santa Cruz sc-10750 rabbit 
polyclonal 
1:1000, 1:100 
V5 WB Invitrogen R960-25 mouse 
monoclonal 
1:2000 
V5 agarose affinity 
gel  
IP Sigma-Aldrich A7345 mouse 
monoclonal 
50 µl per IP 
 
Cell lines 
MycOE Pik3ca Mut cells, MycOE Pten Null cells and mouse embryonic fibroblasts were cultured 
in Dulbecco’s minimal essential medium (Cellgro) supplemented with 10% (vol/vol) fetal bovine 
serum (FBS), 100 IU penicillin, 100 μg/mL streptomycin (Cellgro) and 2mM L-glutamine (total 
6mM L-glutamine) (Cellgro). HEK293 and HeLa cells were cultured in Dulbecco’s minimal 
essential medium (Cellgro) supplemented with 10% (vol/vol) fetal bovine serum (FBS), 100 IU 
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penicillin, 100 μg/mL streptomycin (Cellgro). DBTRG-05MG and HCT116 cells were cultured in 
RPMI-1640 supplemented with 10% (vol/vol) FBS, 100 IU penicillin, and 100 μg/mL 
streptomycin. 
 
Generation of primary Mouse Embryonic Fibroblasts (MEFs) 
Ptenflox/flox mice generated by Hong Wu’s lab (Lesche et al., 2002) in a C57bl/6 background were 
interbred and females were sacrificed 14.5 days after mating. Embryos were dissected in PBS 
to remove the head, limbs and internal organs. They were minced with sterile razor blades and 
incubated in 0.25% trypsin for 10 min at 37°C. Cells were centrifuged at 1000 x g for 5 min at 
RT and resuspended in DMEM (Cellgro) supplemented with 10% (vol/vol) fetal bovine serum 
(FBS), 100 IU penicillin, 100 μg/mL streptomycin (Cellgro) and 2 mM L-glutamine (total 6 mM L-
glutamine) (Cellgro). The next day, media was changed and cartilaginous pieces were 
aspirated. For deletion of Pten, MEFs were infected with adenovirus Adeno-CMV-Cre-
recombinase (Vector Biolabs) or Adeno-CMV-Null (Vector Biolabs) as a control. MEFs were 
used for experiments between passages 3 and 5 after infection. 
 
Immunoblotting 
Samples were lysed in 2x Laemmli sample buffer (125 mM Tris pH 6.8, 10% 2-
mercaptoethanol, 4% SDS, 20% glycerol, 0.05% bromophenol blue, 8 M Urea) and boiled for 5 
min.  Samples were separated by SDS-PAGE on 4-12% or 4-20% Tris-Glycine gels (Invitrogen) 
and transferred onto PVDF membrane by wet electroblotting (Invitrogen). Membranes were 
blocked with 5% nonfat milk in TBS-T and incubated with the appropriate antibody overnight at 
4°C. Membranes were washed three times with TBS-T and incubated with the appropriate 
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secondary antibody for 1 h at room temperature. Blots were developed using ECL Western 
Blotting substrate (Pierce) and HyBlot CL® Autoradiography Film (Denville). 
 
Transfections and infections 
Transfections were done using Lipofectamine 2000 (Invitrogen). 
Retrovirus was produced by transfection of MSCVneo-PTEN WT and point mutation constructs 
into the Phoenix HEK293 packaging cell line using Lipofectamine 2000 according to the 
manufacturer’s protocol (Invitrogen). Titers were collected 48 h after transfection, filtered and 
used for immediate infection of MycOE Pten Null cells. Polybrene (Sigma) was added at a 
concentration of 6 μg/ml to increase infectivity. Virus-containing medium was removed 16 h after 
infection and replaced with the appropriate growth medium. G418 selection antibiotic was added 
to the medium 48 h after the initial point of infection at a concentration of 500 μg/ml and cells 
were grown in the selection medium for 7 days. 
For PTEN knockdown experiments, MISSION Lentiviral Transduction Particles were purchased 
from Sigma-Aldrich (clone IDs: TRCN0000002745, TRCN0000002747, TRCN0000002748, 
TRCN0000002749, TRCN0000230370, TRCN0000230371 and non-targeting control shRNA 
(SHC016V)) and used according to the manufacturer’s instructions. Briefly, HCT116 cells were 
transduced with the viral particles at a MOI = 3, along with a final concentration of 6 μg/mL 
polybrene. Virus-containing medium was removed 16 h after infection and replaced with the 
appropriate growth medium. Puromycin selection antibiotic was added to the medium 48 h after 
the initial point of infection at a concentration of 1 μg/ml and cells were grown in the selection 





CRISPR clone generation 
The pL-CRISPR.EFS.GFP vector containing the PTEN targeting guide RNA 
(ACAGATTGTATATCTTGTAA NGG) was generated by Daniel Herranz (Herranz et al., 2015). 
In brief, a gRNA targeting PTEN was designed using E-CRISP software (http://www.e-
crisp.org/E-CRISP/designcrispr.html). This gRNA was subsequently cloned into the pL-
CRISPR.EFS.GFP vector (Addgene, plasmid 57818). Lentivirus was produced by transfection 
of pL-CRISPR.EFS.GFP empty vector or pL-CRISPR.EFS.GFP PTEN gRNA together with the 
pCMV-DR8.9 packaging plasmid and the VSV-G envelope encoding plasmid into the HEK293T 
cell line using Lipofectamine 2000 according to the manufacturer’s protocol (Invitrogen). Titers 
were collected 48 h after transfection, filtered and used for immediate infection of HeLa cells. 
Polybrene (Sigma) was added at a concentration of 6 μg/ml to increase infectivity. Virus-
containing medium was removed 16 h after infection and replaced with the appropriate growth 
medium. To ensure a pure GFP-positive population, cells were isolated twice using 
fluorescence activated cell sorting of live cells. Single cells were then seeded and the resulting 
clonal cell populations were assessed for their PTEN expression levels by immunoblotting. 
 
Cell proliferation assays 
1500 cells were plated per well in a 96-well plate in triplicate for each experiment. Proliferation 
was monitored by analyzing the occupied area (% confluence) of cell images over time as 
recorded by the IncuCyte ZOOM® live-cell imaging and analysis system (Essen BioScience).  
 
GST fusion protein purification 
Plasmids were transformed into BL21(DE3) pLysE chemically competent cells (Invitrogen). 500 
mL of LB broth were inoculated with 1 mL of an overnight starter culture and grown until OD600 
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0.3-0.5. Protein expression was induced with 0.1 mM Isopropyl β-D-1-thiogalactopyranoside 
(Sigma) for 16 h at 21°C. The bacteria were pelleted at 5000 rpm for 15 min at 4°C and the 
pellet was resuspended in 10 mL of phosphatase buffer (25 mM Tris pH 7.4, 100 mM NaCl). 
The lysate was sonicated for 6 min (30s on, 30 off intervals), and then centrifuged for 30 min at 
20,000 x g at 4°C. The supernatant was incubated overnight with glutathione sepharose beads 
rotating at 4°C (GE Healthcare Life Sciences). Beads were washed four times with phosphatase 
buffer, resuspended with the bead bed volume of phosphatase buffer, snap frozen and stored at 
-80ºC.  
 
GST bead pull-downs 
HEK293 or DBTRG cells were rinsed with PBS and lysed in BC200 (25 mM Tris pH 7.5, 200 
mM NaCl, 1 mM EDTA, 0.2% Triton X-100, 0.2% Glycerol). Lysates were vortexed, sonicated 
for 20 s (5 s pulses) at 4°C, centrifuged at 15000 rpm for 30 min at 4°C and pre-cleared with 
glutathione sepharose beads (GE Healthcare Life Sciences) for 1 h rotating at 4°C. 
Supernatants were then incubated with GST-PTEN or indicated GST-PTEN domains loaded 
onto glutathione sepharose beads rotating at 4°C overnight. Beads were washed eight times 
with BC200 and proteins were eluted by incubation with the elution buffer (25 mM TRIS pH 8.0, 
150 mM NaCl, 50 mM glutathione) for 30 min at 37°C. 
 
Co-immunoprecipitation of V5- or FLAG-tagged proteins 
HEK293 cells were co-transfected with FLAG-C2-Tail and AFF4-V5 or EV-V5, respectively. 48 h 
after transfection, cells were lysed in BC200 buffer (25 mM Tris pH 7.5, 200 mM NaCl, 1 mM 
EDTA, 0.2% Triton X-100, 0.2% Glycerol). Lysates were sonicated for 20 s (5 s pulses) at 4°C, 
centrifuged at 15000 rpm for 30min at 4°C and pre-cleared with protein A/G agarose beads. 
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Lysates were incubated with anti-V5 or anti-FLAG agarose beads (Sigma-Aldrich) overnight at 
4°C. Beads were washed four times with BC200 and four times with PB (25 mM Tris pH 7.4, 
100 mM NaCl, 15 mM MgCl2) for V5-tagged proteins or with TBS (10 mM Tris pH 7.4, 150 mM 
NaCl, 15 mM MgCl2) for FLAG-tagged proteins. Proteins were eluted from beads using 
0.5 mg/mL V5 or FLAG peptides (Sigma-Aldrich) in PB or TBS. 
 
Immunofluorescence 
WT and Pten-/- MEFs were plated in complete MEF medium on gelatin coated glass cover slips. 
Cells were washed twice with 1x PBS and fixed in 2% Paraformaldehyde for 20 min at room 
temperature. Cells were then washed four times with 1x PBS and permeablized in perm/block 
solution (10% goat serum, 0.1% Triton X-100 in PBS) for 30 min at room temperature in a 
humid chamber. The primary antibody (PTEN 138G6 1:200) was diluted in perm/block solution 
and incubated overnight at 4°C. Slides were washed three times with 1x PBS and incubated 
with secondary antibody (FITC- or TRITC-conjugated goat anti-rabbit or mouse (Jackson 
ImmunoResearch, 1:500) diluted in PBS for 2 h at room temperature. Slides were mounted 
using ProLong® Gold Antifade Mountant with DAPI (Invitrogen) and imaged using a Nikon 
Eclipse Ni microscope at 20x magnification. 
 
Proximal ligation assay (PLA) 
20,000 HeLa cells were plated on gelatin-coated, 16-well chamber slides. 24-48 h after plating 
cells were rinsed twice in PBS and fixed with 2% Paraformaldehyde for 20 min at room 
temperature. Cells were then washed four times with 1x PBS and permeablized in perm/block 
solution (10% goat serum, 0.1% Triton X-100 in PBS) for 30 min at room temperature in a 
humid chamber. Primary antibodies were diluted 1:100 in perm/block solution and incubated 
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overnight at 4ºC. The proximal ligation assay detection was performed according to the 
manufacturer’s protocol (DuoLink® In Situ Red Starter kit mouse/rabbit or goat/rabbit, Sigma-
Aldrich). In brief, slides were washed three times with 1x PBS and incubated with the two PLA 
probes, diluted 1:5 in Antibody Diluent, matching the primary antibodies species of origin for 1 h 
at 37ºC in a humid chamber. Slides were washed twice in 1x Wash Buffer A and incubated with 
the ligation solution (1:5 dilution of 5x Ligation Stock and 1:40 dilution of Ligase in H2O) for 30 
min at 37ºC in a humid chamber. Slides were washed twice in 1x Wash Buffer A and incubated 
with the ligation solution (1:5 dilution of 5x Amplification Stock and 1:80 dilution of Polymerase 
in H2O) for 100 min at 37ºC in a humid chamber. Slides were washed twice in 1x Buffer B and 
one time in 0.01x Buffer B, left to dry in the dark at room temperature, mounted using a minimal 
volume of DuoLink® In Situ Mounting Medium with DAPI and stored at -20ºC. Images were 
taken with a confocal microscope (Zeiss LSM 880 with Airyscan) at a magnification of 63x and 
analyzed with the ImageJ software. 
 
Nuclear extraction  
Nuclear extracts from HeLa or HEK293 cells were prepared following a slightly modified 
Dignam-Roeder protocol. 1x108-1x109 cells were scraped into PBS and pelleted at 1850 x g for 
5 min at 4°C. Cells were washed once with PBS, resuspended in 5 x packed cell volume (pcv) 
of Dignam hypotonic buffer (10 mM HEPES-KOH pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM 
DTT, 1x protease inhibitor cocktail), pelleted at 1850 x g for 5 min at 4°C and resuspended in 3 
x pcv of Dignam hypotonic buffer. Cells were incubated on ice for 10 min and homogenized by 
passing them through a 27G needle. Nuclei were pelleted by centrifugation at 3300 x g for 15 
min at 4ºC. Nuclei were then washed twice with PBS, resuspended in 1 x packed nuclei volume 
(pnv) of Dignam high Salt buffer (20 mM HEPES-KOH pH 7.9, 350 mM NaCl, 1.5 mM MgCl2, 
0.2 mM EDTA, 25% glycerol, 0.5 mM DTT, 1x protease inhibitor cocktail), passed through a 
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27G needle and incubated for 1 h rotating at 4ºC. Nuclear extracts were cleared by 
centrifugation at 20,000 x g for 30 min at 4ºC. 
 
Size exclusion chromatography 
1 mL of nuclear extract was loaded onto a size exclusion chromatography column (Superose 6 
10/300 Increase GL, GE Healthcare) connected to an ÄKTA Pure system. The column was 
equilibrated with size-exclusion buffer (40 mM HEPES pH 7.5, 350 mM NaCl, 10% glycerol, and 
0.1% Tween 20). Proteins were eluted with 1.5 column volumes of size exclusion buffer. 0.5 mL 
fractions were collected and analyzed by Western blotting. 
 
Kinase assays 
100 ng of the activated kinase (CDK7/Cyclin H/Mat1 or CDK9/Cyclin T1) and 5 μg of the 
substrate (GST-PTEN, GST-PTEN deletion constructs or GST) were mixed in 1x kinase buffer 
(25 mM HEPES pH 7.4, 10 mM NaCl, 10 mM MgCl2, 1mM DTT). 100 μM unlabeled ATP and 5 
μCi of radioisotope labeled [γ-32P]-ATP (Perkin Elmer) were added and the reaction was 
incubated for 45 min at room temperature. The reaction was stopped by addition of 2x Laemmli 
sample buffer (125 mM Tris pH 6.8, 10% 2-mercaptoethanol, 4% SDS, 20% glycerol, 0.05% 
bromophenol blue, 8 M Urea). Samples were boiled for 5 min at 95ºC and separated by SDS-
PAGE on 4-12% Tris-Glycine gels (Invitrogen). Incorporation of [γ-32P]-ATP was detected using 






RNA extraction, cDNA synthesis and qRT-PCR 
Total RNA was prepared using the RNeasy Mini kit from Qiagen. 300 ng of RNA was used to 
generate cDNA using the Superscript Reverse Transcriptase II (Invitrogen). qRT-PCR was 
performed in a 7500 Fast Real-Time PCR system (Applied Biosystems) using the Fast SYBR 
Green mix (Invitrogen) according to the manufacturer’s protocol. The following primers were 
used:  
Mouse 7SK snRNA forward: 5’-TTCGGTCAAGGGTATACGAGTAG-3’ 
Mouse 7SK snRNA reverse: 5’-CATTTGGATGTGTCTGGAGTCTT-3’  
Mouse Gapdh forward: 5’-GGTGAGGCCGGTGCTGAGTATGTCG-3’ 
Mouse Gapdh reverse: 5’-GAGTGAGTTGTCATATTTCTCGTGG-3’ 
Samples were run in triplicate and quantitative analysis was performed on the basis of the ΔΔCt 
method using the housekeeping gene Gapdh. 
 
RNA Microarrays 
RNA from 4 isogenic pairs of Pten WT and Pten-/- MEFs was collected 4 passages after 
infection with Adeno-virus and extracted using the Qiagen RNeasy Mini Kit. 250 ng of RNA per 
sample was processed according to the Ambion® Whole Transcript (WT) Expression Array (Life 
Technologies) manufacturer’s protocol. In brief, first and second strand cDNA synthesis was 
performed, followed by cRNA synthesis and purification. Second cycle cDNA was synthesized 
and purified, and the quantity was assessed with a nanodrop 2000. Samples were then sent to 
Applied Biosystems for analysis using GeneChips Mouse Gene 2.0 ST Arrays (Affymetrix). 
Results were imported into R for quality control (including consistency of probe hybridization 




RNA from 4 isogenic pairs of Pten WT and Pten-/- MEFs was collected 4 passages after 
infection with Adeno-virus and extracted using the Qiagen RNeasy Mini Kit. 1 µg of total RNA 
per sample was processed using the TruSeq RNA Sample Preparation kit V2 (Illumina) 
according to the manufacturer’s protocol. In brief, mRNA was extracted using oligo-dT RNA 
purification beads and mRNA was fragmented at 94ºC for 12 min to obtain median mRNA insert 
fragments of 140 bp in length. First and second strand cDNA was synthesized using the 
SuperScript II Reverse transcriptase. cDNA fragments were then end repaired, 3’-ends were 
adenylated, adapters were ligated and DNA fragments were enriched by performing 15 cycles 
of PCR using adapter-specific primers. Libraries were sequenced using the NextSeq® 500/550 
High output Kit v2 (75 cycles) on a NextSeq® 500 sequencing system (Illumina). 
mRNA-seq analysis was performed by Dr. Ravi Sachidanandam as described 
previously (Howarth et al., 2014). Custom-built software was used to map the reads to the 
mouse genome (NCBI37/mm9) and estimate the coverage of each gene. Briefly, the reads were 
split into three 32 bp parts after trimming 2 bp at each end and mapped to the genome using a 
suffix-array based approach. The median of coverage across the transcript was used as an 
estimate of gene expression. The expression values were quantile normalized and log-ratios 
were calculated. Each Pten-/- MEF sample was compared to its isogenic Pten WT MEF control. 
 
Native Chromatin Immunoprecipitation (Native ChIP) 
Native ChIP was performed as described before (Umlauf et al., 2004). In brief, cells were 
collected in trypsin, washed with PBS containing 0.5 mM CaCl2 and 0.5 mM MgCl2 and 
resuspended in Buffer I (0.32 M Sucrose, 60 mM KCl, 5 mM MgCl2, 0.1 mM EDTA 15 mM Tris 
pH 7.5, 0.5 mM DTT, 1x protease inhibitor). An equal volume of Buffer II (0.32 M Sucrose, 60 
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mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 15 mM Tris pH 7.5, 0.5 mM DTT, 1x protease inhibitor 
and 0.04% IGEPAL-600) was added, the cell suspension was layered on top of a sucrose 
cushion (1.2 M Sucrose, 60 mM KCl, 5 mM MgCl2, 0.1 mM EDTA 15 mM Tris pH 7.5, 0.5 mM 
DTT, 1x protease inhibitor) and centrifuged at 10,000 x g for 20 min at 4°C. The supernatant 
was removed carefully and the nuclei pellet was resuspended in Buffer A (0.32 M Sucrose, 50 
mM Tris pH 7.5, 4 mM MgCl2, 1 mM CaCl2, 0.5 mM DTT, 1x protease inhibitor). Micrococcal 
nuclease digestion was performed in Buffer A supplemented with 2 mM CaCl2 using 0.06 units 
of micrococcal nuclease per 1 µg of chromatin. The reaction was stopped using 10 mM EGTA 
and centrifuged at 1000 x g for 7 min at 4ºC. The chromatin pellet was resuspended in 10 mM 
EDTA supplemented with protease inhibitors and incubated rotating for 2 h at 4ºC. After addition 
of 0.5 M NaCl samples were incubated for 45 min rotating at 4ºC and centrifuged at full speed 
for 5 min at 4°C. The supernatant containing the digested chromatin was diluted to 100 ng/µl in 
buffer B (20 mM Tris pH 8.0, 5 mM EDTA, 500 mM NaCl), which was supplemented with 1x 
protease inhibitors, 0.5 mM DTT and 0.2% Tween. 1% of the sample was taken as input. The 
diluted chromatin was then pre-cleared with Magna ChIPTM Protein A+G Magnetic Beads 
(Millipore) for 2 h at 4°C. 3 µg of each antibody raised against indicated histone marks were 
added to 50 µg of chromatin for methyl marks or 100 µg of chromatin for acetyl marks. Samples 
were incubated overnight rotating at 4ºC. Samples were washed three times with Buffer B 
(supplemented with 1x protease inhibitors, 0.5 mM DTT and 0.2% Tween) and once with Buffer 
B (supplemented with 1x protease inhibitors, 0.5 mM DTT). After the last wash beads were 
stored at -80ºC before DNA purification. IP samples were diluted in TE plus 0.5% SDS and input 
samples were diluted with protein K stop mix (20 mM Tris pH 7.5, 0.6 M NaCl, 20 mM EDTA, 
1% SDS). RNAse was added for 1 h at 37ºC and proteinase K was added for 4 h at 56°C. DNA 
was extracted using the MinElute PCR Purification Kit (Qiagen) and analyzed using a High 
Sensitivity ChIP on the Agilent 2100 Bioanalyzer. 
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Chromatin Immunoprecipitation (ChIP) 
Cells were grown to ~80% confluency and cross-linked in 1% formaldehyde (Pierce, #28908) for 
5 min at 4ºC. To stop the fixation glycine was added to a final concentration of 125 mM. Cells 
were washed twice with ice-cold PBS, scraped into ice-cold PBS supplemented with fresh 
protease inhibitors and collected by centrifuging at 700 x g for 5 min at 4ºC. The pellets were 
snap frozen and stored at -80ºC. 
To prepare samples for sonication, cell pellets were thawed on ice and resuspended in 2 mL of 
swelling buffer per 10 million cells (25 mM Hepes pH 7.8, 10 mM KCl, 1.5 mM MgCl2 and added 
fresh 0.1% NP-40 1 mM DTT, 1x protease inhibitor). Cells were then vortexed, swelled on ice 
for 10 min and nuclei were isolated by centrifuging at 700 x g for 5 min at 4ºC. The nuclei were 
resuspended in 1 mL of sonication buffer per 10 million nuclei (50 mM Hepes pH 7.9, 140 mM 
NaCl, 1 mM EDTA, 1% Triton X-100 and added fresh 0.1% sodiumdeoxycholate, 1% SDS, 1x 
protease inhibitor) and subjected to sonication using the UCD-400 Bioruptor (Diagenode) for 20-
40 cycles (30s on/30s off). Sonication efficiency was assessed on the Agilent 2100 Bioanalyzer 
by running a DNA High Sensitivity Chip (Agilent Technologies). Ideal sonication conditions 
yielded chromatin ranging in size from 100-1000 bp, with a peak around 500-700 bp and 
preserved the antibody epitope as assessed by immunoblotting.  
After sonication, samples were centrifuged at maximum speed for 20 min at 4ºC, the 
supernatant was pre-cleared by adding 30 μl of Magna ChIP Protein A+G Magnetic Beads 
(Millipore, #16-663) and nutated at 4ºC for 20 min. The beads were then isolated using a 
magnet, 1% of the sample was collected as Input DNA and the remaining chromatin was 
incubated with 5 μg of RNAPII antibody (N-20, Santa Cruz) overnight at 4ºC. The next day 25 μl 
of Magna ChIP Protein A+G Magnetic Beads were added and incubated for 2 h at 4ºC. The 
beads were then washed once with each of the following buffers: Low salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl); High salt wash 
149 
 
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl); LiCl 
wash buffer (0.25 M LiCl, 1% deoxycholate, 1% NP40, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1); 
TE buffer (10 mM Tris-HCl, pH 8.1, 1 mM EDTA). After the last wash beads were stored 
at -80ºC overnight. To elute the chromatin, beads were thawed, and incubated twice with 150 µl 
of elution buffer (1% SDS, 0.1 M sodium bicarbonate) by shaking on a thermomixer for at least 
1 h for each elution at 37ºC. The two elutions were pooled to 300 µl and the volume of the Input 
DNA was adjusted to 300 µl using elution buffer. To reverse-crosslink the chromatin, 12 µl of 
5 M NaCl was added, and the sample was incubated for at 65°C overnight. The sample was 
then treated with RNase for 30 min at 37ºC, and proteinase K for 2 h at 45ºC. The DNA was 
extracted using the MinElute PCR Purification Kit (Qiagen) and analyzed using a High 
Sensitivity ChIP on the Agilent 2100 Bioanalyzer. 
 
ChIP-seq library preparation and sequencing  
ChIP-seq libraries were generated as described before (Hasson et al., 2013). Briefly, 2-10 ng of 
DNA was end-repaired using DNA Polymerase I Klenow fragment (NEB), T4 DNA polymerase 
(NEB) and T4 polynucleotide Kinase (NEB), an A-overhang was added using Klenow Fragment 
(3'→5' exo-) (NEB) and Illumina Truseq adapters were ligated using the Quick DNA Ligase 
(NEB). The DNA was run on a low melting agarose gel and size-selected at 300-400 bp using 
the QIAquick Gel Extraction Kit (Qiagen). Libraries were PCR amplified for 10-15 cycles using 
the KAPA HiFi Library Amplification Kit (Kapa Biosystems). Quality and concentration of the 
libraries were assessed on the Agilent 2100 Bioanalyzer by running a DNA 1000 Chip (Agilent 
Technologies). Libraries were submitted to 75 bp single-end sequencing using the NextSeq® 





All analysis was done using the mouse genome NCBI37/mm9 as the reference genome. 
 
Alignment 
FastQC was run on the ChIP-seq raw data for quality control. The Bowtie short read aligner 
(version 1.1.1) (Langmead et al., 2009) was used to align reads to the genome (NCBI37/mm9). 
The following settings were used (if not specified, the default settings were applied): a seed 
length of 50 bp (-l 50) was used, and only the single (-m 1) best alignment (--best) per read with 
up to two mismatches (-n 2) was reported in the SAM file. 
 
Peak calling 
MACS2: Significant peak calling was performed using MACS2 (version 2.1.0) (Zhang et al., 
2008). For H3K4me1, H3K4me3, H3K27ac and RNAPII the following options were used (if not 
specified, the default settings were applied): --nomodel, --extsize 150 and --keep-dup 2. Peaks 
were called with a q-value cutoff of 1x10-2 for H3K4me1, H3K27ac and RNAPII and 1x10-7 for 
H3K4me3. For H3K9me3, H3K27me3 and H3K36me3 the following options were used (if not 
specified, the default settings were applied): --broad, --nomodel, --extsize 150 and --keep-dup 2. 
Peaks were called with a q-value cutoff of 5x10-3. Pileups were generated using MACS2 (Fold 
enrichment over Input control, --SPMR option).  
SICER: SICER.sh was used to refine peak calling for broad histone marks H3K9me3, 
H3K27me3 and H3K36me3 using the following options: species – mm9; redundancy threshold – 
1; window size – 200; fragment size – 150; effective genome size – 0.8; gap size – 600 (for 
H3K9me3 and H3K36me3) – 400 (for H3K27me3); and FDR 0.01. Input DNA was used as the 




To create stitched enhancers, and to separate super-enhancers from typical enhancers the 
software package “Rank ordering of Super-Enhancers” (Rose) was used as described 
previously (Loven et al., 2013; Whyte et al., 2013). The program ROSE_main.py was run to 
rank enhancers by H3K27ac signal minus input DNA control signal with the following options (if 
not specified, the default settings were applied): exclude regions contained within +/- 2500 bp 
from transcription start site of a gene (-t 2500).  
 
Peak and super-enhancer annotation 
The BEDtools suite (version v2.21.0) (Quinlan and Hall, 2010), specifically the “closest” tool, 
was used to assign called peaks to the most proximal transcript using the NCBI37/mm9 
reference bed-file. The “closest” tool was also used to assign super-enhancers to the active 
transcript most proximal to the center of the enhancer; transcripts were called active if 2 or more 
than 2 rpkm per gene were reported as a result of the mRNA-Seq analysis. 
 
Data visualization 
Wiggle files for gene tracks and files containing peak locations (narrowPeak and broadPeak 
files) generated using MACS2 as well as files containing locations of enhancers and super-
enhancers generated using ROSE were uploaded to the UCSC genome browser 
(http://genome.ucsc.edu) (Kent et al., 2002). 
Plots for average fold enrichment patterns and heat maps were generated using 





Statistical analysis  
All statistical analysis was performed using the GraphPad Prism 6 software. In general, P<0.05 
was considered significant. Significance for GI50 calculations and mRNA quantification by qRT-
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